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ABSTRACT 
 
The past few decades have seen major advances in management of gynaecological 
conditions and multidisciplinary obstetric care in women with inherited bleeding 
disorders (IBDs) and their offspring. However, there remain many unresolved issues 
within the field. A series of observational studies were conducted to address these 
issues with an overarching aim of improving patient care.  
 
A case-control study determined if there was an association between IBDs and 
endometriosis. Women with a surgically confirmed diagnosis of endometriosis (n = 
84) and controls (n = 30) underwent investigations of haemostasis. Women with 
endometriosis had significantly more platelet aggregation defects to one and multiple 
agonists compared to controls (31% vs 4%, p = 0.005 and 15% vs 4%, p < 0.05, 
respectively). Reduced von willebrand factor (VWF) activity correlated with 
increased laparoscopic stage of endometriosis (r = -0.35, p = 0.01).  
 
A 10-year review and questionnaire study was carried out in carriers of haemophilia 
to determine their attitudes towards prenatal diagnosis. Sixty-one carriers of 
haemophilia had obstetric care in 73 pregnancies. Forty-one out of 61 women 
responded to the questionnaire. The uptake for invasive prenatal diagnosis of 
haemophilia was reduced compared to previous studies published at the Royal Free 
Hospital (15% versus 20% in 2008 [1], and 35% in 1997 [2]). Invasive testing to 
confirm the haemophilia status of the fetus was used to guide management decisions 
of labour and delivery. The rate of termination of pregnancy (TOP) for haemophilia 
was lower than in previous case series [1]. Non-invasive determination of fetal gender 
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using free fetal DNA (ffDNA) was carried out in 58 pregnancies (79%). Fifty-nine 
deliveries were managed at the Royal Free Hospital over 10-years. The majority of 
women (66%) in this series underwent elective caesarean section (CS). The primary 
indication for CS was for haemophilia in 59% of deliveries.  
 
A literature review and meta-analysis assessed the incidence of cranial bleeding at 
birth in newborns with haemophilia. The incidence of symptomatic intracranial 
haemorrhage (ICH) was determined by mode of delivery (MOD). Newborns with 
haemophilia were 44 times (95%CI 34.7-57.1, p < 0.01) more likely to experience 
symptomatic ICH, and 8 times (95%CI 5.38-12.6, p < 0.01) more likely to experience 
extracranial haemorrhage (ECH) at birth, compared to the general population. The OR 
of experiencing ICH following an assisted vaginal delivery was 4.4 (95%CI 1.46-
13.7, p = 0.008) compared to vaginal delivery in newborns with haemophilia. The OR 
of experiencing ICH following CS was 0.34 (95%CI 0.14-0.83, p = 0.018) compared 
to vaginal delivery. CS was associated with the lowest risk of ICH in newborns with 
haemophilia. 
 
A prospective MRI screening study in term newborns with severe IBDs was 
undertaken to determine feasibility and incidence of asymptomatic ICH. Cranial MRI 
within 72 hours of delivery excluded asymptomatic ICH in affected infants. No cases 
of ICH were reported among eight participants. One newborn experienced 
cephalohaematoma following an emergency CS. Two of the eight newborns 
experienced spontaneous ICH in early infancy. 
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A case-control study analysed the differences in rotational thromboelastometry 
(ROTEM®) parameters between parturient women with FXI deficiency, and 
parturient and non-parturient controls. Women with FXI deficiency achieved a 
hypercoagulable status during the third trimester of pregnancy; however, the changes 
were not as pronounced as in pregnant controls. Women with prolonged clotting time 
and clot formation time were considered to have an increased risk of bleeding. A 
prospective cohort study evaluated the role of ROTEM® analysis in assessment of 
bleeding risk in women with FXI deficiency. Pregnancy outcomes and haemostatic 
cover was reviewed in 57 deliveries in women with FXI deficiency. ROTEM® 
enabled treatment decision and reduced the need for treatment with factor concentrate 
in women with severe FXI deficiency. 
 
A cohort study assessed the correlation between bleeding score, haemostatic and 
prothrombotic variables in women with VWD and carriers of haemophilia. The 
presence of a thrombotic marker (anticoagulant deficiency or prothrombotic gene 
mutation) altered the bleeding score for a given VWF:RCo level in women with 
VWD (p = 0.015). Co-inheritance of thrombophilia reduces bleeding severity in 
women with IBDs, and thrombotic risk must be considered in these women. 
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1.1      General Introduction 
 
Inherited bleeding disorders (IBDs) result from a deficiency or abnormal functioning 
of coagulation factors or proteins. Obstetric and gynaecological (O&G) bleeding 
specific to IBDs have long been underestimated in women. However, an increasing 
number of publications have reported O&G morbidity in women with IBD in recent 
years [3-5] (Fig 1.1). Bleeding is expected during menstruation and childbirth 
therefore excessive bleeding in women may be overlooked [6]. 
 
Von Willebrand disease (VWD), haemophilia A and haemophilia B are the most 
common IBDs. They account for 75% of all patients registered on the United 
Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) registry in 2012. At 
the Royal Free Hospital, these disorders account for 62% of all patients registered at 
the Katharine Dormandy Haemophilia Centre and Thrombosis Unit. As the centre is 
located in North London, an area with a large Jewish population, factor XI (FXI) 
deficiency constitutes most (22%) of the remaining patients. The centre registry also 
includes patients with platelet function disorders (PFDs) and other rare bleeding 
disorders.  
 
A multidisciplinary, joint O&G and haemophilia clinic was set up in 2002 for women 
with IBDs. The aim was to provide joint specialist expertise in treating 
gynaecological bleeding and provide obstetric input during pregnancy in women with 
IBD. Research conducted at the Royal Free initially reported the high prevalence of 
IBDs in women with heavy menstrual bleeding (HMB) and normal pelvic 
examination [3]. A high frequency of menstrual problems were subsequently reported 
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in women with IBD [7]. Efficacy of various treatments for HMB in women with IBDs 
has been explored [8].  
 
The Royal Free was the first centre to report pregnancy outcomes in carriers of 
haemophilia [1, 2], and in women with VWD, and FXI deficiency [3, 9]. From the 
late 1980s, carriers of haemophilia were offered invasive prenatal diagnosis to 
determine the haemophilia status of the fetus. The Royal Free Hospital is 
collaborating with the Li Ka Shing Institute of Health Sciences in Hong Kong, to 
develop a non-invasive method of diagnosing haemophilia in the fetus using free fetal 
DNA (ffDNA) [10]. Women with rare bleeding disorders (including coagulation 
factor (F) defects; FVII, FX, combined FV and FVIII, and FXIII) are also managed in 
the Joint clinic, as well as women with PFDs, including rare platelet defects such as 
Glanzmann’s thrombasthenia and Bernard-Soulier Syndrome. The Joint clinic is a 
tertiary referral clinic and women are referred from across the UK. This has amounted 
to an increasing experience with managing such rare bleeding disorders, and reporting 
their outcome. In the last 20 years, five MD(Res) theses and over 100 publications 
have been produced from the centre in relation to O&G problems and management in 
women with IBDs. Consequently, the subject of this thesis is focused on O&G issues 
for women with IBDs and their offspring that have not been tackled in previous 
research theses or publications. 
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1.2  Aims and layout of thesis 
 
The main objectives of this thesis are to provide a structured background review of 
O&G morbidity in women with IBDs and their offspring. From the background 
review, the unresolved issues that have not been addressed will be highlighted. The 
series of studies included in this thesis are designed to address these issues and 
provide better evidence to optimise patient care. Due to the diversity of study 
populations, each study presented by chapter will have a distinct hypothesis and a 
description of participants and methods used in that study. Laboratory methodologies 
used throughout the thesis are presented in Chapter 3. 
 
A National Research Ethics Service (NRES) committee approved each study included 
in this thesis, with written informed consent obtained from each participant. 
 
This thesis is comprised of a series of studies that address the unresolved issues in 
women with IBDs and their offspring. These include:  
 
1. Case-control, laboratory-based study to assess the frequency of haemostatic 
abnormalities in women with endometriosis compared to controls (Chapter 4). 
 
2. 10-year cohort study reviewing pregnancy outcomes following prenatal 
diagnosis in carriers of haemophilia. A survey to explore women’s attitudes 
towards prenantal diagnosis and non-invasive methods, and how they have 
affected reproductive choice and MOD was conducted and reported (Chapter 5). 
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3. Systematic review of the literature to assess the incidence of symptomatic and 
asymptomatic intracranial and extracranial haemorrhage in neonates with 
haemophilia compared to the general population. Meta-analysis to assess the 
effect of MOD on rates of ICH (Chapter 6).  
 
 
4. Prospective cohort study to determine the incidence of asymptomatic cranial 
bleeding in newborns with haemophilia, using cranial MRI imaging in the first 
few days of life (Chapter 6) 
 
5. Case-control study to compare rotational thromboelastometry (ROTEM®) 
changes in parturient women with FXI deficiency compared to parturient, and 
non-parturient controls (Chapter 7). 
 
6. Cohort study to assess the role of ROTEM® in the third trimester of pregnancy 
in assessment of bleeding risk and provision of haemostatic cover, in women 
with FXI deficiency (Chapter 8). 
 
7. Cohort study to assess the correlation between bleeding phenotype, and level of 
coagulation factors, and prothrombotic factors in women with IBDs (Chapter 9).  
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Figure 1.1 Women and inherited bleeding disorders – number of published articles in 
the last 20 years. 
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2.1 Inherited bleeding disorders 
 
2.1.1 Von Willebrand Disease 
Von Willebrand Disease (VWD) is the most prevalent IBD in women. Initially 
described by Erik von Willebrand in 1926, his index case was a young girl who bled 
to death at the age of 13 during her fourth menstrual period [11]. Epidemiological 
studies indicate that up to 1% of the general population has the condition [12]. It is 
characterised by a deficiency or dysfunction of von Willebrand factor (VWF).  
 
VWF is a large adhesive glycoprotein synthesised by vascular endothelial cells, bone 
marrow megakaryocytes and subendothelial connective tissue. Multimers of VWF 
can be extremely large > 20,000 kDa, and consist of over 80 subunits. Only the large 
multimers are functional. VWF plays an important role in primary haemostasis by 
promoting the tethering and adhesion of circulating platelets as well as platelet 
aggregation. It also serves as a carrier protein for the procoagulant factor VIII (FVIII) 
in plasma, thus indirectly contributing to the generation of fibrin [13]. Normal 
variations in VWF levels result from ABO blood group, ethnicity and phases of the 
menstrual cycle [14]. VWF levels increase during pregnancy, with the use of 
combined oral contraceptives and are elevated in the neonatal period [15, 16]. The 
disorder is classified into three main categories (Table 2.1).  
 
Classification 
Type 1 VWD is the most common form of VWD, accounting for around 75% of all 
cases. It results from a quantitative deficiency in VWF due to mutations that suppress 
secretion, or enhance clearance [17]. In type 1 VWD the plasma VWF levels are 
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reduced with a proportionate reduction in VWF antigen (VWF:Ag), VWF ristocetin 
cofactor activity (VWF:RCo) and VWF collagen binding capacity (VWF:CB) at 
levels between 10-40 IU/dL (normal range 45-175 IU/dL). The factor VIII activity 
(FVIII:C) is normal or mildly decreased (normal range 50-150 IU/dL).  
 
Type 2 VWD is the result of a qualitative functional deficiency in VWF and is further 
sub-classified into four variants depending on the functional defect present (Table 
2.2). In type 2A VWD there is deficiency of high molecular weight (HMW) VWF due 
to abnormal intracellular processing and/or secretion [18], or due to an increase in 
proteolytic breakdown of large multimers [19]. This results in a reduction in VWF-
dependent platelet adhesion with normal or near normal levels of VWF:Ag and 
FVIII:C but significant reduction in VWF:RCo and VWF:CB.  
 
Type 2B VWD is characterised by the presence of variants of VWF with an increased 
affinity for glycoprotein Ib (GPIb) resulting in spontaneous binding to platelets and 
subsequent rapid clearance of platelet-bound HMW VWF multimers. The condition 
may be associated with thrombocytopaenia, which can be exacerbated by pregnancy, 
surgery or 1-desamino-8-D-arginine vasopressin (DDAVP) [20-22].  
 
Type 2M VWD is characterised by a decreased ability of VWF to bind GP1b receptor 
on platelets [23, 24]. Although laboratory findings are similar to type 2A, it is 
distinguishable by multimeric analysis with the findings of normal levels of ultra 
large HMW VWF multimers. 
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In type 2N VWD there is deficiency in binding to coagulation FVIII. The FVIII:C 
level is disproportionately reduced (5-30 IU/dL) relative to the VWF:Ag. Type 2N 
VWD can be misdiagnosed as mild haemophilia A. An important distinction is the 
pattern of inheritance; autosomal recessive as opposed to X-linked. It can be 
confirmed by laboratory analysis using FVIII binding assay that measures the affinity 
of VWF to FVIII [25]. 
 
Type 3 VWD is characterised by virtual absence of VWF. The coagulation screen 
shows an isolated prolonged APTT and laboratory assays show markedly reduced (<5 
IU/dL) levels of VWF:RCo, VWF:CB, and VWF:Ag and FVIII:C less than 10 IU/dL. 
Multimeric analysis shows no multimers due to a marked reduction in VWF.  
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Table 2.1 Primary classification of VWD 
 
 
 
 
Table 2.2 Secondary classification of type 2 VWD 
 
Subtype 
Platelet- 
associated 
function 
Factor VIII 
binding capacity 
HMW VWF 
multimers 
    
2A Decreased Normal Absent 
2B Increased affinity for 
GP1b 
Normal Usually reduced/absent 
2M Decreased Normal Normal and occasional ultra-large forms 
2N Normal Markedly reduced Normal 
GP1b; glycoprotein 1b. HMW VWF; high molecular weight von Willebrand factor.  
 
 
  
Category Defect VWF protein function Proportion of cases 
    
Type 1 Quantitative partial deficiency Normal 70-80% 
Type 2 Qualitative functional deficiency Abnormal 15-20% 
Type 3 Quantitative complete deficiency Undetectable  1% 
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Genetics and inheritance 
VWD is caused by a mutation(s) in the VWF gene, located on the short arm of 
chromosome 12 [15]. Mutations can affect the complex biosynthesis of VWF 
multimers to impair assembly, intracellular targeting and secretion. Since 
chromosome 12 is an autosome (i.e. not on a sex chromosome), VWD occurs equally 
in men and women. Most VWD type 1, most type 2A, type 2B and type 2M are 
inherited in an autosomal dominant manner [26]. Most affected individuals have an 
affected parent. The proportion of cases caused by a de novo mutation is not known. 
The offspring of an autosomal dominant affected parent has a 50% chance of 
inheriting the condition. 
 
VWD type 2N, type 3 and some VWD type 1 and type 2A are inherited in an 
autosomal recessive manner [26]. Siblings of individuals with autosomal recessive 
VWD have a 25% chance of being affected, a 50% chance of being an asymptomatic 
carrier, and a 25% chance of being unaffected and not a carrier of the condition. 
 
Prenatal diagnosis, carried out mostly for type 3 VWD, is only possible if the genetic 
mutation in the family is known, or linkage analysis using intragenic markers is 
informative  (see section 2.1.2).  
 
Clinical manifestations 
Typical bleeding symptoms in women with VWD are from mucosal surfaces such as 
easy bruising, epistaxis, oral cavity bleeding, PPH and HMB [3, 14, 27, 28]. The 
bleeding phenotype is highly variable and the severity of bleeding symptoms among 
family members with the same genetic mutation varies, reflecting the diverse 
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phenotype and variable penetrance of this disorder [29]. The response to a 
haemostatic challenge such as surgery, childbirth, trauma and invasive procedures 
such as dental extraction is variable. The bleeding risk can be challenging to predict 
and haemostatic prophylaxis requires careful consideration prior to any challenge. 
Type 3 VWD results in a severe bleeding phenotype classically likened to 
haemophilia. Spontaneous gastrointestinal, soft-tissue, joint and cerebral bleedings are 
rare, and only encountered in severe or type 3 VWD [30].  
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2.1.2 Carriers of haemophilia 
Haemophilia A and B are caused by a deficiency in coagulation factors VIII (FVIII) 
and factor IX (FIX) respectively. The factor deficiency is a result of a genetic 
mutation in the corresponding genes, both of which are situated on the long arm of the 
X chromosome. Subsequently, they are X-linked recessive conditions with males 
inheriting the condition, and women are affected as carriers. Although rare, they are 
the most common severe IBD. Haemophilia A occurs with an incidence of 1 in 5,000 
per live male births and haemophilia B affects one in 25,000 live male births. 
Approximately one third of cases of haemophilia A, and one fifth of cases of 
haemophilia B arise from a new mutation, without previous family history of the 
disorder. 
 
Genetics 
Haemophilia A is highly heterogenous at the mutational level with over 1000 
different mutations described on the international Haemophilia A Mutation Database 
(http://hadb.org.uk, formerly the Haemophilia A Mutation, Structure, Test and Resource 
Site [HAMSTeRS] database) [31]. Roughly half of all cases of severe haemophilia A 
are the result of an inversion mutation involving intron 22, and roughly 5% involve 
intron 1. The remaining genetic defects are a result of stop codons, deletions, other 
inversions, or individual missense mutations. For the purpose of genetic counselling 
the large online database is of particular value because it allows inference as to the 
severity of the condition that is associated with a particular mutation. 
 
Haemophilia B is also highly heterogenous at the mutational level with over 1000 
unique mutations described in the international f9 gene database (www.factorix.org 
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[32]. Although smaller than the f8 gene, the mutational variation explains the range in 
clinical severity encountered in affected males. Sequencing the essential f9 gene 
regions or linkage analysis will identify the mutation in around 95% of cases of 
haemophilia B, which can then be used to confirm carrier status [33]. 
 
Inheritance and confirmation of carrier status 
Haemophilia A and B are X-linked recessive disorders, meaning women who are 
carriers have a 50% chance of passing the defective gene mutation to a male offspring 
who will be affected. In addition, there is a 50% change of passing the defective gene 
mutation on to a female offspring, who will also be a carrier. The daughters of men 
with haemophilia are obligate carriers. The sons of men with haemophilia will not be 
affected. The first step in the diagnosis of carrier status, which is still carried out in 
clinical practice today, is the construction of an accurate family tree.  
 
During the 1980s, DNA analysis evolved from haplotyping to mutation analysis, 
which offered certainty of carrier status. Initial genetic diagnosis was carried out 
using linkage analysis that uses a non-pathogenic normal variation in the gene 
sequence to track the mutated gene through a family. Linkage analysis is possible 
without knowledge of the gene mutation of the index family member. When the 
technology for automatic sequencing became available, mutation-specific diagnosis 
became possible. With this technique carrier determination by direct mutation 
detection without an affected family member is possible in 95% of cases [33]. 
 
 
Clinical manifestations 
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Carriers of haemophilia have one normal and one abnormal f8 or f9 gene. Therefore 
they are expected to have FVIII and FIX levels around 50% of the normal range (50-
150 IU/dL). However, a wide range of factor levels (5-219 IU/dL) has been observed 
among carriers of haemophilia [34]. The reason for the lower end of this range in 
haemophilia carriers is attributed to a phenomenon known as extreme lyonisation, 
which can occur in early embryonic life. There is random inactivation of one of each 
pair of X chromosomes [35]. This can result in factor levels that are in the range of a 
male with mild (FVIII/FIX >5 IU/dL to <50 IU/dL) or moderate haemophilia 
(FVIII/FIX >1 IU/dL to <5 IU/dL) and thus carriers can experience bleeding 
manifestations in keeping with this condition. Rarely, the female offspring of a carrier 
mother and a father with the same form of haemophilia may inherit a homozygous 
form of the condition (factor activity levels <1%). In addition full or partial 
monosomy X, as in Turner syndrome, may result in a female with haemophilia [36].  
 
The classification of haemophilia carriers according to the male definition of disease 
severity is controversial because females with factor levels in the low to normal range 
can experience significant bleeding symptoms [34]. This is due to women having the 
additional haemostatic challenges of menstruation and childbirth. Thus, women with a 
self-reported increased bleeding tendency and low FVIII and FIX levels are described 
as ‘symptomatic’ carriers of haemophilia. 
 
Mauser-Bunschoten et al first investigated the bleeding tendency in haemophilia 
carriers in a case-control study in 1988 [37]. This study described a relationship 
between FVIII/FIX activity level and a tendency to bleed. A more detailed assessment 
was subsequently carried out by Plug et al who found an increased prevalence of 
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prolonged bleeding after tooth extraction, tonsillectomy and surgical procedures in 
carriers with factor levels < 40 IU/dL [34]. In addition, haemophilia carriers with low 
to normal factor levels (41-60 IU/dL) had an increased bleeding risk compared to 
non-carrier women (Table 2.3). They were twice as likely to bleed after surgery (RR 
2.2, 95% CI 1.2-4.1) and twice as likely to develop anaemia (RR 2.0, 95% CI 1.0-4.3) 
and have restrictions in daily life (RR 2.0, 95% CI 0.8-4.9) due to HMB [34]. 
 
In a single institutional study, the phenotype of 46 haemophilia A carriers was 
compared to the underlying genetic mutation and FVIII levels. Carriers were 
categorised into three groups according to their underlying bleeding tendency. Thirty-
two (70%) out of the 46 carriers reported spontaneous bleeding symptoms such as 
recurrent easy bruising (31 carriers, 67%), HMB (23 carriers, 50%), recurrent nose 
bleeding (seven carriers, 15%) or recurrent gum bleeding (two carriers, 4%). Whilst 
the FVIII levels were concordant between the groups, significant variations in genetic 
mutations were reported. In Group 1 (no bleeding tendency), 10 missense mutations 
and one small deletion were found. In Group 2 (weak bleeding tendency), 11 
missense mutations and two intron 22 inversion were found, and in Group 3 (strong 
bleeding tendency) 9 missense mutations, seven intron 22 inversion, one deletion and 
two nonsense mutations were found (Fig 2.1) [38]. The study was limited by a small 
study population. In addition, there was no standardised questionnaire or bleeding 
score to objectively assess the severity of bleeding symptoms among participants. The 
correlation with genotype and phenotype in carriers of haemophilia requires further 
consideration. A larger study incorporating the quantification of bleeding symptoms 
using a bleeding score would be more informative. 
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Table 2.3 Bleeding tendency of both carriers and non-carriers according to decreasing 
clotting factor level (reproduced from Plug et al, 2006) 
Figure removed due to copyright restrictions 
 
Women who ever received treatment with clotting factor concentrate, tranexamic acid 
or DDAVP before tooth extraction, tonsillectomy, or operations were excluded from 
the analysis. 
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Figure 2.1 Bleeding tendency and f8 gene mutation (reproduced from Miesbach et al, 
2011 
 
Figure removed due to copyright restrictions 
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2.1.3 Factor XI deficiency 
Severe factor XI (FXI) deficiency is a rare IBD with a prevalence of 1:1,000,000 in 
most populations [39]. Its incidence is much higher in the Ashkenazi Jewish 
population due to the founder effect for three mutations, such that the heterozygous 
state is present in up to 8% of this group. [40] It is also common in the Basque 
population of Southern France [41] with an estimated prevalence of 9% in 
heterozygotes. 
 
Genetics 
FXI deficiency arises from genetic defects in the FXI gene, located on the long arm of 
chromosome 4. Over 190 causative mutations in the FXI gene have been reported and 
are described on the interactive database (www.factorxi.org) [42]. The three most 
common FXI gene mutations were first described in six Ashkenazi Jewish patients 
with severe deficiency [40]: type I – mutation at a splice site of the last intron, type II 
– a Glu117stop mutation, and type III – a Phe283Leu substitution. Types II and III 
mutations predominate in Ashkenazi Jewish populations. An increasing number of 
mutations are also reported in the non-Jewish population, most of which are missense 
point mutations that occur throughout the FXI gene [42].  
 
The exact role of FXI in coagulation is still not fully understood. In the consolidation 
phase of the coagulation pathway FXI is responsible for activating FIX to augment 
thrombin generation on activated platelets [43]. Although originally described as part 
of the contact phase of the intrinsic pathway, the physiological counterpart of this 
pathway remains an enigma. Factor XII (FXII) is auto-activated by negatively 
charged surfaces in the presence of prekallikrein (PK) and high molecular weight 
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kininogen (HK), which in turn activates FXI. However, this pathway was challenged 
by the observation that deficiencies in FXII or HK do not result in a bleeding 
tendency and an alternative activation pathway for FXI was proposed [44]. Thrombin 
activation of FXI in the absence of FXII was confirmed experimentally in a plasma 
environment [45]. In this pathway, thrombin activation of FXI is positive feedback 
that augments further thrombin generation through the activation of tenase 
(aFXI/aFVIII) and prothrombinase (FXa/FVa) complexes. In addition FXI activation 
results in reduced fibrinolysis due to activation of the thrombin activation pathway 
inhibitor (TAFI) [46]. Therefore high concentrations of thrombin are required for 
inhibition of clot lysis and activation of TAFI in contrast to the small amounts of 
thrombin required for platelet activation and fibrin formation [47]. 
 
Inheritance  
The inheritance of FXI deficiency is autosomal recessive with severe deficiency 
occurring in homozygotes or compound heterozygotes (FXI activity levels of 15-20 
IU/dL and below) and partial deficiency in heterozygotes (FXI activity levels 20-70 
IU/dL) [48]. The normal range of FXI activity is 70-150 IU/dL. 
 
Clinical manifestations 
FXI deficiency results in trauma-related bleeding and bleeding from tissue with high 
fibrinolytic activity, such as the endometrium, oral cavity and urogenital tract. 
Spontaneous bleeding is rarely associated with this condition. Woman with FXI 
deficiency are at risk of PPH [49] and HMB [50]. FXI deficiency is notable for its 
wide range of symptom severity that has poor correlation with FXI activity levels. 
This was evident from early case reports [51-53] and has been confirmed in a larger 
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study that assessed bleeding tendency in FXI patients with partial deficiency [54]. 
Individuals with severe FXI deficiency may be asymptomatic whilst individuals with 
mild deficiency may experience severe bleeding symptoms. This variability in 
bleeding tendency and lack of correlation with FXI levels can make the clinical 
management of FXI deficiency particularly challenging. 
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2.1.4 Platelet function disorders 
Inherited platelet function disorders (PFDs) fall into the categories of either disorders 
of platelet function or structure. The prevalence of PFDs in the general population has 
not been properly evaluated. Severe, clearly defined PFDs are rare and usually 
diagnosed in childhood due to the severity of bleeding symptoms. However, mild 
PFDs are less frequently encountered in clinical practice and are likely to be under-
diagnosed due to milder bleeding manifestations and the complexity of investigations.  
 
Classification 
PFDs that arise with inherited thrombocytopathies include defects of platelet 
adhesion, receptors, secretion, enzymes and signalling pathways [55, 56]. The most 
commonly encountered are deficiencies of glycoprotein (GP) mediators of adhesion 
(Bernard-Soulier syndrome [BSS]) and aggregation (Glanzmann thrombasthaenia 
[GT]). Partially reduced or absent expression of the GPIb/IX/V complex due to 
mutations in GPIBA, GPIBB, GP9 genes can give rise to BSS [57]. Partially reduced 
or absent expression of the integrin GPIIb/IIIa (α-IIb/β-3) or qualitative defects of the 
receptor due to mutations in either ITGA2B or ITGB3 genes result in the disorder GT 
[55]. 
 
Disorders of platelet secretion and signal transduction are heterogenous disorders that 
result in the inability of platelets to release intracellular granule contents on activation 
of platelet-rich plasma with agonist. Signal transduction defects result from defects in 
the agonist receptors for thromboxane A2, adenosine diphosphate (ADP) and collagen 
[58]. Platelet granule disorders include storage pool disorders with deficiency in the 
number and/or content of dense granules, alpha granules, or both granules [59, 60]. 
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Quebec platelet disorder is associated with abnormal proteolytic degradation of alpha 
granule proteins. Defects in the membrane G-proteins and in the prostaglandin 
pathway enzymes cyclo-oxygenase and thromboxane A2 synthase can result in 
disorders that interfere with the platelet conformational changes associated with 
activation. Disorders of platelet procoagulant activity have also been reported [61]. A 
classification of inherited PFDs is shown in Table 2.4.  
 
Genetics and inheritance 
BSS is usually transmitted in an autosomal recessive manner, patients being 
homozygous, or compound heterozygous for GPIBA, GPIBB, and GP9 gene 
mutations. The majority of carriers are asymptomatic [62]. However, there are case 
reports of GPIBA mutation being transmitted in an autosomal dominant manner in 
different Mediterranean families [63, 64]. GT is also inherited in an autosomal 
recessive manner, with over 100 defects found in the genes that code for the α-IIb/β-3 
integrin in megakaryocytes [65]. Platelet activation and secretion disorders, and 
platelet storage pool disorders, with a milder phenotype, are usually inherited in an 
autosomal dominant trait.  
 
 
Clinical manifestations 
PFDs give rise to spontaneous bleeding that is usually mucocutaneous in nature and 
of varying clinical severity. Mucocutaneous bleeding includes easy bruising, 
epistaxis, and HMB. Rapid onset of bleeding during surgery or trauma can be severe 
and life threatening although severity of bleeding symptoms varies considerably and 
bleeding may not occur with every haemostatic challenge. Spontaneous joint 
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bleeding, muscle bleeds, urinary, gastrointestinal or ICH are not associated with 
inherited PFDs [57]. 
 
  
49 
 
Table 2.4 Classification of inherited platelet function disorders (reproduced from Rao 
& Gabbeta 2000) 
 
Figure removed due to copyright restrictions 
 
vWF; von Willebrand factor. GPIb; glycoprotein Ib. GP IIb-IIIa; glycoprotein IIb-
IIIa. Tx; thromboxane. PLC; phospholipase 
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2.2 Gynaecological conditions and inherited bleeding disorders 
 
2.2.1 Heavy menstrual bleeding 
Menstruation is a complex, highly regulated physiological process that is under strict 
hormonal control. The cessation of menstrual bleeding relies on both local hormonal, 
endocrine factors and intact systemic haemostasis. HMB is defined as regular 
excessively heavy menstruations with blood loss of greater than 80 mL per cycle. As 
a consequence of modern life women menstruate approximately 10 times more 
frequently from menarche to menopause than in primitive human cultures. Thus HMB 
represents a regular haemostatic challenge and can become a major health problem 
for women with IBDs.  
 
Assessment of menstrual blood loss 
Mean menstrual blood loss is around 30 mL per cycle and menstrual losses of 60-80 
mL per cycle give women a greater tendency towards iron deficiency anaemia [66]. 
The average menstrual course is 5 days duration and is considered abnormal when it 
lasts for longer than 7 days. Due to the inheritable nature of bleeding disorders the 
quantity and/or duration of menses may be overlooked or rationalised as normal when 
comparisons are made with other female family members.  
 
Attempting to ascertain the true prevalence of HMB in women with IBDs is not easy. 
The subjective estimation of a women’s menstrual blood loss can be inaccurate and 
there is limited correlation between self-assessment, quantity of sanitary protections 
required, and duration of menses with actual blood loss [30]. Menstrual blood loss can 
be recorded with a high degree of accuracy using the alkaline haematin method. This 
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compares the venous blood haemoglobin with the measured alkaline haematin content 
of all the soiled sanitary products collected by patients during menstruation [66]. 
However, this method is inconvenient, laborious and costly for women in clinical 
practice. In addition, there has been doubt as to the validity and the clinical usefulness 
of the 80 mL criterion. In a later study, the proportions of women with haemoglobin 
<12g/dl and low ferritin levels were significantly increased only in the group of 
women that had menstrual blood loss >120 mL [67]. 
 
Pictorial blood assessment chart (PBAC) is a semi objective method that takes into 
account the number of towels and tampons used, the degree to which individual items 
are soiled, and the passage of clots and flooding (Appendix 1). From this information 
a score is ascertained, and a score >100 has a sensitivity and specificity of >80% for 
HMB (menstrual blood loss of 80 mL or more with the alkaline haematin method). 
Subsequently PBAC is a useful tool that has been adopted more readily for use in 
research as well as in clinical practice [68]. 
 
The menstrual cup (Mooncup®) is an alternative to using sanitary towels and 
tampons. A high satisfaction and continuation rate has been reported among users 
[69]. The menstrual cup rated significantly higher than towels and tampons for 
comfort, quality, menstrual blood collection, appearance and preference in a 
randomised crossover trial in 124 women [70]. This may provide a simple and more 
accurate method of measuring menstrual blood flow, although studies have not yet 
been published to evaluate this method in women with HMB. 
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HMB in women with inherited bleeding disorders 
HMB is the commonest bleeding symptom in women with IBDs with reported 
prevalence varying depending on the underlying disorder and population studied 
(Table 2.5).  
 
Von Willebrand disease 
HMB is the most common presenting symptom in women with VWD, occurring with 
a frequency of 78-97%, in females with VWD [7, 71]. In a case-control study of 66 
women with VWD assessment of menstrual blood loss was made using a PBAC 
score. Women with VWD had increased menstrual blood loss (PBAC score >100) (p 
= 0.001), increased menstrual flooding (p = 0.001), and longer duration of menses (p 
= 0.001), compared to 69 women without VWD [7]. In addition, women with VWD 
reported significantly increased towel/tampon use during menses (p = 0.002), history 
of anaemia (p = 0.001) [27] and reduced quality of life during menstruation [50].  
 
An international survey of 44 women with severe VWD, mainly types 2 and 3 
reported severe HMB requiring treatment with blood product therapy in 80% [72]. A 
survey undertaken in the Netherlands in 423 women with moderate and severe VWD 
demonstrated that 20% had undergone hysterectomy for HMB [73]. 
 
Carriers of haemophilia 
HMB is a common gynaecological issue for carriers of haemophilia resulting in 
significant morbidity. PBAC chart was used to assess menstrual blood loss in 30 
carriers of haemophilia and 69 age-matched controls. The median PBAC score was 
significantly higher in carriers (113 vs 73) than in the control group (p < 0.001). The 
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incidence of HMB, as defined by a PBAC score greater than 100, was 57% in 
haemophilia carriers compared to 29% in the control group [7]. 
 
FXI deficiency 
FXI deficiency is associated with bleeding during times of high-fibrinolytic activity, 
which occurs during menstruation. In a case-control study, 20 women with FXI 
deficiency were interviewed and invited to fill in a PBAC chart. The median PBAC 
score was 122 (range 38-482) in cases versus 72 (range 9-310) in controls (p = 
0.0001) [7]. HMB (PBAC >100) was reported in 59% of women with FXI deficiency. 
Nineteen of 46 (41%) of premenopausal women had symptoms indicative of HMB 
(flooding, using double towels, staying at home in bed) in the kindred study reported 
by Bolton-Maggs et al. Three women (18%) had undergone early hysterectomy [54].  
 
Platelet function disorders 
HMB has been reported with a high frequency (50-98%) in women with inherited 
PFDs. This is usually dependent on the underlying disorder (Bernard-Soulier 
syndrome and Glanzmann’s thrombasthaenia typically present with severe HMB, 
often in adolescence).  
 
HMB has also been reported in women with rare bleeding disorders such as 
deficiency in prothrombin, fibrinogen, factors V, VII, X, and XIII. In a systematic 
review of the literature HMB was reported in 35-98% of women with these disorders 
[74]. 
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Table 2.5 Prevalence of heavy menstrual bleeding in women with inherited bleeding 
disorders 
Study Sample size and population Type of study Prevalence  
 
Von Willebrand Disease 
Silwer et al. 1973 
[75] 
136 women > 15 years of age with 
VWD and 500 controls 
Case-control 60% among women with 
VWD; 25% among controls 
Kadir et al. 1999 [7] 66 women with VWD  Prospective 
cohort 
74% with PBAC score 
>100 
Ragni et al. 1999 
[71] 
29 females with type 1 VWD Case series 93% 
Kouides et al. 2000 
[27] 
99 females with type 1 VWD Survey 79% 
Lak et al. 2000 [76] 130 females with type 3 VWD Case series 69% 
Woods et al. 2001 
[77] 
921 females > 13 years with VWD Case series 47% 
Perry and Alving. 
1990 [78] 
36 women with VWD Case series 42% 
Greer et al. 1991 
[79] 
8 women with VWD (type 1 and 2) Case series 100% 
Kirtava et al. 2003 
[80] 
102 women with VWD and 88 
controls 
Case-control 
study 
95% among women with 
VWD; 61% among controls 
De Wee et al. 2011 
[73] 
423 women > 16 years with 
moderate and severe VWD 
Nation-wide 
cross-sectional 
study 
81% with >2 menorrhagia 
symptoms 
Foster et al. 1995 
[72] 
30 women with VWD unresponsive 
to DDAVP in an international 
registry 
Case series 80% with at least one 
episode requiring blood 
product 
Federici, 2004 [29] Women with VWD in Italian registry Case series 32% with type 1; 32% with 
type 2; 56% with type 3 
    
Haemophilia Carriers 
Mauser 
Bunschoten et al. 
1988 [37] 
102 carriers of haemophilia A and 
19 carriers of haemophilia B 
Case series 31% in HA; 10% in HB 
Greer et al. 1991 
[79] 
18 carriers of haemophilia A and 5 
carriers of haemophilia B 
Case series 22% in HA; 40% in HB 
Kadir et al. 1999 
[14] 
30 carriers of haemophilia Prospective 
cohort 
57% with PBAC score > 
100 
Plug et al. 2006 
[34] 
274 carriers of haemophilia and 245 
controls 
Postal survey 23% consulted with GP for 
HMB; 20% in controls 
Meisbach et al. 
2011 [38] 
46 carriers of haemophilia A Cohort 50% 
    
Factor FXI deficiency 
Bolton-Maggs et al. 
1995 [54] 
46 women with FXI deficiency Questionnaire 
study 
41% with symptoms 
indicating menorrhagia 
Brenner et al .1997 
[81] 
82 women with FXI deficiency Case series 12% with prolonged 
menstrual bleeding (> 7 
days) 
Kadir et al. 1999 
[14] 
20 women with FXI deficiency  Prospective 
cohort 
59% with PBAC score 
>100 
    
Platelet Function Disorders 
Lopez et al. 1998 
[82] 
35 women with Bernard-Soulier 
syndrome 
Summary of case 
reports 
51% 
George et al. 1990 
[83] 
55 women with Glanzmann’s 
thrombasthaenia 
Summary of case 
reports 
98% 
McKay et al. 2004 
[84]  
3 out of 6 in affected women with 
Quebec Platelet Disorder 
Case series 50% 
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Prevalence of bleeding disorders in women with HMB 
Over the last 10 years there has been increasing realisation that IBDs as a cause of 
HMB are under-estimated in women in terms of their frequency and severity. Up to 
one third of cases of HMB could be due to an undiagnosed bleeding disorder. Thus 
HMB represents an important bleeding symptom that can be used as a predictor for 
identification and diagnosis of women with IBDs. In a systematic review, an overall 
prevalence of 13% (confidence intervals 11%, 15.6%) of VWD was reported among 
988 women in 11 studies [4]. Furthermore, the prevalence of VWD in women with 
HMB varies with ethnicity. A higher prevalence of VWD was reported in the 
European studies of mainly white Caucasian women. A lower prevalence was 
reported in the North American studies that included a higher proportion of black 
African women. It has been demonstrated that black women have higher levels of 
VWF:Ag, VWF:Ac and FVIII:C than white women [7, 85] and that ethnic variations 
in VWF can influence the diagnosis of VWD [86]. The difference in prevalence of 
VWD between white and black women persists even when using race-specific 
laboratory reference ranges [87].  
 
Disorders of platelet function, especially mild defects are also underestimated in 
women with HMB. Laboratory diagnosis of these disorders requires specialised 
experience leading to under diagnosis in general. In women with HMB, PFDs have 
been observed to be more common than VWD [5, 88]. A multicenter study in the US 
included 232 women with unexplained HMB and a PBAC score >100. A laboratory 
defect in haemostasis was detected in 73.3% of the women. The frequency of platelet 
aggregation defects among women with HMB was 51.5%, which was significantly 
higher (17.3%) than the control group [89]. As with VWD, the prevalence of PFDs
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varies depending on ethnicity [5]. In a study that evaluated platelet function defects in 
74 women with unexplained menorrhagia, abnormalities of platelet aggregation were 
seen in 69% of black women compared to 39% of white (p = 0.06).  
 
IBDs are prevalent (10-20%) in adolescents presenting with HMB at menarche [88, 
90-93]. HMB since menarche [92], positive family history of bleeding symptoms, and 
clinical anaemia [91] are predictive of bleeding disorder as an underlying cause for 
HMB in young women. 
 
2.2.2 Other gynaecological conditions 
Bleeding can occur around the time of ovulation as the ovum ruptures from the 
surface of a mature ovarian follicle. Ovulation is a physiological occurrence and 
intraperitoneal bleeding may be experienced as ‘Mittelschmerz’ or mid-cycle pain. A 
high frequency of Mittlesmerz has been reported in women with VWD [27]. Carriers 
of haemophilia also experience significantly more mid-cycle pain which impacts on 
quality of life [50]. The underlying pathology behind these symptoms has not been 
fully explored in women with IBDs.  
 
In an ultrasound study the presence of pelvic fluid was seen more often in cycles 
where women experienced Mittelschmerz [94]. Assuming that the visualised fluid 
was blood, this suggests that Mittelschmerz is associated with bleeding at the time of 
ovulation. Therefore women with IBDs are particularly vulnerable to either bleeding 
into the peritoneal cavity or bleeding into the residual follicle (the corpus luteum) 
resulting in haemorrhagic cyst [74] [95, 96].  
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Women with VWD can present with an acute abdomen from haemoperitoneum due to 
rupture and subsequent bleeding of the corpus luteum [96-98]. Severe intraperitoneal 
bleeding secondary to ruptured corpus luteum has also been reported in carriers of 
haemophilia [14], in women with FXI deficiency [99] and congenital 
afibrinogenaemia [100]. It is particularly associated with FXIII deficiency, occurring 
in 8% of 121 women identified in a systematic review [101]. 
 
Multiple case reports have described women with IBDs presenting, often repeatedly, 
with haemorrhagic ovarian cysts [7, 72, 75, 79]. Jarvis and Olsen reported a case of 
type 1 VWD that presented with recurrent haemorrhagic ovarian cysts [97]. Silwer et 
al reported that nine out of 136 women with VWD experienced this problem [75]. 
Bleeding from haemorrhagic ovarian cysts results in severe pain, and/or severe, life-
threatening haemoperitoneum in women with IBDs. 
 
Endometrial hyperplasia is a condition of increased proliferation of the endometrium 
due to increased exposure to oestrogen. Endometrial polyps arise from proliferation of 
endometrial glandular tissue. Both endometrial hyperplasia and uterine polyps can 
present with HMB and/or irregular intermenstrual bleeding. A case-control study of 
102 women with VWD reported a higher prevalence of endometrial hyperplasia (10% 
in women with VWD versus 1% in controls). In the same group of women there was 
also an increased prevalence of endometrial polyps (8% versus 1%) and fibroids (32% 
versus 17%) [80]. The increased prevalence of these pathologies in women with IBDs 
may be due to the bleeding disorder exacerbating symptoms, leading to increased 
detection and diagnosis. Further research is required to determine if there is a genuine 
increased prevalence of these conditions among women with IBDs. 
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2.2.3. Endometriosis 
 
Background 
Endometriosis is an oestrogen-dependent, benign inflammatory disorder caused by 
deposition of ectopic endometrial glands and stroma. These are usually located within 
the pelvis, but may be found in other locations such as the bowel, diaphragm, 
umbilicus and pleural cavity. The exact prevalence is difficult to determine, partly due 
to the variability in clinical presentation, and partly due to the fact that surgical 
visualisation of endometriotic implants is regarded as the gold standard for a 
definitive diagnosis [102]. Population-based studies report a prevalence of around 
1.5%, compared with 6-15% in hospital-based studies [103]. However, the prevalence 
of endometriosis appears to be around 5% of reproductive aged women, with a peak 
between 25 and 35 years of age [104].  
 
Pathogenesis 
The exact pathogenesis of endometriosis is not known. The most commonly accepted 
hypothesis is the retrograde menstruation theory; viable endometrial fragments pass 
back through the fallopian tubes, possibly due to a pressure gradient originating from 
dysynergic uterine contractions [105]. Once in the peritoneal cavity they can implant, 
grow and invade pelvic structures. The likelihood of this occurrence may be 
influenced by menstrual and reproductive factors that increase pelvic contamination 
to regurgitated endometrium, such as duration and heaviness of menstrual blood flow 
[102]. The risk of developing endometriosis is increased in women with a duration of 
menses > 6 days (OR; 2.5, 95%CI; 1.1-5.9) [106].  
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Aberrant immunological mechanisms are also implicated in the pathogenesis of 
endometriosis with increased activation of circulating monocytes and macrophages 
and release of inflammatory cytokines into the peritoneal fluid, which stimulate 
ectopic endometrial cell proliferation [107]. Another theory is that endometriosis is 
derived from a metaplastic process occurring in the peritoneal mesothelium [108]. 
This theory is still supported for ovarian endometriosis. Over the past few decades 
there has been a concerted research effort to understand the pathogenesis of 
endometriosis. The genetics and molecular make of the ectopic and eutopic cells have 
been well described. The results of genome-wide association studies are consistent 
with a heritable component in endometriosis [109]. 
 
Clinical manifestations 
Endometriosis results in chronic pelvic pain, dysmenorrhoea, deep dyspareunia (pain 
on deep penetration), dyschezia (pelvic pain with defecation) and dysuria (pain with 
micturition). The pain is usually cyclical and can occur with lower back pain. 
Endometriosis rarely results in abnormal bleeding symptoms such as rectal bleeding 
or haemoptysis [110, 111]. A case-control study of 5540 women demonstrated that 
25% of women with endometriosis reported dysmenorrhoea to their general 
practitioner in the three years prior to diagnosis, 24% reported urinary tract 
symptoms, 11% reported symptoms related to painful sexual intercourse, and 2% 
reported rectal bleeding or dychezia [103]. The proportion of women with 
endometriosis who are asymptomatic is difficult to determine. A well-described 
paradox of endometriosis is that severity of disease seen at laparoscopy staging (Fig 
2.2) does not correlate well with severity of symptoms, and the reason for this is 
unclear [112]. 
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An estimated 25-50% of women with infertility have endometriosis, and around 30-
50% of women with endometriosis have infertility [113]. The mechanism for how 
endometriosis affects fertility is not well understood. Causation is thought to be due to 
adhesions that alter tubal patency, reduced ovarian reserve with endometrioma 
formation, altered embryo transport and impaired implantation due to pro-
inflammatory milieu.  
 
The chronicity of the condition has a significant impact on women’s lives including 
work, social functioning and sexual relationships [114]. Endometriosis is a chronic 
condition that affects the young, working-age population. Social, indirect and 
intangible costs contribute to the overall economic burden. These include time lost 
from education and work, the reduced ability to carry out normal everyday activities, 
loss in earned income, social withdrawal and psychological disorders such as 
depression [115]. A prospective, multi-centre European study estimated the average 
annual total cost per patient with endometriosis was €10,000 including cost of 
healthcare, and loss of productivity [116].   
 
Management 
Laparoscopy may be indicated to investigate pain symptoms or subfertility. Diagnosis 
is made by direct visualisation of endometriotic deposits, which are classically dark 
“powder-burn” lesions, although may also resemble more subtle clear vesicles. At 
laparoscopy the stage of the disease can be recorded according to the revised 
American Society for Reproductive Medicine (rASRM) classification (Fig 2.2). 
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Surgical excision or ablation of endometriosis results in effective improvement in 
endometriosis symptom severity and quality of life scores [117, 118]. 
 
The combined oral contraceptive (COC) pill [119], progesterone therapy (i.e. oral 
medroxyprogesterone acetone [120], norethindrone acetate [121], the levonorgestrel-
releasing intrauterine system (LNG-IUS) [122], subcutaneous depot 
medroxyprogesterone acetate (DMPA) injection [123], and etonogestrel subdermal 
implants [124]) and gonadotropin-releasing hormone (GnRH) analogues [125] are 
established hormonal therapies with proven efficacy in reducing pain severity and 
progression of endometriosis. COCs can be used long-term for patients with 
endometriosis until pregnancy is desired. They are contraindicated in women with 
hypertension, history of venous thromboembolism, breast cancer and migraine with 
aura [126]. High dose progesterone therapies are associated with weight gain, mood 
disturbance, depression and irritability [127]. Continuous use COC and progesterone 
therapy are associated with breakthrough bleeding. GnRH analogues are first-line 
therapy for symptomatic patient with moderate and severe endometriosis. Their use is 
restricted to short-term administration (6-12 months) due to side effects of 
hypoestrogenism (hot flushes, bone mineral density loss, and vaginal dryness). 
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Figure 2.2 Revised American Society for Reproductive Medicine (rASRM) 
classification system for endometriosis 
Figure removed due to copyright restrictions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endometriosis is classified into four stages: stage I (minimal), stage II (mild), stage III 
(moderate), and stage IV (severe) depending on the extent, and depth of 
endometriosis implants; presence and severity of adhesions; and the presence and size 
of ovarian endometriomas 
Endometriosis and inherited bleeding disorders 
The only existing evidence to support an association between the two conditions is 
studies that assess the prevalence of endometriosis in women with IBDs, usually 
63 
 
against controls. In a study that assessed the reproductive experience of women with 
VWD, endometriosis was reported in 30% of women with VWD compared to 13% of 
controls (p = 0.005) [80]. In a postal survey that interviewed 168 women, 
dysmenorrhoea and its interference with daily life were reported significantly more 
often (p = 0.001) in women with IBDs compared to controls. Of the 99 women with 
IBDs included in the survey, 50% reported moderate, severe or very severe pain 
during their menses [50]. Surveillance data from the US Centers for Disease Control 
and Prevention (CDC) reported that over 50% of the 217 women with IBDs 
experienced dysmenorrhoea, and the prevalence of a confirmed diagnosis of 
endometriosis in these women was 13% [89].  
 
Menstruation is a complex regulated process that occurs following progesterone 
withdrawal, vasoconstriction of spiral arterioles, and shedding of the endometrium. 
Local factors within endometrial tissue promote a pro-haemorrhagic environment. 
Downregulation of tissue factor (TF) and plasminogen-activator inhibitor 1 (PAI-1) 
occurs following progesterone withdrawal [128]. Inducible nitrous oxide (iNO) 
results in inhibition of platelet aggregation, relaxation of smooth muscle and 
vasodilatation with increased menstrual blood flow [129]. VWF levels fluctuate 
during the menstrual cycle and are lowest (VWF:Ag and VWF:RCo) during the first 
four days of menses [130]. Hormonal fluctuations around the time of menstruation 
may impair both systemic and local primary haemostasis (Fig 2.3). Impaired 
haemostasis leads to increased menstrual blood flow and prolonged duration of 
menses, both of which may exacerbate endometriosis, according to the retrograde 
menstruation/implantation theory [131]. The association between endometriosis and 
IBDs is explored in Chapter 4 of this thesis. 
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Figure 2.3 Pathogenesis of abnormal haemostasis leading to heavy menstrual 
bleeding (reproduced from Kouides and Kadir [132]) 
 
Figure removed due to copyright restrictions 
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2.3 Pregnancy and inherited bleeding disorders 
 
2.3.1  Prenantal diagnosis 
 
Prenatal diagnosis for haemophilia has been available since the mid 1950s when 
amniocentesis was first performed to determine fetal gender. Fuchs and Riis correctly 
reported fetal sex based on the presence or absence of the Barr body found in fetal 
cells of amniotic fluid [133]. In 1979 fetal blood samples obtained by fetoscopy at 18-
20 weeks gestation was undertaken to determine the fetal clotting factor level [134]. 
Due to advances in ultrasound technology, fetal blood sampling under fetoscopic-
guidance was later replaced by cordocentesis under ultrasound-guidance, which was 
associated with a lower rate of procedure-related fetal loss [135]. The technique of 
chorionic villus sampling (CVS) to obtain a specific prenatal genetic diagnosis for 
haemophilia in the first trimester was first reported in 1985 by Gitschier et al [136].  
 
Currently, definitive prenatal diagnosis of haemophilia can only be achieved by 
invasive testing. CVS at 11-14 weeks gestation is the preferred and most commonly 
used method. It involves the biopsy of placental tissue via trans-abdominal 
ultrasound-guided needle aspiration. Fetal DNA is extracted from the chorionic villus 
tissue and used for PCR-based fetal gender determination. Thereafter further testing 
using direct mutation detection or polymorphism linkage analysis is carried out to 
assess the haemophilia status if the fetus is male. Amniocentesis is also used for 
prenatal diagnosis in some centres after 15 weeks gestation. It involves an ultrasound-
guided collection of amniotic fluid containing fetal cells (amniocytes). The incidence 
of procedure-related pregnancy loss following both CVS and second-trimester 
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amniocentesis is less than 1% [137, 138]. Cordocentesis at 18-20 weeks remains an 
option when genetic testing is non-informative, or when genetic services are not 
available in developing countries [9]. 
 
Preimplantation genetic diagnosis (PGD) is another method of very early prenatal 
diagnosis, pioneered during the late 1980s [139]. It combines assisted reproduction 
techniques with molecular genetics and cytogenetics to identify abnormal mutations 
in embyros prior to implantation. The advantage of this technique is that the couple 
are reassured from the outset that the pregnancy is unaffected and can avoid invasive 
prenatal testing and the difficult decision regarding whether to have a termination of 
pregnancy (TOP). Attitudes towards PGD vary considerably worldwide owing to 
scientific, cultural and religious differences. The PGD-related legal and ethical issues 
have been debated both nationally in the UK, and internationally, in particular in 
relation to its potential eugenic dimension [140]. Nevertheless, PGD has been widely 
practiced worldwide for various indications and can substantially reduce the risk of 
passing an undesirable genetic condition to offspring [141-144]. The first successful 
live birth of a baby unaffected by haemophilia following PGD was reported in 2002 
[145]. This case involved diagnosis of haemophilia status through testing of the polar 
body extruded during meiosis, thus avoiding the requirement to biopsy the embryo. 
However, due to concerns regarding ‘crossing over’ of genetic material during 
meiosis this technique was not considered ideal. In many countries, PGD for families 
with haemophilia provides diagnosis only by sex determination of the embryos. This 
results in the unnecessary disposal of healthy male embryos and reduces success rates 
by diminishing the pool of embyros available for transfer. In 2006, the UK reported 
the first live birth following PGD with mutation specific diagnosis of embryos [146]. 
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A recent Spanish cohort reported 12 live births amongst 34 couples affected by 
haemophilia, using a combination of embryo sexing and direct mutation analysis 
PGD, with a live birth rate of 10-24% per cycle [147]. 
 
Third trimester amniocentesis is offered to couples who wish to avoid the risk of 
miscarriage associated with early prenatal diagnosis but wish to know the 
haemophilia status of the fetus in advance of labour. This information can help to 
determine management of labour and delivery including the decision regarding mode 
of delivery (MOD). The procedure-related complications are approximately 1% and 
include preterm labour, rupture of membranes, and infection [148]. Another 
disadvantage of third trimester amniocentesis is the approximate 1% risk of failure to 
obtain a sample and a higher culture failure rate (10% versus 1%) compared to 
samples obtained in the second trimester [149]. This could result in the onset of 
labour prior to obtaining a diagnosis in the potentially affected fetus. Current data on 
the safety and efficacy of third trimester amniocentesis are limited. A recent case 
series reported the outcome in 9 pregnant carriers of haemophilia that underwent 
amniocentesis for prenatal diagnosis at or after 34 weeks gestation [150]. There were 
no reported complications associated with the procedure and all women delivered 
after 37 weeks gestation. One out of the 9 cases had an inconclusive result. Five out 
of 9 were confirmed to be unaffected which enabled routine obstetric management 
[150]. 
 
The discovery of cell-free fetal DNA (ffDNA) in maternal plasma proved to be an 
important step in the advance of non-invasive prenatal diagnosis technology. Fetal 
gender determination using amplified Y chromosome sequences (Y-PCR) found in 
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ffDNA is now a well-established aspect in prenatal diagnosis of sex-linked conditions 
such as haemophilia [151]. ffDNA in maternal plasma has been detected as early as 
five weeks gestation, however sensitivity and specificity increases with advancing 
gestation. A meta-analysis and systematic review of the literature found a sensitivity 
and specificity of 94.5% and 98.9% respectively in tests performed from 7 to 12 
weeks gestational age [152]. 
 
Y-PCR testing with ffDNA has the advantage of negating the need for invasive 
testing and its associated risk of fetal loss for female fetuses [151]. However, invasive 
testing is still required for pregnancies with male fetuses that have a 50% chance of 
being affected with haemophilia. Despite recent advances in ffDNA technology, its 
use for prenatal diagnosis of haemophilia in pregnancies with a male fetus remains 
challenging because the mothers are carriers of the mutation and the maternally 
inherited fetal allele is indistinguishable from the maternal DNA. In a recent study, 
using quantitative PCR technology and relative mutation dosage approach, accurate 
identification of the mutant or wild type alleles was achieved in pregnant carriers of 
haemophilia with male fetuses [10]. The fetal genotype was identified from as early 
as 11 weeks gestation demonstrating the potential of a non-invasive method for 
specific prenatal diagnosis of haemophilia in the first trimester. However, this 
specialised technology currently has important limitations. A specific real time PCR 
assay is necessary for each mutation of haemophilia A and B [33]. About 50% of 
cases of severe haemophilia are caused by intron 22 inversion mutation. Therefore a 
specific assay targeting this mutation would be highly beneficial in providing a 
universal non-invasive test that can be used globally for carriers of severe 
haemophilia A, who are more likely to opt for and benefit from prenatal diagnosis. 
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Attitudes of haemophilia carriers towards prenatal diagnosis 
The uptake for prenatal diagnosis varies worldwide but remains generally low in high 
resource countries that can provide effective lifelong care [153]. The determinants 
affecting the choice for prenatal diagnosis were evaluated in a nationwide survey in 
the Netherlands. Forty-eight out of 207 carriers underwent early prenatal diagnosis in 
the first trimester (Y-PCR testing or CVS), 26 pregnancies were positive for 
haemophilia and 18 underwent termination of pregnancy. The decision to have early 
prenatal diagnosis was associated with having severe haemophilia in the family 
(relative risk (RR) 20.2; 95% confidence interval (CI) 2.7-153.6), a liberal view 
towards termination of pregnancy (TOP) (RR 12.5; CI 3.1-51.2), older age (RR 2.0; 
CI 1.0-3.9) and absence of a religion (RR 1.9; CI 1.1-3.1) [154]. Many carriers of 
haemophilia did not consider the condition to be severe enough to justify TOP [154]. 
In addition, haemophilia carriers state fear of fetal loss associated with invasive tests, 
as reasons against opting for prenatal diagnosis [154]. The attitudes of haemophilia 
carriers towards non-invasive options, including the potential for ffDNA prenatal 
diagnosis of haemophilia, have not been addressed. In addition the impact of 
knowledge of haemophilia status towards decision regarding MOD and risk of cranial 
bleeding has not been evaluated. This is addressed through a questionnaire study 
presented in Chapter 5 of this thesis. 
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2.3.2 Haemostatic changes in normal pregnancy 
 
Normal pregnancy is associated with a progressive increase in procoagulant activity 
due to elevated levels of coagulation factors VII (FVII), FVIII, FX, FXII, fibrinogen 
and von WIllebrand factor (VWF) [155-157]. The rise in coagulation factors, 
especially FVIII and VWF, are most pronounced in the third trimester [155]. FII, FV 
and FIX levels are slightly increased or unchanged during normal pregnancy [157, 
158] (Table 2.6). Reports are inconsistent regarding FXI levels in normal pregnancy, 
with some studies reporting a slight increase [159], no change [158], or a decrease 
[155]. The change in coagulation factor levels is accompanied by a reduction in 
physiological anticoagulants, most significantly a reduction in protein S activity levels 
and an acquired protein C resistance [160]. Placental derived plasminogen activator 
inhibitor 2 (PAI-2) impairs fibrinolytic activity. Local endometrial haemostasis is 
enhanced at the placental trophoblast level by increased tissue factor expression and 
reduced expression of the inhibitor thrombin activatable fibrinolysis inhibitor (TAFI) 
[160]. Pregnancy is associated with a reduction in platelet count due to the increase in 
plasma volume and resultant physiological haemodilution. However, there is limited 
data on changes in platelet function during normal pregnancy and these changes are 
poorly understood. Some studies indicate there is change in platelet activation during 
pregnancy with increased platelet aggregation and reactivity at term [161-163]. Other 
studies have found no change in platelet function [164] or else platelet hypoactivity 
[165]. In a small prospective longitudinal study that assessed platelet reactivity 
throughout pregnancy, a significant reduction was reported in the first trimester, 
compared to non-pregnant controls. In addition a significant increase was seen in third 
compared to first trimester [166].  
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Table 2.6 Haemostatic changes in normal pregnancy 
 
Clotting	  factor	   Increase (!) 
No	  significant	  change ("#) 
Fibrinogen	   !! 
FVII	   ! 
FVIII	   !! 
FX	   ! 
FXII	   ! 
VWF	   !! 
FII	   "# 
FV	   "# 
FIX	   "# 
FXI	   "# 
F, factor; VWF, von willebrand factor 
 
This table gives an overview of haemostatic changes in normal pregnancy. The 
changes in haemostatic variables and inhibitors result in a global hypercoagulable 
status considered a physiological protective mechanism to prevent excessive bleeding 
at the time of delivery.   
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2.3.3 Postpartum haemostatic changes  
 
Following expulsion of the placenta, the pro-haemostatic changes associated with 
pregnancy are reversed. Not all haemostatic indices have been studied in the 
postpartum period; for example, there is a lack of data on postpartum FXI levels.  
 
James et al performed a case-control study measuring postpartum changes in von 
Willebrand factor activity levels (VWF:RCo, VWF:Ag and FVIII:C) in 40 parturient 
women without VWD [167]. VWF:RCo and VWF:Ag levels rose in the immediate 
postpartum period (within 24 hours), fell rapidly after delivery, approached the nadir 
within 1 week and appeared to plateau for 3 weeks following delivery [167]. In 
contrast, FVIII:C levels dropped to 20% of their value in the immediate postpartum 
period, and then gradually declined to baseline by 3 weeks postpartum (Fig 2.4). The 
initial decline in FVIII:C was more gradual than VWF, which was also observed in a 
longitudinal study assessing factor levels on days 1-3 postpartum [8].  
 
Saha et al performed a prospective observational study measuring platelet count and 
function, fibrinogen levels and fibrinolysis, and performed ROTEM® analysis, in 46 
healthy parturient women from pre-delivery to 6 weeks postpartum [168]. Platelet 
count decreased further and reached a nadir by day 2 postpartum. Platelet count rose 
rapidly due to the release of fresh platelets [169]. There was a significant increase, 
compared to pre-delivery platelet count, with maximum levels reached by day 11-15 
(Fig 2.5). Platelet function also increased although the change was gradual, and not as 
significant (Fig 2.6) [168]. Increased platelet aggregation to agonist ADP and 
epinephrine have been noted in postpartum women [170].  
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Fibrinogen levels initially peaked on day 3, and then reduced to baseline and appeared 
to stabilise by day 25 postpartum (Fig 2.5) [168]. Fibrinolysis is reduced during 
pregnancy due to decreased t-PA activity. A brisk fall in PAI-1 and rise in t-PA 
activity immediately following delivery results in a rapid reversal with an increase in 
fibrinolytic activity, and a return to non-pregnant levels within 3-5 days [157, 171]. 
However, high levels of PAI-2 antigen are detected in maternal serum for a further 
few days. Free protein S appears to return to pre-pregnancy levels by the end of the 
first week postpartum [172]. Saha et al found a sharp rise in all three anticoagulants 
(protein S, protein C and antithrombin) by day 3-5 (Fig 2.6) [168]. Table 2.7 
summarises postnatal haemostatic changes. 
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Figure 2.4 Postpartum VWF:RCo, VWF:Ag and FVIII levels  
 
Figure removed due to copyright restrictions 
 
 
 
 
Trends in mean and 95% confidence intervals of (a) von Willebrand factor ristocetin 
activity level (VWF:RCo), (b) von Willebrand factor antigen (VWF:Ag) and (c) 
factor VIII (FVIII) activity level from predelivery to day 42 postpartum. Reproduced 
from James et al [167].   
 
 
Table 2.7 Postpartum haemostatic changes  
 
Clotting factor Change Normalisation to baseline  
Factor	  VIII	   !	  and	  then	  $ 3 weeks 
VWF	   !	  and	  then	  $$ 1 week 
Fibrinogen	   !	  and	  then	  $$ 3-5 weeks 
Fibrinolysis	   !! 3-5 days 
Platelet	  count	   $	  and	  then	  !  2 weeks 
Antithrombin	   !! 3-5 days 
Protein	  C	   !!! 3 days 
Free	  Protein	  S	   !!	   3-5 days 
 
VWF, von willebrand factor 
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 Figure 2.5 Postnatal changes in platelet count, fibrinogen, PT and APTT 
Figure removed due to copyright restrictions 
 
 
Trends in the mean and 95% confidence intervals of (A) platelets (PLT), (B) 
fibrinogen (FBG), (C) prothrombin time (PT), and (D) activated partial 
thromboplastin time (APTT) at different intervals from predelivery to day 40/42 
postnatal. Reproduced from the Haemostatic changes In the Pueriperium (HIP) study 
[168]. 
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 Figure 2.6 Postnatal changes in protein C, protein S, antithrombin and platelet 
function  
Figure removed due to copyright restrictions 
 
 
 
Trends in the mean and 95% confidence intervals of (A) protein C (PC), (B) free 
protein S (PS), (C) antithrombin (AT), and (D) platelet function assessment (PFA -
100) at different intervals from predelivery to day 40/42 postnatal. Reproduced from 
the Haemostatic changes In the Pueriperium (HIP) study [168]. 
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2.3.4 Changes in factor levels during pregnancy in women with IBDs 
 
Carriers of haemophilia  
Due to the physiological changes mentioned above, carriers of haemophilia A may 
experience partial or complete correction in the haemostatic defect during pregnancy. 
Carriers of haemophilia A with low baseline FVIII:C may have factor levels in the 
normal range (>50 IU/dL) by term. However, as FIX levels do not rise significantly 
during pregnancy, carriers of haemophilia B with low baseline levels will not have an 
increase and thus remain at risk of bleeding at delivery [1]. The study performed by 
Chi et al assessed 90 pregnancies in 53 carriers of haemophilia to clearly demonstrate 
this trend (Fig 2.7).  
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Figure 2.7 Pregnancy changes in factor VIII and factor IX levels in carriers of 
haemophilia (reproduced from Chi et al, 2008) 
 
Figure removed due to copyright restrictions 
 
 
 
The median pre-pregnancy and third trimester FVIII:C in haemophilia A carriers was 
42 IU dL (range 20-85) and 120 IU dL (range 38-205) respectively. The median pre-
pregnancy and third trimester FIX levels in haemophilia B carriers was 27 IU dL 
(range 21-48) and 45 (range 36-68) [1]. The risk of bleeding at delivery is inversely 
related to FVIII and FIX levels, although carriers with mildly reduced factor activity 
levels (41-60 IU/dL) also have an increased risk of bleeding [2, 37].  
 
Von Willebrand disease 
Due to the progressive increase in FVIII:C and VWF:Ag associated with pregnancy 
most women with type 1 VWD have normal haemostasis (factor levels > 50 IU/dL) 
by term [79, 173] (Fig 2.8). However, pregnancy in women with specific mutations 
(C1130F and R1205H) that result in severe type 1 VWD (increased clearance of 
VWF) are associated with a lack of correction of the haemostatic defect with only a 
slight increase in FVIII and VWF levels [174] (Fig 2.8). Similarly, women with type 
3 VWD have little or no increase in factor levels during pregnancy [175]. Women 
with type 2 VWD may have an increase in FVIII and VWF levels but there is an 
ongoing functional defect with abnormal multimers. Variations between the different 
subtypes of VWD type 2 have been observed. In type 2A usually VWF:RCo remains 
markedly low compared to the increase of VWF:Ag and, by far more significant, of 
FVIII (Fig 2.8) [176, 177]. Women with subtype 2M have no significant change in 
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both VWF and FVIII levels during pregnancy, and the abnormal VWF:Ag/VWF:RCo 
remains unchanged [178]. In homozygous subtype 2N, FVIII is normalised by the end 
of pregnancy, but its level remains significantly reduced compared to largely 
increased VWF, which maintains its reduced ability to bind FVIII (Fig 2.8). Women 
with subtype 2B may have a worsening of thrombocytopaenia in pregnancy due to the 
increased production of abnormal VWF multimers, with an increased affinity for 
GP1b, causing spontaneous platelet aggregation [21, 179]. When this subtype presents 
for the first time in pregnancy it is frequently misdiagnosed as idiopathic 
thrombocytopaenic purpura, resulting in inappropriate management [180]. 
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Figure 2.8 Changes in FVIII and von Willebrand factor levels during normal 
pregnancy and in women with the more frequent types of von willebrand disease. 
Reproduced from Castaman 2013 [181]. 
 
Figure removed due to copyright restrictions 
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Factor XI deficiency 
FXI levels are unaffected by pregnancy [157, 158] and the persistence of low factor 
levels in the third trimester is common in women with this condition [49, 175, 182]. 
Chi et al demonstrated no significant change in FXI levels during pregnancy in 30 
deficient women in 61 pregnancies [49]. Myers et al found no consistent change in 
FXI levels during pregnancy in 33 women with FXI deficiency [182]. 
 
Platelet function disorders 
There is currently a lack of data in the literature on the effect of pregnancy on platelet 
function in women with PFDs [183].  
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2.3.5 Antenatal bleeding complications 
 
An increased risk of miscarriage is only confirmed in rare bleeding disorders; 
congenital factor XIII deficiency and fibrinogen disorders. In a systematic review of 
192 pregnancies in women with factor XIII deficiency, 127 (66%) resulted in 
miscarriage [101]. A high miscarriage rate is reported in women with untreated 
congenital afibrinogenaemia [184, 185]. At present there is limited evidence to 
support an increased rate of early pregnancy loss in women with VWD, carriers of 
haemophilia, or women with FXI deficiency. Most studies report a rate that is 
comparable to the 10-12% rate of clinically recognised first trimester miscarriage 
documented in cohort studies in the general population [186].  
 
Women with IBDs are exposed to several haemostatic challenges throughout 
pregnancy. In the first trimester bleeding can occur following spontaneous 
miscarriage, invasive prenatal diagnostic procedures, and TOP. The pregnancy 
associated increase in FVIII and VWF levels (see Chapter 2.3.1) is typically not 
pronounced in the first trimester, in haemophilia A carriers and women with VWD. In 
haemophilia B carriers and women with FXI deficiency there is unlikely to be any 
change from baseline levels. Therefore these women may be at increased risk of 
prolonged or excessive bleeding during such events [1, 2, 9, 175, 182].  
 
Bleeding that occurs after the 24th completed week of pregnancy and prior to delivery 
is less common and termed antepartum haemorrhage (APH). APH occurs in 3-5% of 
all pregnancies and is a leading cause of perinatal and maternal morbidity worldwide 
[187]. APH occurs from bleeding at the placental site, lesions of the cervix or vagina 
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and occasionally is of fetal origin. Among the most important causes that result in 
major haemorrhage include placenta praevia (low implantation of the placenta), and 
placental abruption (premature detachment of placenta from the uterus), which 
account for 31% and 22% of APH, respectively. Vasa praevia is the presence of 
unsupported fetal blood vessels below the fetal presenting part, usually resulting from 
a valementous cord insertion. It complicates approximately 1 in 6000 deliveries, but if 
undiagnosed, carries a 60% mortality rate in the infant following rupture of 
membranes [188]. 
 
The risk of antepartum bleeding complications was significantly increased compared 
to controls in a large case-control study conducted in the United States including 4067 
pregnancies in women with VWD (odds ratio [OR] 10.2, 95% confidence interval 
[CI]: 7.1-14.6) [189]. In two published reviews of 172 pregnancies among 65 carriers 
of haemophilia A, and 20 carriers of haemophilia B, there were no reported episodes 
of APH [1, 2]. Severe placental abruption necessitating urgent caesarean delivery 
occurred in one out of 28 (3.6%) pregnancies in woman with FXI deficiency reported 
by Kadir et al [175]. Mild and self-limited APH was reported in three out of 61 
(4.9%) pregnancies reported in the case series by Chi et al [49]. Numerous case 
reports and case series have reported an increased risk of bleeding complications in 
pregnancy in women with BSS and GT. In a systematic review of the literature, APH 
complicated four out of 30 pregnancies in women with BSS [190]. GT is associated 
with adverse perinatal outcome, although APH rate does not appear to be increased, 
according to a literature review in 20 pregnancies [83]. 
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APH occurs more frequently in congenital factor XIII deficiency and fibrinogen 
disorders. APH affected 5 out of the 65 (8%) pregnancies that reached viability in the 
systematic review of congenital FXIII deficiency [101]. Placental abruption, reported 
in numerous case reports and case series, is particularly associated with congenital 
afibrinogenaemia [184, 191, 192]. 
 
Regional analgesia/anaesthesia  
Regional block provides the most effective pain relief in labour. It is required for 
instrumental vaginal delivery and caesarean section. It is regarded as the safest option 
as general anaesthesia in term pregnant women is associated with a higher morbidity 
and mortality, from complications such as failed intubation and aspiration pneumonia 
[193]. Women with IBDs have previously been denied this option as coagulopathy is 
regarded as a contraindication. Blood vessel puncture after placement of epidural 
catheter and bleeding into the epidural space can result in spinal haematoma leading 
to permanent neurological damage. However, the incidence of this potentially 
devastating complication is extremely low (5 per million in the general obstetric 
population) [194]. In a retrospective review of 80 pregnancies amongst 63 women 
with IBDs (including 19 women with FXI deficiency, 16 carriers of haemophilia, 15 
with VWD, 7 with PFDs) regional block was administered safely following 
individualised assessment involving a multidisciplinary team [195]. However, due to 
the small number of participants, and the low incidence of spinal epidural haematoma, 
an increased incidence of this complication in women with IBDs could not be 
excluded. FXI deficiency in particular poses a unique challenge, as the bleeding risk 
does not correlate well with factor levels. Chapter 8 of this thesis addresses 
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haemostatic assessment and provision of haemostatic prophylaxis for regional 
anaesthesia in women with FXI deficiency. 
 
 
2.3.6 Postpartum haemorrhage 
 
Postpartum haemorrhage (PPH) is an important global cause of maternal morbidity 
and mortality.	   Obstetric haemorrhage was the third most common direct cause of 
maternal death from the 2015 MBRRACE-UK report, with a rate of 0.59 per 100,000 
maternities [196]. Primary PPH is defined as an estimated blood loss greater than 500 
mL following vaginal delivery, and 1000 mL following caesarean delivery. The 
prevalence of primary PPH varies according to definition, but is estimated to be 
around 3-6% according to hospital discharge summaries in the United States, Canada 
and Australia [197-199]. There is no standard definition of massive obstetric 
haemorrhage (MOH). It is variably defined as estimated blood loss > 1500 mL within 
24 hours of delivery, a decrease in haemoglobin of > 4 g dL-1, or transfusion 
requirement of > 4 units packed red cells [200, 201].  
 
The most common cause of primary PPH is uterine atony, or failure of the uterus to 
adequately contract, which accounts for up to 80%. [202]. Genital tract or uterine 
‘trauma’ is responsible for around 20%, and comprises perineal, vaginal, and cervical 
lacerations, in addition to spontaneous or iatrogenic uterine rupture during operative 
delivery. Other aetiologies include retained placenta, and abnormal placental 
implantation, which account for 10%, and often coexist with uterine atony [201]. 
Coagulopathy is a recognised cause of PPH, which can be either congenital or 
acquired. Acquired coagulopathy develops during a PPH due to consumption of 
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coagulation factors and fibrinogen, and haemodilution due to massive transfusion 
[203]. This is also accompanied by hyperfibrinolysis with rapid clot turnover. Certain 
obstetric events can result in an acquired coagulopathy, including pre-
eclampsia/eclampsia, placental abruption, amniotic fluid embolism or intrauterine 
stillbirth causing disseminated intravascular coagulopathy [204]. Congenital 
coagulopathy, as in IBDs, are another important aetiology of PPH, which may be the 
presenting symptom. 
 
Secondary PPH is excessive lochia loss from 24 hours until six weeks postnatal [205]. 
The prevalence of secondary PPH in the general population is harder to measure as it 
is often managed in the community and therefore under-reported. Current estimates 
are that secondary PPH complicates around 1% of deliveries in the UK [206]. In a 
study that assessed quantity and duration of lochia loss using a PBAC chart, the 
median duration of lochia loss was significantly higher (39 days; range 21-58, versus 
31 days; 10-62 days, p = 0.03) in women with IBDs compared to controls [207]. 
 
Von Willebrand disease 
Women with all types of VWD are at an increased risk of bleeding complications at 
the time of delivery. Kouides et al reported a significant increase in childbirth related 
bleeding in 99 women with type 1 VWD compared to 150 controls (31% versus 10%, 
p = 0.001) and furthermore 17% had PPH that required a blood transfusion compared 
to 3% of controls (p = 0.002) [27]. A case-control study in women with known IBD 
demonstrated that primary PPH occurred with a significantly higher frequency in 
women with VWD (32% versus 7.5%) compared to controls [208].  
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A large epidemiological study including 4067 deliveries among women with VWD in 
the United States showed that 6% of women with VWD experienced a PPH compared 
with only 4% of women without VWD. These numbers were small and the odds did 
not reach statistical significance. However, there was a statistically significant risk of 
other bleeding complications such as perineal haematoma (OR, 3.3; 95% CI: 0.8, 
13.4), a five fold increased risk of receiving blood transfusion (OR, 4.7; 95% CI: 3.2, 
7.0) and the maternal mortality rate was 10 times higher in women with VWD than in 
women without (123 vs 12.7 per 100 000 deliveries)[189]. In a large population-based 
study that assessed risk factors for MOH in Norway, VWD was second only to 
emergency caesarean delivery in having the highest adjusted OR (3.31, 95% CI; 1.01-
10.85) [209][101]. 
 
Carriers of haemophilia 
Carriers of haemophilia are at a significantly increased risk of bleeding during labour 
and delivery. Whilst some haemophilia A carriers have normal FVIII levels at term, a 
significant proportion may still have low factor level (< 50 IU/dL), especially those 
with severe deficiency [1, 2, 79]. Factor IX levels are not affected by pregnancy, 
therefore haemophilia B carriers will be at an increased risk of bleeding if they have 
low baseline factor levels. 
 
The incidence of primary PPH among haemophilia carriers is significantly higher (12-
22%) [1, 2, 79] than in the general population (5-8%) [210]. The incidence of 
secondary PPH is also increased in carriers of haemophilia (2-11%) [1, 2] compared 
to the incidence reported in the general population (0.8%) [206]. FVIII and FIX 
activity correlates with the risk of bleeding among carriers of haemophilia with the 
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most significant PPH occurring in those with baseline factor levels below 50 IU/dL 
[2, 37].  
 
FXI deficiency 
The incidence of both primary and secondary PPH is increased in women with FXI 
deficiency, as demonstrated in numerous case series and cohort studies [49, 175, 182, 
211]. Chi et al evaluated 49 deliveries in women with both partial and severe FXI 
deficiency and found an incidence of both primary and secondary PPH to be 11% of 
all deliveries [49]. Similarly, the incidence of PPH in 33 women with FXI deficiency 
was 13% in the study performed by Myers et al [182]. In a study performed in Israeli 
women with severe FXI deficiency (FXI:C <17 IU/dL), 19 out of 62 women (30%) 
experienced PPH in one or more pregnancies [211]. 
 
Platelet function disorders 
There is a lack of data in the literature in relation to mild PFDs and pregnancy 
complications [212]. In women with severe disorders such as BSS and GT, the 
published literature is limited to case reports and small case series only, which 
indicate a high risk of severe bleeding complications in both mother and neonate 
[212]. In a systematic review of the literature, 30 pregnancies among 18 women with 
BSS were identified [190]. Primary and secondary PPH occurred in 34% and 40% of 
deliveries, respectively, with 50% requiring blood transfusion. Two women 
underwent obstetric hysterectomy at the time of delivery. In a systematic review of 
the literature, 40 pregnancies in 35 women with GT were identified. Similarly, the 
rate of primary and secondary PPH was high (34% and 20%, respectively), and PPH 
was frequently severe.  
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There are multiple case reports and small case series that document incidence of PPH 
in women with rare IBDs. PPH was the most common obstetric complication 
occurring in 14 out of 31 deliveries (45%) among 10 women affected with 
hypofibrinogenaemia. Blood transfusion was required in all cases and two women 
underwent hysterectomy [213]. Women with FV deficiency are at increased risk. PPH 
was reported in 13 out of 17 deliveries (76%) among nine women [214]. PPH was 
reported at a rate of 30% in 13 and 14 pregnancies in women with FVII and FX 
deficiency, respectively [215, 216]. PPH occurred in 16 (25%) out of 65 pregnancies 
in women with FXIII deficiency. There is limited data on pregnancy in women with 
combined FV and FVIII deficiency. Due to the rarity of these IBDs, there is limited 
data available of haemostatic assessment and prophylactic treatment at delivery. 
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2.3.7 Haemostatic assessment and haemostatic agents used for bleeding 
prophylaxis and treatment in pregnancy 
 
Von Willebrand disease 
Haemostatic assessment in women with VWD includes regular monitoring of 
VWF:Ag, VWF:Ac and FVIII:C, particularly during the third trimester to determine 
the risk of bleeding at delivery. The platelet count should be monitored in women 
with type 2B VWD as pregnancy may exacerbate thrombocytopaenia [21]. A personal 
and/or family history of bleeding complications is an important factor to consider in 
the management of these women.  
 
Prophylaxis and treatment of pregnant women with VWD depends upon the 
anticipated MOD and use of regional anaesthesia, factor levels, VWD subtype, 
previous bleeding history and response to 1-deamino-8-D-arginine (DDAVP) 
treatment, the presence of an inhibitor and the potential risks of treatment [217]. 
Haemostatic cover is not usually required for women with type 1 VWD, unless third 
trimester VWF:Ag or FVIII:C are less than 50 IU/dL [183]. The bleeding risk can be 
challenging to predict in women with type 2 VWD. The defect is functional therefore 
changes in factor levels in pregnancy do not necessarily affect bleeding risk. The 
treatment will depend on the subtype, and is individualised for each woman. 
Treatment with factor concentrate is almost always necessary for women with type 3 
VWD. The main therapeutic options available include pharmacological agents such as 
tranexamic acid and DDAVP, or VWF/FVIII-containing concentrates. 
 
Antifibrinolytic agents 
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The three main antifibrinolytic agents are Epsilon-Amino Caproic Acid (EACA), 
tranexamic acid and Aprotinin (APR). APR is the most potent antifibrinolytic agent 
but due to increased mortality rates reported with several clinical trials it has been 
withdrawn from the market and its use is currently not recommended [218]. 
Tranexamic acid is more potent than EACA and it is the main antifibrinolytic agent 
used for the treatment of VWD. It inhibits the binding of plasminogen to fibrin by 
reversible blockage of lysine-binding sites and thus inhibition of fibrinolysis. It has a 
maximum clinical efficacy if administered prior to delivery when there is a sufficient 
circulating volume in plasma [217]. It can be used in combination with DDAVP or 
factor concentrates as prophylaxis to prevent bleeding during surgery or delivery.  
 
The use of tranexamic acid during pregnancy, delivery and postpartum was evaluated 
in a systematic review [219]. Tranexamic acid demonstrated a small reduction (33 
mL, 95%CI, -4.1-69.1; p = 0.08) in blood loss during elective caesarean section and 
vaginal delivery in prospective studies. Another systematic review found a significant 
reduction in blood loss (92 mL; 95%CI, 76-109 mL) following administration of 0.5-
1 gram of intravenous tranexamic acid for PPH in three trials [220]. This review 
stressed that the evidence of tranexamic acid use for reducing blood loss in PPH was 
weak, as the studies included were not randomised or blinded to bias. A French 
randomised controlled trial administering high dose tranexamic acid to women with 
PPH > 800 mL demonstrated a significant reduction in blood loss over six hours (173 
mL versus 221 mL, p = 0.04), shorter duration of bleeding and reduction in 
progression to severe bleeding in the treatment group compared to controls [221]. The 
World Maternal Antifibrinolytic (WOMAN) trial is a large multinational trial that is 
currently ongoing to evaluate the efficacy and safety of tranexamic acid use in PPH 
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[222]. An extended course of tranexamic acid is recommended in women with VWD 
with low baseline factor levels, as these are likely to decrease rapidly after delivery, 
resulting in secondary PPH [167] 
 
Tranexamic acid can be given orally (15-25 mg kg-1 tds), intravenously (10 mg kg-1 
tds), or specifically for dental and oral cavity bleeding as a mouthwash (10 mL of a 
5% v/w solution qds). The adverse effects of tranexamic acid include nausea, 
vomiting and gastrointestinal upset, especially during prolonged durations of 
treatment. Rapid intravenous infusion can result in dizziness and hypotension. 
Tranexamic acid should be used with caution in patients with a previous history of 
thromboembolism, and is currently contraindicated in the UK in patients with active 
thromboembolic disease [223]. 
 
1-deamino-8-D-arginine (DDAVP) 
DDAVP is a synthetic vasopressin analogue that enhances endogenous levels of VWF 
and FVIII [224]. Despite the extensive clinical use of DDAVP as a haemostatic agent 
the cellular mechanism of action is not fully understood. DDAVP induces a release in 
VWF stores in endothelial Weibel-Palade bodies and tissue plasminogen activator (t-
PA), which subsequently stabilises plasma FVIII levels [225]. However, in patients 
with type 2N VWD, where there is a decreased affinity of VWF for FVIII, DDAVP 
also induces a rise in FVIII concentration. This indicates that DDAVP induces a 
direct release from FVIII storage pools [226]. Recent experimental models have 
proven the source of FVIII to be predominantly derived from endothelial cells in the 
liver and elsewhere throughout the circulation [227, 228].  
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DDAVP can be administered by slow intravenous or subcutaneous infusion  (0.3 µg 
kg-1 over 20 mins), or via intranasal spray (300 µg). Typically the effect of one 
metered-dose intranasal spray, which can be easily administered at home, is 
comparable to that of a 0.2 µg kg-1 intravenous injection and sufficient to induce the 
required haemostatic effect [229]. The side effects of DDAVP are attributed to the 
vasodilatory effect and include mild tachycardia, headache and flushing. 
Hyponatraemia and volume overload due to the antidiuretic effect of DDAVP are 
rarely encountered. The risk is greater in patients receiving multiple doses, and can be 
minimised by fluid restriction at the time of treatment [230]. 
 
DDAVP is usually very effective at inducing an increase in VWF and FVIII levels in 
patients with type 1 VWD. It has no therapeutic benefit in type 3 VWD. In types 2A 
and 2M VWD, DDAVP enhances the levels of abnormal VWF and has a variable 
clinical effect. A trial of DDAVP administration to measure the response is 
recommended in these patients. DDAVP can be used in patients with type 2N VWD, 
but the short half-life of the FVIII response makes this of limited therapeutic benefit. 
The use of DDAVP in patients with type 2B VWD is controversial as the abnormal 
VWF with an increased affinity for GPIb may induce platelet aggregation and 
thrombocytopaenia [20, 231].  
 
DDAVP can be used with caution during pregnancy but prolonged administration is 
not recommended due to the risk of fluid retention and should be avoided in 
pregnancies complicated by pre-eclampsia. DDAVP has a greater affinity for V2 
receptors and therefore has little if any oxytocic effect. It should be used with caution 
in women receiving a synthetic oxytocin infusion (Synotocinon®) to induce or 
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augment labour. A systematic review reported on the safe and efficacious use of 
DDAVP for prophylaxis during invasive procedures carried out during the first and 
second trimester in 50 pregnancies [232]. In addition, there were no postpartum 
bleeding complications in 167 out of 172 pregnancies where DDAVP was 
administered. One case of water intoxication was reported and one case of premature 
delivery in all 216 pregnancies in 30 studies of DDAVP use in pregnancy. VWD was 
the most common indication for DDAVP use. 
 
Blood products 
A plasma-derived concentrate containing VWF is the optimum treatment when 
DDAVP is not effective or contraindicated. There are various concentrates available 
that have different ratio of VWF/FVIII. The dose and duration of treatment is 
dependent on the haemostatic challenge. The most commonly used blood products 
that are licenced in the UK are Haemate-P®, and Alphanate SD/HT®. Haemate-P is a 
lyophilised, intermediate-purity concentrate that contains a similar quantity of VWF 
HMW multimers compared to normal plasma. The concentrate contains 
approximately 2.5 IU of VWF:Ag for every FVIII:C [233]. Its efficacy has been rated 
as good to excellent at achieving haemostasis in VWD patients with acute bleeding or 
for surgical prophylaxis [234]. Alphanate SD/HT® is a high-purity, lyophilised 
concentrate of VWF and FVIII and other plasma proteins. The concentrate contains 
approximately 0.6 IU VWF:Ag for each unit of FVIII:C [235]. A multicentre 
prospective study in 81 patients with VWD demonstrated adequate haemostasis for 
surgical interventions with Alphanate SD/HT® usage. The concentrate effectively 
stopped active bleeding in most cases following administration of one or two doses, 
even when the bleeding time was not adequately corrected [235]. Although 
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VWF:RCo and FVIII levels required for haemostasis in VWD patients have not been 
established in clinical trials. The general consensus however, is that VWF:RCo and 
FVIII should be raised above 50 IU/dl for delivery and for at least 3-5 days 
postpartum, or until haemostasis and wound healing is achieved [236]. Sustained high 
levels of FVIII increases the risk of venous thromboembolism (VTE) therefore when 
repeated infusions of VWF:FVIII concentrates are necessary, the FVIII:C levels 
should be monitored daily to avoid excess of 150 IU/dL [237-239]. In addition to the 
pregnancy induced hypercoagulable state there may be other VTE risk factors such as 
surgery or immobility [237]. Wilfactin® is a highly purified VWF concentrate 
containing very little FVIII. Combined data from various clinical trials assessing the 
efficacy of Wilfactin® have shown excellent or good haemostasis control in 89% of 
patients with spontaneous bleeding [29]. Wilfactin® is therefore considered safer in 
pregnant women with hormonally induced enhanced FVIII levels who require VWF 
replacement. Other adverse symptoms of plasma product usage include allergic 
reactions and anaphylaxis, chest tightness, urticaria, prutitis and oedema. 
 
Carriers of haemophilia 
The risk of bleeding at delivery in carriers of haemophilia correlates well with FVIII 
and FIX levels, which should be assessed during the third trimester of pregnancy. 
This is especially important in women with low pre-conceptual (baseline) factor 
levels. Carriers with factor levels < 50 IU/dL at term require appropriate haemostatic 
cover. 
 
The treatment of symptomatic haemophilia carriers is dependent on baseline factor 
levels, the presenting bleeding complaint and/or haemostatic challenge anticipated. In 
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the majority of circumstances tranexamic acid are sufficient to prevent bleeding in 
carriers of haemophilia with mildly reduced factor levels (50-60 IU/dL). DDAVP is 
used in carriers of haemophilia A with moderately reduced (40-50 IU/dL) factor 
levels. Usually only one or two intravenous administrations provide sufficient cover 
during labour, and tranexamic acid can be continued thereafter. DDVAP has no effect 
on FIX levels therefore cannot be used in the treatment of haemophilia B. 
 
Factor concentrates are reserved for the treatment of haemophilia carriers who do not 
respond to DDAVP and have factor levels < 50 IU/dL at term. Recombinant factor 
products (rFVIII and rFIX) are the treatment of choice if available. FVIII and FIX 
levels should be maintained at > 50 IU/dL for three days after delivery. An extended 
course of tranexamic acid is recommended in carriers with low baseline factor levels, 
as these are likely to decrease rapidly after delivery, resulting in secondary PPH 
[207]. 
 
Factor XI deficiency 
Factor XI (FXI) deficiency poses a particular problem for the obstetrician as the 
bleeding phenotype is highly variable and does not correlate well with the underlying 
FXI level. An early cohort study of bleeding tendency yielded an odds ratio (OR) of 
13 (95% CI, 3.8-45) in homozygotes or compound heterozygotes, and of 2.6 (95% CI, 
0.8-9.0) in heterozygotes [81]. However, excessive bleeding has been well 
documented in heterozygotes with borderline FXI level between 50-70 IU/dL [39, 
54].  
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Criteria have been suggested, based on personal bleeding history, to categorise 
patients with FXI deficiency into ‘bleeders’ and non-bleeders’ (Table 2.8). Two 
haematologists with expertise in haemostasis independently obtained a bleeding 
history in 172 patients with FXI deficiency, and any patient with 2 ≥ positive criteria 
were described as ‘bleeders’. In addition, they evaluated FXI deficient patients for co-
inheritance of von Willebrand disease (VWD). Patients with blood group O had a 
lower von Willebrand factor (VWF) level, and an increase in bleeding symptoms 
[54].  
 
Bleeding tendency in relation to genotype has also been assessed. In a cohort study 
including 52 patients with severe FXI deficiency, the mean number of injury or 
surgical related bleeding was significantly higher in patients with the II/II genotype 
(1.6 ± 2.4) versus patients with a II/III (1.4 ± 1.5) or a III/III (1.0 ± 1.1) genotype (p < 
0.05 for both comparisons) [40]. In contrast, another study found no difference in 
bleeding tendency in relation to genotype. Twenty patients who were compound 
heterozygotes for the type II mutation were compared with 41 partially deficient 
patients with an unknown mutation [54]. Approximately half the patients in each 
group were classified as ‘bleeders’; 45% in compound heterozygotes compared with 
49% in patients with an unknown mutation. In a study by Salomon et al the type II/III 
mutation was reported to be associated with the highest frequency (12%) of PPH 
among women with severe FXI deficiency [211]. This genotype was associated with a 
mean FXI level of 20 IU/dL. The frequency of PPH was lowest (2%) in women with 
type II/II mutation, where the mean FXI level was 60 IU/dL. However, the difference 
in frequency of PPH between the groups did not reach statistical significance (p = 
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0.24), and there was no statistical correlation between PPH and FXI level (p = 0.46) 
[211].   
 
Lately there has been a growing interest in using thrombin generation studies to 
distinguish bleeding risk in FXI deficient patients. Low velocity and delayed 
thrombin generation suggests a higher bleeding tendency, independent of FXI level 
[240]. Thrombin generation induced by recalcification is able to distinguish between 
bleeding and non-bleeding phenotype in patients with severe FXI deficiency [241]. In 
a study including 24 patients with both mild and severe FXI deficiency, those 
exhibiting severe bleeding tendency had markedly impaired thrombin generation. The 
opposite was also demonstrated in that patients with severe deficiency (FXI level = 1 
IU/dL) and normal thrombin generation had a non-bleeding phenotype [240]. Clot 
structure and stability has also been analysed in patients with severe FXI deficiency to 
distinguish bleeding tendency. Symptomatic ‘bleeders’ were found to exhibit a lower 
fibrin network density and clot stability compared with asymptomatic ‘non-bleeders’ 
[242].  
 
Personal bleeding history, factor level, the presence of any co-inherited VWD, blood 
group and the nature of the haemostatic challenge should be taken into account when 
determining the need for therapy. Relying on FXI levels alone may result in 
inappropriate assessment of the bleeding risk and overuse of plasma products, which 
are associated with a risk of thromboembolic complications, and the potential for viral 
transmission. In addition, regional anaesthesia may be withheld in a woman with FXI 
deficiency due to concerns over bleeding complications resulting in spinal injury. Part 
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of this thesis aims to assess the role of rotational thromboelastometry (ROTEM®) in 
assessment of bleeding tendency in pregnant patients with FXI deficiency. 
 
Table 2.8 Criteria to assess bleeding tendency in patients with FXI deficiency [54]  
 
1. Bruising tendency 
2. Mucous membrane bleeding; epistaxis; GI; haematuria 
3. Menstrual bleeding: Requiring treatment – OCP; TXA; surgical procedure 
4. Bleeding post surgery 
5. Bleeding post dental extractions(s) 
6. Bleeding in relation to parturition 
 
GI; gastrointestinal, OCP; oral contraceptive pill, TXA; tranexamic acid 
Criteria to classify as ‘bleeder’; requires presence of 2 out of 6 bleeding symptoms on 
assessment by haematologist with expertise in haemostasis 
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Current treatment options for FXI deficiency at delivery include FXI concentrates, 
fresh frozen plasma (FFP), recombinant factor VIIa (rFVIIa) or antifibrinolytic agents 
such as tranexamic acid. In the majority of patients with mild heterozygous FXI 
deficiency, tranexamic acid is sufficient to prevent bleeding. The combined use of 
tranexamic acid with FXI concentrates or rFVIIa is not recommended due to the 
increased risk of thromboembolism. A course of oral tranexamic acid can be 
administered in the postnatal period, 14-48 hours following blood product 
administration. 
 
Only a plasma-derived FXI concentrate is currently licenced for use in the UK 
(Hemoleven®, LPB, Lille, France). Even though the risk of viral transmission is 
negligible with modern inactivation processes, viruses can still be present in 
commercial blood derivatives and the transmission rates of prion disease are unknown 
[243]. FXI concentrates have a considerable thrombotic potential and should be 
administered with caution in pregnancy [244, 245]. Due to the thrombotic risk 
associated with FXI concentrates, treatment should be initiated with caution, and 
avoided if possible in older patients with a history of cerebrovascular disease. The 
target plasma FXI level should ideally be in the lower end of normal range (60-70 
IU/dL) with avoidance of peak FXI levels >70 IU/dL.  
 
The disadvantages with FFP administration are due to the larger volumes required 
which increase risk of volume overload and take longer to infuse. In addition there is 
potential for serious hypersensitivity reactions (i.e. transfusion related acute lung 
injury [TRALI]) [246].  
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Low dose rFVIIa, previously used as a bypassing agent for patients with FXI 
deficiency with inhibitors, is now an established treatment for patients without 
inhibitors who wish to avoid plasma-derived products. However, high levels of FVII 
activity have been reported following rFVIIa administration resulting in thrombotic 
complications [247, 248].  
  
Platelet function disorders 
Predicting bleeding risk can be challenging in patients with platelet function 
disorders. Bleeding occurs following surgery therefore MOD is an important 
consideration. However, bleeding does not occur with every haemostatic challenge. 
Women with severe PFDs should be managed in a tertiary unit affiliated with a 
haemophilia centre where the relevant expertise and access to platelets and blood 
products are available. The options for haemostatic prophylaxis are DDAVP, 
tranexamic acid, rFVIIa and platelet transfusion. Platelet transfusion should be 
avoided where possible due to the associated risk of alloantibody formation [57, 249].  
 
There is limited data on patients with mild PFD, such as storage pool disease, 
signalling defects or ADP receptor abnormality. DDAVP and tranexamic acid only 
are usually sufficient to prevent bleeding at delivery in these women [212]. 
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2.3.8 Mode of delivery and cranial bleeding 
 
Special consideration should be given to reduce the bleeding risk in a potentially 
affected fetus. It is recommended that women with a severe IBD have a 
multidisciplinary management plan drawn up in advance of labour, and delivery 
should be at a centre affiliated with a haemophilia laboratory with readily available 
factor concentrates [250]. If the woman is carrier of a severe condition with a 
potentially affected fetus this is also recommended to minimise the risk of bleeding 
complications in the offspring. During labour, invasive procedures such as fetal blood 
sampling or fetal scalp electrode monitoring should be avoided where possible. 
 
The most serious bleeding complication that can arise in the affected offspring is 
cranial bleeding during labour and delivery. Intracranial haemorrhage (ICH), defined 
as an accumulation of blood within the cranial vault, can result in serious long-term 
neurological sequelae or death. Extracranial haemorrhage (ECH), defined as 
haemorrhage or haematoma that occurs outside the cranial vault, can be rapid and 
result in life threatening hypovolaemia, due to persistent bleeding into the subgaleal 
space. In the general population the risk of cranial bleeding is increased with assisted 
deliveries and prolonged labour. Planned caesarean section (CS) is associated with the 
lowest risk [251]. The safest MOD for fetuses at risk of IBDs is still debated. There is 
limited data available from prospective studies on the risk of cranial bleeding 
according to MOD in newborns with IBDs.   
 
Prenatal diagnosis and multidisciplinary management have potential to reduce the risk 
of cranial bleeding in deliveries where an affected offspring is anticipated. Chapter 
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6.2 summaries the available literature on the risk of cranial bleeding in newborns with 
haemophilia compared to the general newborn population. A meta-analysis is 
presented to determine the effect of MOD on rates of ICH in newborns with 
haemophilia. 
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2.4 The neonate and inherited bleeding disorders 
 
2.5.1  Neonatal haemostasis  
 
The haemostatic system develops with age and is an evolving process in the fetus and 
neonate. The capacity of newborns to generate thrombin is reduced at birth due to a 
physiological reduction in vitamin K-dependent coagulation factors (FII, FVII, FIX 
and FX) and contact factors (FXI, FXII, prekallikrein and high molecular weight 
kinnogen) that are about 50% of the normal adult range [252]. The reduction in 
procoagulant factors in neonates may be the result of decreased production, 
accelerated renal clearance, or consumption due to angiogenesis and inflammation. 
Therefore the deficiencies of prematurity are further exacerbated by sepsis and 
asphyxia [253]. 
 
The risk of bleeding secondary to reduced coagulation factors is counterbalanced by a 
physiological deficiency in natural anticoagulants (protein C and antithrombin) and 
coagulation inhibitors (tissue plasminogen activator inhibitor) as well as a reduction 
in fibrinolysis [254]. Consequently, in the healthy term infant the haemostatic system 
is sufficiently balanced for appropriate clot formation and haemostasis. 
 
Platelet number and volume are relatively similar to adult ranges in the neonate. 
There is a reduction of platelet surface glycoproteins, resulting in a reduced response 
to agonists and granule secretion. However reduced platelet function is not observed 
in the neonate, which may be explained by a compensatory increase in plasma 
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concentrations of VWF levels and a greater percentage of large VWF multimers [254, 
255].  
 
2.5.2 Bleeding manifestations in the neonate with IBD 
 
The pattern of bleeding in the neonate is decidedly different from that of an older 
child or adult with an IBD. Bleeding in the neonatal period was thought to be a rare 
event, however more recent studies suggest that 15-33% of newborns with IBDs 
present with bleeding manifestations during the first few weeks of life [256]. Birth 
trauma can result in cranial bleeding that remains a major cause of mortality and 
morbidity in this group. Cranial bleeding in relation to labour and deliver is the most 
serious bleeding manifestation in the neonate with an IBD, because it has potential to 
be life threatening or to cause life-long neurological morbidity. This is covered in 
detail in Chapter 6. 
 
A significant proportion of bleeding manifestations in the neonate are iatrogenic, 
caused by intramuscular injections for vitamin K administration, heel prick, 
venepuncture, and procedures such as circumcision. In a study conducted in the US 
that assessed the sites of initial bleeding episodes in the first 30 days of life in 207 
infants with haemophilia, 135 (65%) were due to iatrogenic causes [256]. The 
majority of these bleeding events occurred in infants with no previous family history 
of haemophilia. Prolonged umbilical stump bleeding is characteristic of an inherited 
defect in fibrinogen production or function and FXIII deficiency.    
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CHAPTER 3 
LABORATORY INVESTIGATIONS OF HAEMOSTASIS  
 
3.1 Routine coagulation tests and factor assays 
3.2 Platelet light transmission aggregometry 
3.3 Rotational thromboelastometry 
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3.1 Routine coagulation tests and factor assays 
 
The principle tests of haemostasis are described below with a brief methodology for 
each test. These investigations have been employed throughout this research project 
and each study will refer back to this section when a description is required. 
  
Activated partial thromboplastin time 
The activated partial thromboplastin time (APTT) is the so-called measure of the 
intrinsic and common pathway of coagulation in recalcified citrated plasma. It 
depends upon the mixing of citrated plasma with ‘partial thromboplastin’, a reagent 
that lacks the apoprotein component of complete thromboplastin. Thus this excludes 
the involvement of FVII and tissue factor (TF) of the extrinsic pathway. Theoretically 
APTT should detect deficiencies in coagulation factors II, V, VIII, IX, X, XI, XII and 
fibrinogen, although the sensitivity to fibrinogen deficiency is low. Due to the 
variability in the composition of phospholipids available for reagents there is marked 
variation in the sensitivity of different reagents to coagulation factor levels and 
inhibitors. In addition the performance of APTT can be affected by incubation time, 
type of coagulometer, and type and concentration of activator used to provide a 
surface area for the initiation of coagulation (e.g kaolin or celite). This can produce 
inconsistencies in APTT results in different laboratories [257]. Isolated prolonged 
APTT can occur in the presence of a lupus anticoagulant, which targets the 
phospholipid used to determine APTT. An additional limitation of the APTT is that it 
detects deficiencies in factors XII, prekallikrein and high-molecular weight kininogen 
that are of no clinical significance and prevalent in up to 2% of the population [258]. 
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The principle of APTT measurement uses an automated system to determine the 
optical density that determines the threshold for clot formation. Platelet poor plasma 
(PPP) is incubated at 37°C, the phospholipid (cephalin) and contact activator (kaolin) 
are added followed by calcium (all pre-warmed to 37°C). Addition of calcium 
initiated coagulation and timing begins. The APTT is the time taken from addition of 
calcium to clot formation [259]. 
 
Prothrombin time 
The prothrombin time (PT) assess the extrinsic and common pathways. It measures 
the time for clot formation when TF, thromboplastin and calcium are mixed with 
citrated plasma. The PT should detect deficiencies in FII (prothrombin), factors V, 
VII and X, in addition to very low fibrinogen levels. However, like APTT the PT 
sensitivity is also dependent on reagents used [257]. The international normalised 
ratio (INR) was developed to overcome the reagent-dependent variability for the 
purposes of monitoring patients on oral anticoagulants. Prolongation to PT is seen 
most often in clinical practice as a result of hepatic impairment or nutritional 
deficiency of vitamin K from malabsorption.  
 
The principle of PT measurement uses an automated system to determine the optical 
density that determines the threshold for clot formation. PPP is mixed with TF 
(containing phospholipid) incubated at 37°C. An excess of calcium chloride (25 mM) 
is added to initiate coagulation [259]. 
 
 
  
109 
 
Coagulation factor assays 
The principles of coagulation factor assays rely upon measuring the degree of 
correction of the APTT when plasma is added to a sample specifically deficient in the 
factor to be measured. Coagulation factor assays can be performed by a standardised 
one-stage or two-stage technique or by chromogenic assay. The one-stage assays are 
simple and easy to perform but are limited by susceptibility to interference from 
preactivation of FVIII or anti-phospholipid antibodies and misleading results when 
assaying rFVIII. Two-stage assays require an initial step to produce activated factor X 
(FXa) in a quantity proportional to the amount of factor present that is being 
measured. The chromogenic assay measures the amount of FXa present through its 
action on a highly specific chromogenic substance. FXa is formed by the conversion 
of factor X (FX) by activated FIX and FVIII to cleave a chromogenic substrate. The 
sample is combined into a mixture with activated FXI in the presence of factor IIa 
(thrombin), incubated, combined with FX and FVIII, and incubated [260]. The colour 
intensity produced is directly proportional to the amount of FXa, which in turn is 
directly proportional to the amount of factor present. The factor levels can be 
calculated from absorbance of the sample at the specific wavelength [259]. In this 
thesis FVIII, FIX, and FXI were assayed on thawed PPP by one-stage clotting 
methods as described above. FXIII antigen levels were measured using a FXIII 
ELISA assay [Affinity Biologicals, Quadratech Diagnostics Ltd, UK]. 
 
Von Willebrand factor assays 
A summary of the VWF assays used to help distinguish the different type and 
subtypes of VWD are given in Table 3.1 
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Table 3.1 Summary of von Willebrand factor assays 
 
Designation	   Abbreviation	   Summary	  
von	  Willebrand	  Factor	  
Ristocetin	  Cofactor	  Activity	  
VWF:RCo	   A	  functional	  assay	  of	  plasma	  VWF	  based	  upon	  the	  
degree	  of	  platelet	  agglutination	  induced	  after	  the	  
addition	  of	  ristocetin	  
	  
von	  Willebrand	  Factor	  
Collagen	  Binding	  Activity	  
VWF:CB	   A	  functional	  assay	  of	  plasma	  VWF	  that	  quantifies	  the	  
ability	  of	  VWF	  to	  bind	  collagen	  coated	  ELISA	  plates	  
	  
von	  Willebrand	  Activity	   VWF:Ac	   A	  functional	  assay	  of	  plasma	  VWF	  that	  uses	  
monocloncal	  antibody	  that	  targets	  the	  part	  of	  VWF	  
molecule	  that	  binds	  to	  GP1b	  receptor.	  Usually	  reduced	  
in	  all	  types	  of	  VWD.	  Most	  sensitive	  assay	  used	  for	  
screening	  purposes	  
	  
von	  Willebrand	  Factor	  
Antigen	  
VWF:Ag	   An	  immunological	  assay	  that	  quantifies	  the	  amount	  
rather	  than	  the	  function	  of	  VWF	  in	  plasma.	  Usually	  
reduced	  in	  type	  1	  VWD,	  and	  absent	  in	  type	  3	  VWD	  
	  
Factor	  VIII	   FVIII	   A	  clotting	  factor	  that	  acts	  as	  a	  cofactor	  in	  the	  formation	  
of	  Xase	  ‘Tenase’	  complex	  
	  
Factor	  VIII	  activity	   FVIII:C	   A	  functional	  assay	  of	  FVIII	  coagulant	  activity	  
	  
Ristocetin-­‐Induced	  Platelet	  
Aggregation	  
RIPA	   A	  test	  that	  measures	  the	  ability	  of	  VWF	  to	  bind	  to	  
platelets	  
ELISA, enzyme-linked immunosorbent assay; GP1b, glycoprotein 1B 
 
The ratios of VWF assays can help to distinguish the types, and subtypes of VWD. 
For example, a VWF Ristocetin Cofactor activity (VWF:RCo) to VWF antigen 
(VWF:Ag) ration <0.7 suggests a dysfunctional VWF which differentiates type 2A, 
2B and 2M VWD from type 1 VWD. The ratio of VWF Collagen Binding activity 
(VWF:CB) to VWF:Ag helps to distinguish the different subtypes of type 2 VWD. In 
VWD type 2A the ratio is usually low. In VWD type 2B the ratio is usually low but 
can be normal. In VWD type 2M the ratio is usually <0.7.  
 
Specialised laboratory tests for VWD include FVIII binding studies that are of value 
in diagnosis of VWD type 2N, and Ristocetin Induced Platelet Agglutination (RIPA) 
which is of value in distinguishing VWD type 2B. In addition a VWF multimeric 
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analysis is a qualitative assay that depicts the variable concentrations of different 
sized multimers [259]. 
 
3.2 Platelet light transmission aggregometry 
 
Principles of LTA 
The gold standard for ex vivo measurement of platelet reactivity is light transmission 
aggregometry (LTA) on platelet rich plasma (PRP). There is an increase in light 
transmission as platelets aggregate in response to an agonist, which is recorded over a 
predetermined time.  
 
Prior to aggregation testing 
Platelets are separated from white and red cells by centrifugation at 150 x g for 12 
minutes at room temperature to make a platelet suspension in plasma. The supernatant 
PRP is transferred into a 10 mL capped tube (D10 plastic tube) avoiding red cells or 
the buffy coat layer disturbance. The PRP samples are held at room temperature 
undisturbed for at least 30 minutes prior to testing. The prepared PRP samples are 
checked visually for haemolysis and/or red cell contamination, in which case these 
samples are discarded. The aggregation test was completed within four hours of 
venous blood collection. After removing the PRP, the original tubes are centrifuged 
again at 450 x g for 15 minutes and then the supernatant poor platelet plasma (PPP) is 
transferred into a 5 mL capped tube, avoiding contamination with buffy coat residues 
[261]. Prior to the LTA, platelet count is measured using an aliquot of 0.5 mL PRP on 
a SYSMEX analyser (Sysmex, UK) to ensure platelet count is within appropriate 
range of 100,000µL- 600,000µL. 
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LTA methodology 
Platelet aggregation was carried out using a dual channel Payton aggregometer 600B 
(Payton Associates, Canada). Using 10 millivolts deflection, the PRP settings were 
0.5 and 5.5 millivolts for channel one and two respectively which represent 0% 
aggregation and the corresponding blank value setting using PPP was 4.5 and 9.5 
millivolts for each channel which represent 100% aggregation. The aggregometer was 
turned on and set at 37°C to warm up and stirring speed was set at 9000 rpm.  
 
Prior to LTA a stir bar was deposited into two clean cuvettes containing 360 µL PRP 
and 400 µL PPP. The cuvettes were placed into the incubation wells of the 
aggregometer and heated to 37°C for 3 minutes. The PPP cuvette was placed into 
channel one of the aggregometer and after few seconds the PPP button was set. When 
the PPP light was activated this indicates that the aggregometer calibration for the 
PPP sample was set. The PPP cuvettes were replaced with PRP cuvettes and the PRP 
button on the aggregometer is pushed. After a few seconds, the PRP button lights up 
indicating that the machine was calibrated for the PRP sample. These steps are 
repeated for channel two. The aggregometer pen for channel one was at 45% of full 
scale of the chart sheet and for channel two was at 95% of the full scale. The chart 
speed was 1cm/min and the chart drive was switched on. The pen was lowered to the 
baseline trace for 2 minutes. 
 
To obtain an aggregation curve, 40 µL of working reagent was added to the PRP 
sample. The aggregation trace was monitored by a chart recorder. PRP optical density 
and percentage of aggregation was recorded at 3 and 5 minutes on a work sheet for 
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both ADP and epinephrine and at 3 minutes for collagen, ristocetin, arachidonic acid 
and U46619. The optical density (light transmission) was measured using work sheet 
small squares. The maximum number of small squares reached by platelet 
aggregation curve over a fixed period of time was converted to percentage using a 
platelet aggregation conversion table. The parameters recorded while monitoring the 
aggregation curve for each agonist included lag phase, shape change, maximal 
aggregation amplitude, primary and secondary aggregation phase, disaggregation and 
delay response [262]. Usually with weak aggregation agonists (ADP and epinephrine) 
there would be biphasic aggregation curve (primary and secondary waves) whilst with 
strong agonists like collagen, ristocetin, arachidonic acid and U46619 only a single 
aggregation phase was seen. The minimum final aggregation cut off was considered 
to be 65% for all used reagents apart from ristocetin 0.5 mg/mL, which was less than 
10%. 
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3.3 Rotational thromboelastometry 
 
Thromboelastometry measures the viscoelasticity during blood clot formation. The 
resistance measured is quantified by computer software that produces the 
thromboelastogram. The method was first developed by Hartert over 50 years ago 
[263]. Two commercially available devices for performing thromboelastometry are 
TEG (Thromboelastograph; Haemoscope/Haemotinics, Nils, Ill) and ROTEM® 
(Rotational thromboelastometry; TEM International, Munich, Germany). The TEG 
system has been in use particularly in the United States for many years. 
 
Point-of-care devices such as ROTEM®/TEG are predominantly used to guide 
transfusion during cardiac and hepatic surgery or major haemorrhage. 
Thromboelastometry is used to estimate clot formation, thrombin generation, 
fibrinogen levels, platelet function, and clot dissolution by fibrinolysis [264]. It 
provides information regarding the interactions of coagulation factors during the 
different phases of coagulation and lysis over time. 
 
Principles of thromboelastometry 
A sample of citrated whole blood is placed into a cuvette into which a cylindrical pin 
is immersed. A gap of 1mm exists between the pin and cuvette, which is bridged by 
blood. In the TEG system, a disposable cup moves back and forth through an arc of 
4.75 degrees around a fixed plastic pin. In case of ROTEM®, the plastic pin rotates 
back and forth through an angle of 4.75 degrees in the centre of the plastic cup. 
During clot formation, fibrin strands are formed, increasing the torque between the 
pin and the cup. During clot retraction, dissociation of fibrin strands and degradation 
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of fibrin by fibrinolysis reduces the torque [265]. The change in torque is detected by 
a strain gauge, which converts the output into a signal, which is delivered to a 
computer where it is processed by proprietary software, into a trace (Fig 3.1). 
 
Figure 3.1 Rotational thromboelastogram (reproduced from http://www.rotem.de) 
 
 
Figure removed due to copyright restrictions 
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ROTEM® is used with specific assays to measure different aspects of coagulation. 
EXTEM uses tissue factor as an activator of the extrinsic pathway; INTEM uses 
ellagic acid/phospholipids for contact activation. The HEPTEM is a modified version 
of INTEM that includes a heparin-degrading enzyme. FIBTEM assesses the extent of 
fibrin polymerisation by inhibiting platelet function with cytochalasin-D after tissue 
factor activations [266]. NATEM is without an added activator or inhibitor and 
although it takes longer to perform it is highly sensitive to the equilibrium of 
coagulation. 
 
ROTEM® assays can detect changes in coagulation including hypo and 
hypercoagulation and hyperfibrinolysis [267]. Clotting Time (CT) is representative of 
clot initiation and clot formation time (CFT) and alpha angle are representative of clot 
consolidation. Maximum Clot Firmness (MCF) is an indication of clot strength and 
the Lysis Index in 60 minutes (LI 60) and Maximal Lysis (ML) are representative of 
clot dissolution (Table 3.2). 
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Table 3.2 ROTEM® parameters (reproduced from http://www.rotem.de) 
Curve	  parameter	   Definition	  
	  
Clotting	  time	  (CT)	  in	  seconds	  
	  
	  
The	  period	  of	  time	  from	  the	  start	  of	  the	  measurement	  until	  a	  2	  mm	  
amplitude	  occurs	  
	  
Clot	  formation	  time	  (CFT)	  in	  
seconds	  
	  
The	  period	  of	  time	  in	  seconds	  starting	  from	  an	  amplitude	  of	  2	  mm	  
(CT)	  until	  an	  amplitude	  20	  mm	  is	  reached	  
Alpha	  angle	  in	  degrees	  
	  
The	  angle	  between	  the	  centre	  line	  and	  a	  tangent	  to	  the	  curve	  
through	  2	  mm	  amplitude	  point	  
	  
Maximum	  clot	  firmness	  (MCF)	  
in	  millimetres	  
	  
The	  maximal	  amplitude	  of	  clot	  firmness	  during	  60	  minutes	  
Lysis	  index	  at	  60	  minutes	  (LI	  60)	  
in	  percentage	  
	  
The	  percentage	  of	  maximum	  clot	  strength	  present	  at	  60	  minutes	  	  
Maximum	  lysis	  (ML)	   The	  percentage	  of	  lost	  clot	  stability	  (relative	  to	  MCF)	  at	  60	  minutes	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4.1 Introduction 
 
Endometriosis is a complex gynaecological condition that affects around 5% of 
women of reproductive age. It is characterised by the presence and growth of ectopic 
endometrial tissue outside of the uterus resulting in dysmenorrhoea, dyspareunia, and 
subfertility. The chronicity of the condition has a significant impact on women’s lives 
including work, social functioning and sexual relationships.  
  
The formation of endometriotic lesions depends on attachment and invasion at ectopic 
sites. This may be due to abnormalities of the eutopic endometrium itself, 
predisposing the cells to survive and implant ectopically [268]. Endometriosis 
deposits continue to be under hormonal regulation and as such still undergo monthly 
proliferation, differentiation and shedding [268]. The pain resulting from 
endometriosis is cyclical suggesting there is localised internal bleeding within or 
around the endometrial deposits. Endometriomas or ‘chocolate cysts of the ovary’, 
arise due to repeated haemorrhage into ovarian tissue. The cyst contents contain a 
dark, gelatinous material that is high in iron content and indicative of chronic 
bleeding [269]. 
 
The aim of this study was to assess whether laboratory abnormalities of haemostasis 
are increased in women with endometriosis, which may in turn be implicated as part 
of the pathogenesis of endometriosis. In addition the correlation between symptom 
severity, stage of disease and a bleeding tendency is investigated.  
 
  
120 
 
4.2 Materials and methods 
 
The study was conducted from July 2013 until July 2014 at the Royal Free Hospital, 
north London.  
 
4.2.1 Study population 
 
Case participants were identified through a local hospital database that provided 
diagnostic information regarding laparoscopic procedures. Women aged 18-55 years 
with a surgically confirmed diagnosis of endometriosis were invited to attend the 
Royal Free Hospital for an interview and laboratory investigations of haemostasis. 
Participants were excluded if they had a known IBD such as VWD, PFD, carriers of 
haemophilia or other rare factor deficiency. Age-matched female control subjects 
were staff members recruited from the Royal Free Hospital without a diagnosis of 
endometriosis, or symptoms suggestive of the condition. Control subjects were 
matched, as far as possible, in ethnicity, blood group, and smoking status. Participants 
were only included if they were willing to abstain from taking medication that 
interfered with platelet function for seven days prior to laboratory testing. In addition 
they were asked to avoid herbal preparations, caffeine, and excessive exercise on the 
day of testing. Participants found to have abnormal results were invited back for 
repeat testing and consultation with a specialist in haemostasis. 
 
Participants meeting the inclusion criteria were asked to complete the Pain Impact 
Questionnaire (PIQ-6) (Appendix 2), a six question health survey designed to 
subjectively measure severity and impact of pain on an individual’s functional health 
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and wellbeing [270]. Each participant completed a pictorial blood assessment chart 
(PBAC) to semi-objectively quantify menstrual blood loss [68]. The stage of 
endometriosis was recorded according to laparoscopic findings where documented. 
The revised American Society for Reproductive Medicine (rASRM) classification 
system was used to define disease severity (Fig 2.2) [271].  
 
4.2.2 Laboratory methods 
 
A sample of 30 mL venous blood was collected from each participant using a 19-
gauge butterfly with minimal occlusion of the antecubital fossa vein into blood 
collection tubes containing 106 mol/L sodium citrate [Sarstedt monovettes, Sarstedt, 
Leicester, UK].  Samples were analysed within 30 minutes of collection. Please refer 
to Chapter 3.1 Coagulation tests and factor assays, and Chapter 3.2 Platelet light 
transmission aggregometry for laboratory methods used in this study. 
 
4.2.3 Statistical analysis 
 
Student’s t test was used to assess difference in age, and mean haemostatic variables 
between cases and controls. Chi squared or Fisher’s exact test was used to compare 
nominal demographic data, frequency of factor deficiencies, and abnormal platelet 
aggregation responses between cases and controls. Multiple logistic regression 
analysis was used to determine if there were any correlation between PIQ-6 score, 
PBAC score and haemostatic variables. Ordinal data (laparoscopic stages), PIQ-6 
score and haemostatic variables were analysed by Spearman’s Rho test. All statistical 
tests were carried out using SPPS version 22.0. 
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3.3 Results  
 
A total of 84 women with a surgical diagnosis of endometriosis were recruited in the 
case group. Three women were excluded from the final analysis as they had a 
previously confirmed diagnosis of IBD. Thirty asymptomatic women without a 
diagnosis of endometriosis were recruited as controls. There was no significant 
difference in age, ethnicity, blood group O, or smoking status between cases and 
controls (Table 4.1).  
 
The primary indication for undergoing laparoscopy in women with endometriosis 
was: 51/81 (63%) for dysmenorrhoea/pelvic pain, 10/81 (12%) for subfertility, 8/51 
(10%) for ovarian cysts, and 6/81 (7%) for abnormal menstrual bleeding. Seven 
women (8.6%) had undergone hysterectomy for treatment of endometriosis. rASRM 
laparoscopic staging was available for 65 case participants and were distributed as 
follows: 18 (28%) women with stage I, 15 (23%) women with stage II, 14 (22%) 
women with stage III, and 18 (28%) with stage IV endometriosis.  
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Table 4.1 Baseline characteristics of cases and controls 
 
    
Characteristic Cases (n = 81) 
N (%) 
Controls (n = 30) 
N (%) 
P value 
    
Median age (range) 39  (22-55) 35 (23-53) 0.174 
Ethnicity     
    White 57 (70) 22 (73) 0.742 
    Black  4   (5) 1   (7) 1.00* 
    Asian 20 (25) 7   (23) 0.716 
Smoking status    
    Current smoker 4   (5) 1   (3.3) 1.00* 
    Non smoker 77 (85) 29 (97) 1.00* 
Blood group ‘O’** 19/42 (45) 6/12 (50) 0.972 
    
 
p value determined by Chi squared test for parametetric data (frequency > 5) or 
Fisher’s exact test (*) for non-parametric data (frequency < 5). Missing data (**) 
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There were significantly more defects of platelet aggregation with one agonist among 
the women with endometriosis compared to the control group (31% versus 4%, p = 
0.005). A significantly higher frequency of abnormal platelet aggregation response to 
epinephrine was detected in women with endometriosis compared to controls (25% 
versus 4%, p = 0.02) (Table 4.2). In addition, there were significantly more abnormal 
aggregation responses to multiple agonists (≥2) in women with endometriosis (15% 
versus 4%, p < 0.05). Three women (4%) in the endometriosis group were diagnosed 
with a PFD following retesting. Two women had reduced aggregation response to 
weak agonists ADP and epinephrine. Another woman had an inappropriate response 
to ristocetin at low concentration. One woman in the control group had abnormal 
aggregation to multiple agonists, which was normal on repeat testing.  
 
Among the women with endometriosis, two had abnormalities of VWF consistent 
with mild VWD. One woman had both VWF:Ag and VWF:RCo level below 45 IU 
dL-1 and another had a VWF:RCo level below 45 IU dL-1. The woman with low 
VWF:RCo was diagnosed with type 2 VWD, whilst the other woman had normal 
VWF on repeat testing. Among the control group, there was one woman with low 
VWF:Ag and VWF:RCo level, which was normal on repeat testing. Thus the 
frequency of VWF below the laboratory reference range did not differ significantly 
between cases and controls (p = 0.57) (Table 4.3).  
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Table 4.2 Frequency of platelet aggregation abnormalities in cases and controls 
 
 
 Cases 
(n = 81) 
n (%) 
 Controls 
 (n = 30) 
    n (%) 
 
p value 
       
Platelet count  
Mean (± SD) 
 384 
(102) 
  344  
(81) 
0.060 
       
Agonist       
 Adenosine diphosphate 12  (14.8)  1  (3.6) 0.179 
 Epinephrine 20  (24.7)  1 (3.6) 0.023 
 Collagen 3 (3.7)  1 (3.3) 1.000 
 Arachidonic acid 4  (4.9)  0   (0) 0.578 
 Ristocetin 3  (3.7)  0 (0) 0.497 
 U46619 0 (0)  0 (0)  
       
One agonist 25 (30.9)  1 (3.6) 0.005 
Multiple agonists  
(2 or more) 
12 (14.8)  1 (3.6) 0.047 
       
Platelet function disorder 3 (3.7)  0 (0) 0.385 
 
 
p value computed by Fisher’s exact test. Areas highlighted in grey are statistically 
significant (p < 0.05) 
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Table 4.3 Abnormal haemostatic variables  
 
 Reference range Cases (n = 81) Controls (n = 30) p value 
   n (%) Level n (%) Level  
       
Factor XI 
 
70-150 IU dL-1 4 (4.9) 48, 61, 65, 
67, 
1 (3.3) 64 1.000 
Factor XIII 
 
70-175 IU dL-1 5 (6.2) 59, 62, 63, 
64, 66 
3 (10) 64, 65, 67 0.680 
VWF:Ag 
 
45-145 IU dL-1 1 (1.2) 44 1 (3.3) 41 0.566 
VWF:RCo 
 
45-145 IU dL-1 2 (2.4) 38, 27 1 (3.3) 39 1.000 
 
p value computed by Fisher’s exact test 
VWF:Ag, von willebrand factor antigen; VWF:RCo, von willebrand factor ristocetin 
cofactor activity level 
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Deficiencies in coagulation FXI or FXIII (below the laboratory reference range) were 
detected in both cases and controls (Table 4.3). Four women (5%) with endometriosis 
and one woman (3%) in the control group had FXI level below 70 dL-1. These women 
were tested for the common FXI gene mutations and no abnormalities were detected. 
Similarly, five women (6%) with endometriosis and three women (10%) in the control 
group had FXIII below 70 IU dL-1. The isolated deficiencies in either FXI or FXIII 
levels were between 48-67 IU dL-1 and were thought to represent >2 standard 
deviations from the mean in the general population. No significant differences in the 
frequency of abnormalities were detected between the groups (p = 1.00 and 0.68 for 
FXI and FXIII, respectively).  
 
Overall no significant difference was detected in the mean haemostatic variables 
between women with endometriosis and controls (Table 4.4). The only haemostatic 
variable that approached clinical significance (p = 0.06) was difference in mean 
platelet count (384 x 109/L in cases versus 344 x 109/L in controls).  
 
VWF:RCo level demonstrated a significant downward trend with increasing rASRM 
stage (r = -0.35, p = 0.01) (Fig 4.1). Five women out of 18 with severe endometriosis 
had a VWF:RCo level < 50 IU dL-1 (two women had VWF:RCo level below the 
laboratory reference range of 45 IU dL-1). Patients with severe (stage IV) 
endometriosis (n = 18) had a significantly reduced mean VWF:RCo level compared to 
controls (60 IU dL-1 in severe cases versus 77 IU dL-1 in controls, p = 0.02). Patients 
with severe endometriosis had an increased platelet count compared to controls (429 x 
109/L in severe cases versus 344 x 109/L in controls, p = 0.01) (Table  4.5).  
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Figure 4.1 Scatter plot demonstrating the distribution of von Willebrand Factor 
Ristocetin Cofactor activity level (VWF:RCo) according to revised American Society 
For Reproductive Medicine (rASRM) stages of endometriosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
p = 0.012 
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Table 4.4 Difference in haemostatic variables between cases and controls 
 
  
Reference 
range 
 
Cases  
Mean (± SD) 
 
Controls  
Mean (± SD) 
p value 
  (n = 81) 
 
(n = 30) 
 
 
     
PT 9-13.5 secs 11.3 (0.9) 11.3 (0.8) 0.810 
     
INR 0.9-1.2 0.9 (0.1) 1.0 (0.1) 0.362 
     
APTT 28-36 secs 30.9 (3.0) 30.8 (3.0) 0.820 
 
Fibrinogen 
 
1.5-4.0 g L-1 
 
2.6 (0.6) 
 
2.5 (0.5) 
 
0.852 
     
Platelet count 150-450x109/L 384 (102) 344 (81) 0.060 
 
Factor VIII 
 
50-150 IU dL-1 
 
98 (28.0) 
 
97 (30.0) 
 
0.887 
 
Factor IX 
 
50-150 IU dL-1 
 
104 (20.7) 
 
104 (16.6) 
 
0.924 
 
Factor XI 
 
70-150 IU dL-1 
 
91 (14.8) 
 
88 (14.2) 
 
0.563 
 
Factor XIII 
 
70-175 IU dL-1 
 
103 (30.1) 
 
104 (24.3) 
 
0.974 
 
VWF:Ag 
 
45-145 IU dL-1 
 
92 (34.3) 
 
91 (32.6) 
 
0.904 
 
VWF:RCo 
 
45-145 IU dL-1 
 
72 (25.5) 
 
77 (23.1) 
 
0.385 
 
 
p value determined by student’s t test  
PT; prothrombin time, INR; internal normalised ratio, APTT; activated partial 
thromboplastin time, VWF:Ag, von willebrand factor antigen; VWF:RCo, von 
willebrand factor ristocetin cofactor activity level 
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Table 4.5 Difference in haemostatic variables in cases with severe (stage IV) 
endometriosis compared to controls 
 
  
Reference 
range 
 
Severe cases  
Mean (± SD) 
 
Controls  
Mean (± SD) 
p value 
  (n = 18) 
 
(n = 30) 
 
 
     
PT 9-13.5 secs 11.1 (0.6) 11.3 (0.8) 0.285 
     
INR 0.9-1.2 0.9 (0.1) 1.0 (0.1) 0.317 
     
APTT 28-36 secs 31.2 (2.5) 30.8 (3.0) 0.987 
 
Fibrinogen 
 
1.5-4.0 g L-1 
 
2.6 (0.7) 
 
2.5 (0.5) 
 
0.797 
     
Platelet count 150-450x109/L 429 (116) 344 (81) 0.005 
 
Factor VIII 
 
50-150 IU dL-1 
 
93 (25.0) 
 
98 (29.7) 
 
0.569 
 
Factor IX 
 
50-150 IU dL-1 
 
108 (21.8) 
 
103 (16.4) 
 
0.387 
 
Factor XI 
 
70-150 IU dL-1 
 
92 (15.5) 
 
91 (16.2) 
 
0.820 
 
Factor XIII 
 
70-175 IU dL-1 
 
112 (47.7) 
 
104 (24.3) 
 
0.535 
 
VWF:Ag 
 
45-145 IU dL-1 
 
90 (37.9) 
 
88 (30.6) 
 
0.773 
 
VWF:RCo 
 
 
45-145 IU dL-1 
 
60 (18.6) 
 
   77 (22.17)             0.024 
 
 
 
 
p value determined by student’s t test  
PT; prothrombin time, INR; internal normalised ratio, APTT; activated partial 
thromboplastin time, VWF:Ag, von willebrand factor antigen; VWF:RCo, von 
willebrand factor ristocetin cofactor activity level 
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Women with endometriosis had significantly increased mean PBAC score compared 
to controls (319, SD ±366 in case group vs 147, SD ±166 in controls, p = 0.024). No 
statistically significant difference was detected between any haemostatic variable and 
the PBAC score. However, the mean PBAC score was significantly increased in 
women with platelet aggregation defects to one agonist (408, SD ±418, p = 0.021), 
and multiple agonists (489, SD ±589, p = 0.015) compared to the mean PBAC score 
of women without platelet aggregation defects (266, SD ±297).  
 
Platelet count was the only haemostatic variable to demonstrate a weak positive 
correlation with PIQ-6 score in the logistic regression analysis (r2 = 0.031, p = 0.03) 
(Table 4.6). No statistically significant difference was detected between any 
haemostatic variable and the PBAC score. Figure 4.2 shows distribution of PIQ-6 
scores across the rASRM laparoscopic stages. No significant trend in PIQ-6 score was 
detected across the different stages (p = 0.241).  
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Figure 4.2 Scatter plot demonstrating the distribution of Pain Impact Questionnaire 
(PIQ-6) score according to revised American Society For Reproductive Medicine 
(rASRM) stages of endometriosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
p = 0.24 
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Table 4.6 Correlation between Pain Impact Questionnaire (PIQ-6) Score and 
haemostatic variables 
 
 
 
 
 
 
 
 
 
 
p value determined by multiple regression analysis 
VWF:Ag, von willebrand factor antigen; VWF:RCo, von willebrand factor ristocetin 
cofactor activity level 
 
  
  
Correlation 
coefficient 
 
p value 
   
 
Fibrinogen 
 
0.069 
 
0.696 
 
Factor VIII 
 
0.051 
 
0.795 
 
Factor IX 
 
-0.219 
 
0.315 
 
Factor XI 
 
-0.049 
 
0.781 
 
Factor XIII 
 
0.086 
 
0.583 
 
VWF:Ag 
 
0.083 
 
0.611 
 
VWF:RCo 
 
-.162 
 
0.423 
   
Platelet count 0.351 0.033 
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4.4 Discussion 
 
In this study a significantly higher proportion of women with endometriosis had 
abnormal platelet aggregation response to one and multiple agonists compared to 
controls. Furthermore the women with platelet aggregation defects were more 
symptomatic with HMB and increased PBAC score (p = 0.024). A high frequency of 
HMB has been reported in women with PFDs and VWD (Table 2.5) [27, 50, 71, 80, 
82, 83]. The increased frequency of abnormal platelet aggregation and low VWF:RCo 
seen in women with stage IV endometriosis indicate that primary haemostasis defects 
are associated with the condition.  
 
These findings could have implications in the pathogenesis of endometriosis; firstly 
with increased retrograde menstruation, which may in turn increase the rate of 
endometriosis formation. Secondly, impaired local haemostasis within endometriotic 
implants may result in recurrent cyclical internal bleeding, exacerbating the spread of 
the condition throughout the pelvic cavity. Endometrial tissue that implants 
ectopically continues to be under hormonal regulation and undergoes monthly 
proliferation and shedding [268]. The pain results from localised internal bleeding 
within or around the endometrial deposits. 
 
The downward trend of VWF activity level (VWF:RCo) with increased disease 
severity detected in this study indicates that endometriosis may be associated with a 
functional defect in primary haemostasis. Inflammation and chronic bleeding 
associated with severe endometriosis may result in a consumptive microvascular 
process that could explain reduction in VWF:RCo level. In addition, severe 
135 
 
endometriosis may be different from minimal/mild stages, and more likely to be 
associated with impaired local haemostasis. Alternatively, impaired systemic platelet 
aggregation may result in progression to more advanced disease. Future research 
should include VWF multimeric analysis in women found to have low VWF:RCo 
levels, which would help to determine the nature of the functional impairment. 
 
Other studies have suggested that there might be an association between VWD and 
endometriosis. In a study that assessed the reproductive experience of women with 
VWD, endometriosis was reported in 30% of cases compared to 13% of controls (p = 
0.01) [80]. However, the increased detection of endometriosis may be higher in 
women with VWD, who suffer from HMB, and therefore are more likely to consult 
with a gynaecologist.  
 
An increased platelet count was seen in women with severe endometriosis and a 
positive correlation with platelet count and PIQ-6 score. An increased platelet count 
in women with severe endometriosis has been confirmed previously [272]. 
Thrombocytosis is a marker of chronic inflammation, and inflammation is strongly 
implicated in the pathogenesis of endometriosis. In addition, platelet count increases 
with chronic active bleeding and iron deficiency states [273]. There was no 
correlation with bleeding tendency and symptom severity. This may indicate that a 
bleeding tendency does not exacerbate endometriosis symptoms. However, the 
women were asked to objectively assess symptom severity over the past four weeks, 
and thus the PIQ-6 score may not have reflected the women’s’ symptoms when they 
were at their peak of severity (i.e. prior to laparoscopic ablation).  
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Traditional testing of platelet function such as bleeding time, light transmission 
aggregation (LTA), impedance aggregometry, and investigation of platelet activation 
by flow cytometry require a high degree of expertise to perform and interpret, and are 
limited to specialised haemostasis laboratories. In addition, LTA is limited by lack of 
reproducibility. The platelet aggregation defects reported in this study were found at 
initial testing. Only three women with endometriosis had abnormal platelet function 
when repeat testing was performed. Thus, future research should address this and any 
abnormalities found at initial testing should be reproducible.  
 
More recently point-of-care testing dedicated to platelet function has become 
available using the platelet function analyser (PFA-100®, VerifyNow System, 
Multiplate Electrode Aggregometry). This devise employs simpler methodologies 
using whole blood without the necessity of sample processing, which is rapid, easier 
to use and more readily available in general laboratories [274]. The PFA-100® is also 
sensitive at detecting type 1 VWD [275]. In addition thromboelastometry platelet 
mapping (TEGPM), primarily used to detect platelet inhibition to antiplatelet 
medication, is a novel method of assessing platelet function that is far more 
convenient for large scale studies [276].    
 
Routine testing for a disorder of primary haemostasis in women with endometriosis 
would be laborious and time consuming using traditional laboratory methods such as 
those utilised in this study. On the other hand, a diagnosis of a PFD would aid 
treatment decisions in such cases; women with a positive diagnosis should be advised 
to avoid non-steroidal anti-inflammatory medication, which further impairs platelet 
function and is commonly used to treat the pain of endometriosis. In addition, it 
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would be an important diagnosis to establish before undergoing surgical treatment. In 
a large prospective study that attempted to identify haemostatic disorders in 5649 
patients prior to surgical intervention, the addition of screening with a standardised 
bleeding questionnaire and PFA-100® testing ensured the identification of impaired 
haemostasis in almost every case [277]. Those patients identified as having a bleeding 
disorder were treated with DDAVP to minimise the bleeding risk during surgery 
[277]. Thus, a more cost-effective approach to identify a haemostatic disorder in 
women with endometriosis could include screening with a concerted bleeding history 
or bleeding score prior to laboratory testing.  
 
One of the limitations of this study is that the control population comprised of 
asymptomatic women who had never sought medical attention for symptoms of 
endometriosis (including subfertility). The prevalence of endometriosis in 
asymptomatic women ranges from 1-22%, depending on the diagnostic criteria and 
the population studied [278-281]. Thus, it is not feasible to fully exclude whether 
women in the control population had the condition. In addition, abnormalities in 
platelet aggregation detected with LTA do not always signify a bleeding disorder. An 
individual with suboptimal response to epinephrine only, and no bleeding history 
should not be considered as having a functional platelet abnormality with current 
clinical testing [282]. All abnormalities in platelet aggregation found on initial testing 
should be repeated with the addition of flow cytometry, nucleotide studies, and 
genetic testing if appropriate to establish or exclude a diagnosis of PFD. Further 
research is required to determine whether the finding of a high frequency of abnormal 
platelet aggregation in women with endometriosis is detected in a larger cohort, 
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ideally with control subjects including women who attend for laparoscopic 
sterilisation.  
 
The impact of haemostatic treatment during menstruation should be investigated in 
women with endometriosis who are found to have a disorder of haemostasis. The 
effect of administering haemostatic therapy, in addition to hormonal treatment, to 
women with a primary haemostatic disorder and endometriosis should be assessed in 
a clinical trial. Antifibrinolytic agents (i.e. oral tranexamic acid) or DDAVP (i.e. 
intranasal desmopressin) can be administered prior to or during menses to assess the 
effect on endometriosis symptom severity and/or rate of endometriosis stage 
progression.  
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4.5 Conclusion 
 
A significantly higher frequency of abnormal platelet aggregation response to one 
agonist (p = 0.005), multiple agonists (p < 0.05) and epinephrine (p = 0.02) was found 
in women with endometriosis compared to controls. Three women with endometriosis 
were diagnosed with a PFD. A reduced level of VWF:RCo was seen in women with 
severe (stage IV) endometriosis compared to controls, with a downward trend of 
VWF:RCo seen with increasing rARSM stage (p = 0.02). A higher platelet count was 
noted in women with endometriosis compared to controls, and was associated with 
increased symptom severity. A dysfunction in primary haemostasis may account for 
disease progression and thus contribute to the underlying pathogenesis of 
endometriosis. Selective screening of symptomatic women with a positive bleeding 
history could have important implications for the treatment of endometriosis. Women 
found to have a co-existing platelet aggregation abnormality should be managed 
accordingly, and advised to avoid antiplatelet medication. 
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5.1 Introduction 
 
Haemophilia carriers face difficult choices in relation to prenatal diagnosis and 
management of delivery. Non-invasive cell free fetal DNA (ffDNA) in maternal 
plasma is now used to determine fetal gender in early pregnancy. This has the 
advantage over ultrasound scan (US), as gender can be determined more accurately in 
early pregnancy prior to invasive testing [151]. Using ffDNA to determine fetal 
gender in early pregnancy means that invasive testing in female fetuses can be 
avoided. A woman can then opt for chorionic villus sampling (CVS) or amniocentesis 
to determine if the male fetus is affected. This is usually offered to women who are 
carriers of severe or moderate haemophilia. It may also be indicated for other reasons 
(i.e. to rule out chromosomal abnormalities) and the haemophilia status of the fetus is 
determined opportunistically. Both CVS and amniocentesis are invasive procedures 
that are associated with an approximate 1% risk of pregnancy loss [137, 138].  
 
Invasive prenatal diagnosis is offered to women with IBDs if they wish to opt for 
termination of an affected pregnancy. Prenatal diagnosis is also undertaken to 
determine whether the fetus is affected, to guide intrapartum management, and 
decision making regarding place and mode of delivery (MOD) to minimise the risk of 
fetal and neonatal haemorrhagic complications. If the result from invasive testing is 
negative, the woman can be referred back to her local hospital for obstetric 
management. On the other hand, if the fetus is affected with haemophilia, the mother 
is advised to deliver at the Royal Free Hospital; being a tertiary centre with access to 
expertise in the field of haemophilia. MOD is planned in advance of delivery, 
ensuring optimal circumstances to minimise cranial bleeding. In addition, delivery at 
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a tertiary centre ensures access to haemostatic laboratory facilities and factor 
concentrate if required, for the mother and the newborn.  
 
Research is currently ongoing in the field of non-invasive prenatal diagnosis of 
haemophilia to determine the status of the fetus through analysis of ffDNA in 
maternal plasma. A previous pilot study at the centre has proven the feasibility of this 
approach [10]. The technique for this is undergoing further development with the aim 
of providing a universal diagnostic test for prenatal diagnosis of inversion 22 
mutation, the most common mutation resulting in severe haemophilia A.  
 
Preimplantation genetic diagnosis (PGD) is an early method of prenatal diagnosis that 
involves in-vitro fertilisation and selection of non-affected embryos to implant back 
into the uterus. This can be offered to couples with haemophilia who wish to avoid 
invasive testing and termination of affected pregnancy.  
 
A previous study reported aspects of pregnancy care, including prenatal diagnosis, in 
carriers of haemophilia at the Royal Free Hospital over a 10-year period [1]. The aim 
of this study was to review prenatal diagnosis in carriers of haemophilia over the 
subsequent 10-years, and to determine if the introduction of non-invasive prenatal 
diagnosis had impacted on reproductive choice and management of delivery. In 
addition, the attitudes of carriers towards non-invasive prenatal diagnosis and mode of 
delivery were explored. 
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5.2 Methods 
 
Carriers of haemophilia who attended the Royal Free Hospital for obstetric 
management from January 2006 until January 2016 were invited to participate in the 
study. A standardised questionnaire (Appendix 3) was sent by post to all eligible 
carriers over the age of 18. Carriers who attended the joint Obstetric Haemophilia 
clinic were consented to be contacted by telephone to complete the questionnaire. 
Written informed consent was obtained to review medical records, to obtain clinical 
data, including; age at the time of pregnancy, year of pregnancy, severity of 
haemophilia, baseline factor levels, invasive and non-invasive prenatal diagnosis, 
mode of delivery (MOD), estimated blood loss, and outcome of each pregnancy. 
 
The questionnaire consisted of three parts. Part 1 included general information 
regarding the type and severity of haemophilia, relationship of carrier to index case, 
and family history of haemophilia-related complications. Part 2 included details of 
each pregnancy, including details of prenatal diagnostic testing, the reasons for and 
against opting for different types of prenatal diagnosis, and the outcome of that 
pregnancy. In part 3 the women were asked about their views on future developments 
in non-invasive prenatal diagnosis of haemophilia, and of obstetric management. This 
included their views regarding risk of intracranial haemorrhage and mode of delivery 
in affected pregnancies.  
 
5.2.3 Statistical analysis 
Descriptive statistics was used to demonstrate pregnancy outcomes and responses to 
the questionnaire. Chi-squared and Fisher’s exact was used to detect whether any 
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factors had a significant effect on the proportion of women who opted for invasive 
testing. 
 
5.3 Results 
 
Sixty-one carriers of haemophilia (44 haemophilia A and 17 haemophilia B) had 
obstetric care in 73 pregnancies at the Royal Free Hospital from January 2006 until 
January 2016 (Fig 5.1). Of the 73 pregnancies, 11 women received shared antenatal 
care between the Royal Free Hospital and their local maternity unit where they 
delivered. The median age at the time of pregnancy was 33 years (range 21-41). 
Eighteen pregnancies (25%) were in carriers of mild, twelve (16%) were in moderate, 
and forty-two (58%) were in severe haemophilia. The carriers’ median baseline (non-
pregnant) FVIII and FIX levels were 53 IU/dL (range 16-148 IU/dL), and 63 IU/dL 
(range 23-120 IU/dL), respectively.  
 
Thirty-one out of 61 women responded to the postal questionnaire. A further ten 
questionnaires were completed by telephone interview following carriers’ consent to 
be contacted by the haemophilia research team. Considering the nature of the 
questionnaire, the non-responders were not followed up with a telephone call without 
consent as this was felt to be too intrusive. The response rate was therefore 61% (41 
out of 61) from those invited. Of the 41 women who responded to the questionnaire, 
22 were carriers of severe haemophilia, seven were moderate, and twelve mild.  
Thirty were carriers of haemophilia A and eleven were carriers of haemophilia B. 
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Figure 5.1 Flowchart to show participants included in questionnaire study 
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5.3.1 Invasive prenatal diagnosis  
Invasive prenatal diagnosis was carried out in seventeen out of 73 pregnancies (23%), 
which was CVS in the majority (16 out of 17) of cases (Table 5.1). One patient 
underwent CVS due to a balanced translocation, which increased the risk for 
chromosomal abnormality. This was inconclusive and therefore she underwent 
amniocentesis, with successful karyotyping. In 15 out of 17 cases the woman was a 
carrier of severe haemophilia. In six pregnancies invasive testing was indicated for 
reasons other than haemophilia. One carrier of moderate haemophilia underwent CVS 
due to a previous pregnancy affected by trisomy 18. Another carrier of mild 
haemophilia underwent CVS due to a fetal anomaly diagnosed at the routine 11-13 
week scan. One carrier of severe haemophilia underwent CVS in two pregnancies as 
she and her partner were both carriers of the cystic fibrosis gene mutation. CVS was 
undertaken to rule out chromosomal abnormalities following a high risk combined 
screening result in two carriers of severe haemophilia. Thus, the uptake for invasive 
prenatal diagnosis to rule out haemophilia solely was 15% (undertaken in 11 out of 73 
pregnancies).  
 
Early determination of fetal gender using ffDNA in maternal plasma, to confirm the 
presence or absence of Y chromosome specific sequences (Y-PCR), was introduced at 
the Royal Free Hospital as a research project in 2003 [151]. Following accurate 
confirmation of fetal gender using this method, it is now routinely offered to all 
pregnant carriers of haemophilia who book at the Royal Free. Non-invasive ffDNA 
Y-PCR was carried out prior to invasive testing from 8 to 12+6 week gestation in all 
cases. Repeat testing was required for an inconclusive result in three cases, when 
initial blood samples were obtained from 8-9+6 weeks gestation. Two repeat samples 
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obtained from 10-11+6 week gestation yielded a positive result. ffDNA Y-PCR was 
100% accurate in all cases where a conclusive result was available. One case out of 
17 (6%) was inconclusive following two samples, and confirmation was through CVS 
(Case No.7, Table 5.1).  
 
Figure 5.2 shows the outcome following invasive prenatal diagnosis. Overall invasive 
testing was carried out in twelve male, and five female pregnancies. Invasive testing 
was undertaken in female pregnancies to rule out chromosomal abnormality or cystic 
fibrosis in four cases, and due to inconclusive ffDNA Y-PCR in one case (Table 5.1). 
In the twelve pregnancies where invasive prenatal diagnosis was performed on male 
fetuses, nine were unaffected, of which five women elected to deliver at a local 
maternity hospital. Three were affected and one woman elected to undergo 
termination of pregnancy (TOP). The two remaining affected male fetuses were 
delivered by elective caesarean section (ELCS) at the Royal Free Hospital. In the five 
pregnancies where invasive prenatal diagnosis was performed on female fetuses, one 
woman opted for TOP for fetal abnormality, one delivered elsewhere, and the 
remaining two were delivered by caesarean section for obstetric reasons at the Royal 
Free. Three carriers of haemophilia A, and one carrier of haemophilia B had 
FVIII/FIX levels of less than 50 IU/dL in the first trimester, and were administered 
factor concentrate or DDAVP for haemostatic prophylaxis prior to undergoing CVS. 
There were no complications associated with invasive prenatal testing (i.e. no 
bleeding/miscarriage) reported in the seventeen pregnancies. 
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Figure 5.2 Flowchart to show outcomes following invasive testing 
 
 
TOP; termination of pregnancy, ELCS; elective caesarean section, EMCS; emergency 
caesarean section, SVD; spontaneous vaginal delivery 
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Table 5.1 Invasive prenatal diagnosis in pregnancies at risk of haemophilia  
Case	   Year	   Non	  Invasive	   Indication	   Invasive	  (CVS)	   Outcome	  
	   	   	   	   	   	  
1	   2006	   ffDNA	  10+2	  Male	  
	  
Carrier	  severe	  	   46XY,	  unaffected	   LB,	  unaffected	  male	  
2	   2006	   ffDNA	  11+5	  Male	  
	  
Carrier	  severe	  	   Amniocentesis	  	  
46XY	  unaffected	  
LB,	  unaffected	  male	  
3	   2006	   ffDNA	  11+6	  Female	  
	  	  
Carrier	  moderate	  and	  
fetal	  anomaly	  
46XX	  chromosomal	  
abnormality	  
TOP	  
4	   2006	   ffDNA	  13+0	  Male	  
	  
Carrier	  severe	  	   46XY,	  unaffected	   LB,	  unaffected	  male	  
5	   2006	   ffDNA	  12+0	  Male	  
	  
Carrier	  severe	  	   46XY,	  affected	   LB,	  affected	  male	  
6	   2007	   ffDNA	  12+2	  Male	  
	  
Carrier	  severe	  and	  high	  
risk	  on	  combined	  
screening	  
46XY,	  unaffected	  	   LB,	  unaffected	  male	  
7	   2008	   ffDNA	  8+3	  and	  10+0	  
inconclusive	  
US	  11+6	  Male	  
Carrier	  severe	  
	  
46XX	  
	  
LB,	  female	  
	  
8	   2009	   ffDNA	  12+2	  Male	   Carrier	  severe	  	   46XY,	  unaffected	   LB,	  unaffected	  male	  
9	   2009	   ffDNA	  12+0	  Male	  
	  
Carrier	  mild	  and	  
previous	  trisomy	  18	  
46XY,	  unaffected	   LB,	  unaffected	  male	  
10	   2010	   ffDNA	  and	  
US	  11+6	  Female	  
	  
Carrier	  severe	  and	  cystic	  
fibrosis	  
46XX,	  carrier	  of	  cystic	  
fibrosis	  
LB,	  female	  
11	   2011	   ffDNA	  9+1	  Female	  
	  
Carrier	  severe	  and	  high	  
risk	  on	  combined	  
screening	  
CVS	  inconclusive,	  
Amniocentesis	  46XX	  
LB,	  female	  
12	   2012	   ffDNA	  9+6	  Male	  
	  
Carrier	  severe	  and	  cystic	  
fibrosis	  
46XY,	  affected	  both	  
haemophilia	  and	  
cystic	  fibrosis	  
LB,	  affected	  male	  
13	   2012	   ffDNA	  8+2	  (repeated)	  
	  12+5	  Female	  
Carrier	  severe	  and	  high	  
risk	  on	  combined	  
screening	  
46XX	   LB,	  female	  
14	   2012	   ffDNA	  11+2	  Male	  
	  
Carrier	  severe	  	   46XY,	  unaffected	   LB,	  unaffected	  male	  
15	   2013	   ffDNA	  9+3	  (repeated)	  	  
11+0	  Male	  
Carrier	  severe	  	   46XY,	  unaffected	   LB,	  unaffected	  male	  
16	   2015	   ffDNA	  10+4	  Male	   Carrier	  severe	  	   46XY,	  unaffected	   LB,	  unaffected	  male	  
17	   2015	   ffDNA	  11+5	  Male	   Carrier	  severe	  	   46XY,	  affected	   TOP	  	  
CVS, chorionic villus sampling; ffDNA, free fetal DNA; LB, live birth; TOP, 
termination of pregnancy; US, ultrasound scan 
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Table 5.2 Factors affecting uptake of invasive prenatal diagnosis 
 
* Data derived from questionnaire responses. P value determined by chi-squared or 
Fisher’s exact test. 
 
 
 
  
	   Invasive	  (%)	   Non-­‐invasive	  (%)	   P	  value	  
	   	   	   	  
Age	  ≥	  35	  years	   11	  out	  of	  17	  	  
(65)	  
19	  out	  of	  56	  	  
(34)	  
0.046	  
	   	   	   	  
Year	  of	  pregnancy	  	  
(pre	  2012)	  
11	  out	  of	  17	  	  
(65)	  
16	  out	  of	  56	  	  
(28)	  
0.010	  
	   	   	   	  
Severe	  haemophilia	   15	  out	  of	  17	  	  
(88)	  
27	  out	  of	  56	  
	  (48)	  
0.004	  
	   	   	   	  
Family	  history	  *	  
(>	  3	  haemophilia	  complications)	  
9	  out	  of	  11	  	  
(81)	  
10	  out	  of	  30	  
(37)	  
0.012	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Age at the time of pregnancy was a significant factor with a higher proportion of 
women undergoing invasive prenatal testing if they were 35 years or older (Table 
5.2). The year of pregnancy was another factor. The proportion of women undergoing 
CVS was significantly higher in the early half of the decade (2006-2011) compared to 
the latter half of the decade (2012-2016) (p = 0.01). The severity of haemophilia was 
a significant factor in determining uptake of invasive prenatal diagnosis  (p = 0.004). 
A higher proportion of women who underwent invasive testing were carriers of severe 
haemophilia. A family history of haemophilia-related complications also impacted on 
rate of uptake (p = 0.01), with a higher proportion of women opting for invasive 
testing with a positive family history of three or more haemophilia-related 
complications (Table 5.2). 
 
Eleven women who responded to the questionnaire opted for invasive testing in 
twelve pregnancies; ten were carriers of severe haemophilia, and one was a carrier of 
mild haemophilia. Five women responded that CVS had been indicated for reasons 
other than haemophilia. 
 
The carriers were asked about their reasons for opting for invasive testing of 
haemophilia. Seven women who opted for this stated that they would have opted to 
undergo a TOP if the fetus was affected. Three women had wanted to know the 
haemophilia status to make a plan for delivery, and one woman did not state reasons 
for opting for invasive testing. 
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One woman stated: 
“I have had CVS in all four pregnancies, all very safe. I appreciated the early 
information from the blood test, not the ‘non-invasiveness’ of it. The real issue 
is taking the risk of having an affected child/termination.”  
 
Whilst another woman stated: 
“We would not terminate a baby with haemophilia, I only wanted to ensure a 
safe delivery.” 
 
Overall, third trimester amniocentesis was offered in thirteen out of 73 pregnancies 
(18%). This was usually offered in cases of severe haemophilia and was declined in 
all cases.  
 
Carriers were asked in the questionnaire about whether they would consider 
amniocentesis in the third trimester of pregnancy, to avoid the risks associated with 
invasive testing in early pregnancy. Thirty-three out of 41 (80%) women who 
responded to the questionnaire stated they would not consider this as an option. Seven 
women (17%) said they were unsure, and one woman (2%) responded that she would 
consider this method of prenatal diagnosis in future pregnancies. 
 
5.3.2 Non-invasive prenatal diagnosis 
Non-invasive ffDNA was used to determine fetal gender in 56 pregnancies (77%). 
Figure 5.3 shows the outcome following non-invasive prenatal diagnosis. In four 
cases repeat testing was required to obtain a positive result. US only was used to 
determine the fetal gender in 15 cases. This was largely due to the fact that carrier 
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status was not confirmed until late in pregnancy, when the woman was referred to the 
Royal Free Hospital. The fetal gender had already been determined at the local 
hospital during the routine 18-23 week anomaly scan.  
 
Women were also asked about reasons for not opting for invasive testing in the 
questionnaire. Eleven women out of 30 (37%) who opted for non-invasive testing 
stated ‘fear of fetal loss from the procedure’ as a reason not to undergo invasive 
testing. Eleven out of 30 (37%) felt that ‘haemophilia was not a severe enough 
condition to warrant invasive testing’, and 15 out of 30 (50%) women felt that ‘they 
were prepared for the responsibility of having a child with haemophilia (i.e. accepting 
of the outcome either way)’.  
 
One woman stated: 
“I only carry mild haemophilia and this would absolutely not put me off 
having children. Having the test (ffDNA) made me more comfortable and 
confident that I had the right people at hand to help with the delivery. I wish I 
could’ve been sure, as my son is not affected. I would have preferred not to 
have had a caesarean section, but I was happy to do so for his safety.” 
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Figure 5.3 Flowchart to show outcomes following non-invasive testing  
 
 
ffDNA Y-PCR; polymerase chain reaction detection of Y chromosome in free fetal 
DNA, EMCS; emergency caesarean section, ELCS; elective caesarean section, TOP; 
termination of pregnancy, SVD; spontaneous vaginal delivery, US; ultrasound scan 
* In 7 out of 34 ELCS deliveries (total) there was another indication for ELCS (i.e. 
previous CS, breech presentation, previous myomectomy) 
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5.3.3 Impact of prenatal diagnosis on reproductive choice 
 
Fourteen out of 41 (34%) respondents had made a conscious decision not to have 
children, or not to have any more children. Multiple reasons were given for this 
decision, however 9 out of 14 stated that this was due to fear of passing on 
haemophilia to their children/other children, 4 out of 14 stated that this was due to the 
stress of dealing with haemophilia, and 3 respondents (21%) stated this was due to the 
stress of undergoing invasive prenatal diagnosis in pregnancy. 
 
When asked whether they would consider opting for a non-invasive blood test to 
diagnose the haemophilia status of the fetus during pregnancy, all 41 respondents 
(100%) stated that they would opt for this if it became available. However, when 
asked whether they thought having the availability of such a test would impact on 
their future reproductive choices, 12 out of 41 (29%) thought it would, 24 out of 41 
(59%) thought it would not, and 5 out of 41 (12%) were unsure. 
 
One woman stated: 
“Having a diagnosis through ffDNA would be far less stressful than having 
CVS. I always knew I wanted children, and my carrier status did not put me 
off this decision.” 
 
5.3.4 Prenatal diagnosis and mode of delivery 
 
Of the 73 pregnancies managed initially at the Royal Free Hospital, three resulted in 
TOP; one was for severe haemophilia, one for a fetal abnormality and one for social 
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reasons. In the 70 ongoing pregnancies, 11 women delivered at their local maternity 
hospital. Fifty-nine deliveries (including 12 female and 46 live male births) were 
therefore managed at the Royal Free Hospital over the 10-year period.  
 
Thirty-nine (66%) were ELCS fifteen (25%) were vaginal deliveries (VD), four (7%) 
were emergency caesarean (EMCS), and one (1.7%) was a forceps delivery. There 
was one case of a primary PPH (estimated blood loss 1000 mL following ELCS for 
previous myomectomy) among 59 deliveries, giving an incidence of 1.7%. The 
incidence of secondary PPH was not recorded. 
 
 
A high proportion (41%) of the female and male pregnancies that were diagnosed as 
unaffected following invasive prenatal diagnosis were delivered locally. A higher 
proportion of live male births were managed at the Royal Free Hospital (79%). In 
addition, the majority of male babies were born by ELCS. The caesarean rate among 
carriers with male babies was 78% compared to 25% among carriers with female 
babies.  
 
 
When asked about the estimated risk of intracranial haemorrhage (ICH) at delivery in 
babies with haemophilia; 5% considered the risk to be <1%, 60% of carriers 
considered the risk to be around 1-5%, 17.5% thought the risk was >10%, and 17.5% 
were unsure. When asked at what level of risk would they opt for ELCS, 27.5% 
responded that they would opt for a ELCS if the risk was <1%, 40% stated this to be 
around 1-5%, 15% responded if the risk was  >10%, and 17.5% were unsure. 
 
 
157 
 
5.4 Discussion 
 
In this study there was a high uptake of non-invasive prenatal diagnosis. Fetal sex 
determination was carried out using ffDNA in the first trimester in 58/73 (79%) 
pregnancies, or through routine second trimester US in 70/70 (100%) pregnancies. 
Invasive testing to rule out haemophilia was opted for in 11/73 (15%) of pregnancies. 
The rate of uptake for invasive testing to rule out haemophilia appears to be 
decreasing. In an early case series published in 1997 the rate of uptake for invasive 
testing was 17/48 (35%) in carriers of haemophilia managed at the Royal Free 
Hospital [2]. A follow up series published in 2008 showed the uptake to be 13/65 
(20%) [1]. In addition, the proportion of women who opted for invasive testing was 
higher in the first part of the decade (Table 5.2). This downward trend in the uptake 
for invasive testing could be explained by the availability of an early non-invasive test 
to determine fetal gender using ffDNA, which was introduced at the Royal Free 
Hospital in 2003. Prior to this it was offered as part of a research project [151], and 
found to reduce the requirement for invasive testing in female pregnancies.  
 
The rate of TOP for haemophilia was also lower in this series than reported in 
previous studies (1/73 [1.4%] compared to 5/90 [5.5%][1]). It is not easy to make any 
inference regarding the decreased TOP rate. From the questionnaire responses, 
severity of haemophilia, and family history of complications appear to impact on rate 
of uptake for invasive testing. This is similar to a Swedish study, where the rate of 
uptake of invasive testing (14% among 376 carriers) was influenced by family 
history, and a positive attitude towards TOP [283]. Although seven out of 11 women 
who responded to the questionnaire stated that they had opted for invasive testing to 
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undergo TOP if the fetus was affected, our data suggests that some women chose to 
continue with the pregnancy following a positive result from CVS. Improved 
haemophilia treatment and the prospect of gene therapy providing a cure may be 
important considerations, but the decision to continue with the affected pregnancy is 
clearly highly personal, and influenced by many complex factors. Attitudes towards 
PGD were not including in the survey. As rates of TOP for haemophilia are reducing, 
future research could address whether PGD would be considered more acceptable. 
However, currently its availability is limited in the UK, and it may be regarded as 
being too invasive for the woman, who has to undergo in-vitro fertilisation 
procedures. 
 
Three out of 11 women (27%) had stated that they opted for invasive testing to make 
a plan for the delivery. Seven pregnancies where invasive testing demonstrated non-
affected male and female pregnancies were subsequently referred back to their local 
maternity units. This highlights the advantage of having a definitive diagnosis about 
the haemophilia status of the fetus in advance of delivery. 
 
Twenty seven per cent of carriers who responded to the questionnaire did not opt for 
invasive testing in pregnancy due to fear of fetal loss from the procedure. Many 
carriers (11/30) did not consider haemophilia to be sufficiently serious a condition to 
justify invasive testing. Three women stated that they had made a conscious decision 
not to have any more children due to the stress of undergoing prenatal testing. Having 
a safe, reliable non-invasive method of diagnosing haemophilia during the pregnancy 
would be highly welcome, and all carriers that completed our survey stated that they 
would opt for this if it became available in the future. Not only would this reduce the 
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psychological and emotional burden from invasive testing, its uptake would allow for 
more advanced planning of labour, and more options with regard to MOD. The 
majority of carriers (60%) correctly estimated the risk of ICH at birth in newborns 
with haemophilia to be around 1-5%, and 68% (28/41) would opt for ELCS if the risk 
was 5% or lower. Safely excluding a diagnosis of haemophilia in male fetuses will 
increase the birth options available to women. When the haemophilia status of the 
male fetus is unknown, the recommendation is to avoid any risk of cranial bleeding 
during labour and delivery by avoiding invasive monitoring, prolonged labour and 
pushing, as well as instrumental delivery. This leads to early resource to CS, possibly 
unnecessarily in those unaffected with haemophilia.  
 
CS carries an inherent increased risk of bleeding for the carrier mother, and the risks 
are higher with multiple CS due to potential for abnormal placentation (placenta 
praevia/accrete) [284]. There is also increased risk of surgical complications such as 
cystotomy, bowel injury, ureteral injury, ileus and hysterectomy from multiple repeat 
CS. When prenatal diagnosis confirms the fetus to be unaffected with haemophilia, 
vaginal delivery without restrictions can be offered, thus avoiding unnecessary CS, 
and its potential risks for the mother and in future pregnancies. In addition, referral 
back to a local maternity unit closer to home can be planned, avoiding the 
inconvenience for the mother and her partner, of delivery far away from home. 
 
Of note, the incidence of primary PPH was low (1.7%) among this cohort. The study 
from the previous decade reported a 19% incidence of primary PPH, although this 
was defined as an estimated blood loss >500 mL within 24h post delivery, regardless 
of MOD [1]. The case series from the preceding decade reported an incidence of 22% 
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[2]. The majority of women (66%) in this series underwent ELCS for a variety of 
indications, although the primary indication was for haemophilia (23/39 [59%] of 
deliveries). The estimated blood loss ranged from 300-1400 mL among women who 
delivered by ELCS, with a median of 500 mL. There was only one PPH with an 
estimated blood loss of 1400 mL in a woman with additional obstetric risk factors. 
This data supports the argument that ELCS with appropriate multidisciplinary input 
and careful consideration of the bleeding risk does not appear to be associated with 
excessive bleeding in carriers of haemophilia. All the women had a plan for labour 
and delivery in advance when they attended the Joint clinic at 30-32 weeks gestation. 
Bleeding risk was assessed and prophylaxis arranged with tranexamic acid, DDAVP 
or factor concentrate if appropriate. Active management of the third stage was 
implemented using uterotonic agents (intravenous syntocinon and per rectal 
misoprostol) for all women. Furthermore, women were instructed to take tranexamic 
acid until their lochial loss was minimal. Management guidelines were readily 
available and updated regularly for management of these patients. A copy of the 
management plan was given to the mother, and a copy was saved on her electronic 
records, which was circulated to the necessary care providers on the labour ward. 
Twenty-four hour contact with the team running the Joint clinic was made available. 
Thus, the incidence of PPH in this cohort (1.7%) was lower than the 3-6% incidence 
reported in the general population [197, 199].  
 
This study has limitations. The sample size was small and a large proportion of 
respondents to the questionnaire were women who had delivered recently, and had 
undergone invasive testing. There may have been characteristics about respondents, 
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which resulted in bias, and their answers may not be representative of all haemophilia 
carriers who delivered at the Royal Free Hospital over the past decade.  
 
5.5 Conclusion 
 
The uptake for invasive prenatal diagnosis among haemophilia carriers is now low, 
and affected by factors such as severity of haemophilia, age, year of pregnancy and 
family history of haemophilia-related complications. These should be considered 
when counselling carriers, and each case should be managed individually. The rate of 
TOP of affected pregnancies is reduced compared to that reported in previous case 
series. This is may be due to the improved long-term management, and availability of 
treatment for patients with haemophilia.  
 
Non-invasive prenatal diagnosis was able to confirm fetal gender in most cases. 
Introducing this method means that invasive testing for haemophilia can be avoided in 
in female fetuses. Thirty-seven per cent of carriers wished to avoid invasive testing 
due to fear of fetal loss from the procedure. The majority of carriers who do undergo 
invasive testing do not terminate the pregnancy, but opt for prenatal diagnosis to 
guide management decisions of labour and delivery. The majority of carriers (67.5%) 
stated that they would opt for ELCS if the risk of ICH at birth was ≤ 5%. A non-
invasive test to confirm the haemophilia status of the fetus is of exceptional 
importance and required urgently. This will help to reduce the emotional impact and 
reduce fear associated with invasive testing. 
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6.1 Introduction 
 
Cranial bleeding can have devastating consequences for newborns with IBDs. Cranial 
bleeding can occur during labour and delivery due to overlapping or moulding of the 
infant’s cranial bones as it passes through the birth canal. Instrumentation causes 
further moulding and the sheering forces results in mechanical damage to the 
underlying blood vessels and dural sinuses. Intracranial haemorrhage (ICH), defined 
as an accumulation of blood within the cranial vault, can result in serious long-term 
neurological sequelae or death [285, 286]. Extracranial haemorrhage (ECH), defined 
as haemorrhage or haematoma occurring outside the cranial vault, can be rapid and 
life threatening due to persistent bleeding into the subgaleal space [287]. 
 
In the 1960s ICH accounted for over one-third of all deaths in patients with 
haemophilia [288]. Despite advances in treatment, mortality rates of over 20% are 
still reported in recent publications [289]. The risk of ICH and consequential long-
term neurological sequalae is dependent on age, severity of the condition and inhibitor 
development. In 1978, Eyster et al reported a case series in an estimated population of 
2500 haemophilia patients and found that 51 out of the 71 (72%) cases of ICH 
occurred in patients younger than 18 years of age [290]. Recent studies suggest that 
15-33% of newborns present with initial bleeding manifestations in the neonatal 
period [252] and 41% of these early manifestations involve cranial bleeding [291]. A 
national survey conducted in the French haemophilia population demonstrated that 
the highest lifetime frequency of ICH occurred during the neonatal period (Fig 5.1) 
[289].  
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Figure 6.1 Age at the time of intracranial haemorrhage (ICH) in haemophilia patients. 
Main histogram: distribution of ICH by 2-year-age brackets; small histogram: 
distribution of ICH for children ≤ 2 years by 1-month-age brackets (reproduced from 
Stieltjes et al, 2005) 
 
Figure removed due to copyright restrictions 
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Although haemophilia A and B are the most prevalent IBD, other rare congenital 
bleeding conditions have also been associated with ICH in the newborn. These 
include severe cases of VWD, congenital afibrinogenaemia, and deficiencies of 
coagulation factors including factors II, V, VII, X and XIII (see Table 6.6) [292-295]. 
Fetal neonatal alloimmune thrombocytopaenia (FNAIT) results in severe bleeding, 
often recognised in the antenatal period. Severe fetal thrombocytopaenia develops due 
to maternally derived allo-reactive antibodies attacking human platelet antigens 
(HPA) inherited from the father. This condition is not classified as an inherited 
bleeding disorder and therefore not included in this thesis. 
 
6.1.1 Classification of cranial bleeding 
 
ECH is defined as haemorrhage or haematoma that occurs outside the cranial vault. 
They include cephalohaematoma and subgaleal haemorrhage (SGH). 
Cephalohaematoma arises from haemorrhage of the periosteum. This type of 
haemorrhage does not cross suture lines between the cranial bones, which classically 
differentiate cephalohaematoma from SGH (Fig 6.2). They occur in approximately 
1% of live births and are more common with instrumental deliveries. They may 
increase in size slightly following delivery and take several weeks to resolve, usually 
with no long-term clinical sequelae [296].  
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Figure 6.2 Anatomical representation of extracranial haemorrhage in the newborn 
 
 
 
SGH results from bleeding into the potential space inferior to the epicranium 
aponeurosis and the periosteum of the cranium. These collections usually increase in 
size during the first few days after delivery. They are more frequently encountered 
following difficult ventouse delivery [297]. Boo et al assessed obstetric factors that 
increased the likelihood of SGH associated with ventouse delivery [298]. Five factors 
where identified which included; failed ventouse extraction (adjusted odds ratio [OR] 
16.4; 95% confidence interval [95%CI], 2.0-135.6), leading edge of vacuum cup < 3 
cm away from the anterior fontanelle (suggestive of deflexion application) (adjusted 
OR 6.0; 95%CI, 1.7-21.0), cup marks on the sagittal suture (implicating a paramedian 
application) (adjusted OR 4.4; 95%CI, 1.7-21.0) and maternal nulliparity (adjusted 
OR 4.0; 95%CI, 1.6-10.0). Blood may tract down into the cervical regions below the 
attachments of the occipto-frontalis muscles and consequently blood loss can be 
massive. Neonates with coagulation disorders can develop hypovolaemic shock and 
exsanguinate due to SGH [297, 299].  
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ICH is defined as an accumulation of blood within the cranial vault. It is classified 
according to anatomical compartments and has six major types: subdural haematoma 
(SDH), subarachnoid haemorrhage (SAH), intraventricular haemorrhage (IVH), 
cerebellar haemorrhage, parenchymal (intracerebral) haemorrhage and epidural 
haemorrhage.  
 
SDH and SAH are the most common types of ICH encountered in the term newborn 
and are classically associated with traumatic delivery. Improvements in obstetric care, 
and a global trend towards elective caesarean deliveries for fetuses presenting in the 
breech position at term, have resulted in an overall reduction in these haemorrhages in 
healthy term newborns [300]. SDH arises from excessive vertical molding and fronto-
occipital elongation causing stretching of the dura mater, the falx and tentorium 
during prolonged and difficult labour. Haemorrhage into the subdural space may also 
occur due to tearing of bridging veins from the cortex to the superior sagittal sinus or 
from superficial cortical veins without tearing of the dura [296]. SDH are usually 
infratentorial (located inferiorly to the tentorium cerebelli), but can occur in a 
supratentorial location in association with more extensive bleeding and midline shift. 
SAH are typically clinically silent and benign, thus the exact incidence is unknown. 
Bleeding occurs from anastomoses between the penetrating leptomeningeal arteries or 
the bridging veins. More extensive SAH may be difficult to distinguish from SDH 
and the two may co-exist.  
 
IVH are classically associated with preterm delivery. IVH arises from the germinal 
matrix, chorid plexus, or parenchyma. The germinal matix area is formed of primitive 
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neuroblast and glioblast cells surrounded by immature, fragile blood vessels. 
Fluctuations in cerebral blood pressure due to poorly regulated immature vasculature 
in the preterm infant cause rupture of the germinal matrix capillary bed [301]. By 
term gestation these vessels undergo rapid maturation with a greater continuity of the 
basement membrane to enhance vascular support. Thus, the incidence of germinal 
matrix IVH in term infants is low, and if encountered is attributed to trauma or severe 
asphyxia. Term infants with germinal matrix IVH are often asymptomatic and the 
prognosis is good. Long-term neurological sequelae are seen in infants with IVH and 
parenchymal involvement.  
 
Cerebellar haemorrhages are associated with preterm delivery and have been reported 
in 20% of prospectively imaged preterm infants [302]. In the term infant cerebellar 
haemorrhage may be primary or related to venous infarction, or may complicate 
extensive IVH or SAH. The vermis is reported to be the initial site of haemorrhage in 
the majority of term infants. Lacerations of the cerebellum may result from traumatic 
vaginal breech deliveries [296]. Mortality from cerebellar haemorrhage is high in 
preterm infants. In term infants the mortality is lower, however in survivors there is a 
high incidence of residual motor and intellectual impairment with prominent 
cerebellar signs [303].  
 
Parenchymal haemorrhages are rare in the full-term infant. The proposed aetiologies 
include asyphyxia, hypoxia, haemorrhagic infarction and birth trauma [304]. In 
addition they have been reported in association with structural anomalies such as 
arteriovenous malformation, aneurysm and cavernous malformation. Outcome varies 
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widely, but can be surprisingly good, even in patients with sizeable parenchymal 
haemorrhages.  
 
In contrast to adults, newborns rarely develop epidural haemorrhage because the usual 
mechanism is related to skull fracture and tearing of the middle meningeal artery in its 
groove within the temporal bone. However, in newborns the process of moulding 
reduces skull fractures and the middle meningeal artery, which is not yet encased 
within the bone, moves freely away from displacement of the skull [305]. Skull 
fracture with epidural haemorrhage may result from a difficult forceps delivery, or 
pressure from the maternal symphysis pubis, sacral promontory, or ischial spines.  
  
6.1.2 Screening for intracranial haemorrhage in neonate with IBD 
 
As approximately one third of all cases of haemophilia arise from de novo mutations, 
many affected infants are born to women who are unaware that they are carriers of the 
condition. Therefore overt bleeding signs and symptoms such as ECH, persistent 
bleeding following invasive procedures, circumcision or a heel prick test may indicate 
the presence of an underlying IBD and prompt haematological investigation. 
Prolonged oozing from the umbilical stump is characteristic of a defect in fibrinogen 
production or function and FXIII deficiency.  
 
ICH in the full term infant can present with diverse and often non-specific 
neurological symptoms (Fig 6.3). It is the second leading cause of fever (after 
infection), and the second leading cause of seizures (after asphyxia). It may produce 
‘late jaundice’, peaking late in the first week of life, irritability, apathy, high-pitched 
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crying or abnormal muscle tone [306]. Once focal neurological signs have developed 
the bleed is often extensive therefore a high index of suspicion is required to prompt 
radiological investigations of non-specific symptoms. 
 
 
Figure 6.3 Possible clinical signs of intracranial haemorrhage in newborns  
 
Figure removed due to copyright restrictions 
 
† Hypotension, tense fontanelle, pupillary/ocular changes, and apnoea. 
* The most frequent first documented symptoms among children aged <2 years; often 
nonspecific. 
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To date there is a lack of consensus on whether to routinely screen for ICH in 
newborns diagnosed with IBD. In addition, the optimum imaging modality and timing 
is unknown. Cranial ultrasound scan (US) is often used as a first line investigation due 
to accessibility, low-cost, and absence of exposure to radiation. However, cranial US 
lacks sensitivity for detecting haemorrhages in the posterior fossa of the brain. 
Cerebellar haemorrhages can remain undetected using cranial US through the anterior 
fontanelle and result in cerebellar atrophy later in life [307]. The paediatric working 
party of the UK Haemophilia Centre Doctor’s Organisation (UKHCDO) carried out a 
survey in 2002 to ascertain current practice with regard to management of neonates 
with IBD. The routine use of cranial US in all newborns with severe haemophilia was 
reported by 17/42 (41%) of responders. A further 16/42 (38%) would scan in specific 
circumstances where trauma at delivery may have been excessive. Nine out of 42 
(21%) would only consider cranial US in the presence of clinical signs suggestive of 
ICH [308].  
 
Cranial computerised tomography (CT) scanning is widely utilised in the emergency 
paediatric setting and has increased accuracy of diagnosis of ICH in the posterior 
fossa. However as CT exposes the particularly susceptible neonatal brain to ionising 
radiation it is not an acceptable modality for screening purposes. Magnetic resonance 
imaging (MRI) is non-invasive and non-ionising and produces excellent soft tissue 
differentiation, making it the modality of choice for screening for haemorrhages in the 
neonatal brain [309]. 
 
MRI appearances of haemorrhage vary over time and thus can be used to evaluate the 
age of a lesion. This is due to the different susceptibilities of oxyhaemoglobin, 
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deoxyhaemoglobin, and haemosiderin, which result in different signals on various 
pulse sequences. When haemorrhage is acute the signal is usually deeply hypointense 
with respect to brain tissue on T2-weighted images and intermediate on T1-weighted 
images; subacute haemorrhage is hyperintense on both T1- and T2-weighted images; 
and chronic haemorrhage becomes deeply hypointense on both T1- and T2-weighted 
images (Table 6.1) [310]. However, impaired coagulation may result in this sequence 
of changes in signal intensity to be disrupted due to aberrations in clot formation and 
clot dissolution, and therefore breakdown of haemoglobin. There is limited data on 
normal MR images of the neonatal brain in patients with impaired coagulation; if ICH 
is clinically suspected in a newborn with haemophilia or severe IBD, cranial CT is 
usually performed instead of MRI, as it is more rapidly available.  
 
Table 6.1 MRI appearance of intracerebral haemorrhage (reproduced from Augilar & 
Brott, 2011 [311]) 
 
Stage	   Age	   Haemoglobin	   T1-­‐weighted	   T2-­‐weighted	  
	  
Hyperacute	   <24	  h	   Intracellular	  
oxyhaemoglobin	  
Isointense	   Slightly	  hyperintense	  
Acute	   1-­‐3	  d	   Intracellular	  
deoxyhaemoglobin	  
Slightly	  hypointense	   Very	  hypointense	  
Early	  subacute	   >3	  d	   Intracellular	  
methemoglobin	  
Very	  hyperintense	   Very	  hypointense	  
Late	  subacute	   >7	  d	   Extracellular	  
methemoglobin	  
Very	  hyperintense	   Very	  hyperintense	  
Chronic	  centre	   >14	  d	   Extracellular	  
hemichromes	  
Isointense	   Slightly	  hyperintense	  
Chronic	  rim	   >14	  d	   Intracellular	  
hemosiderin	  
Slightly	  hypointense	  
	  
Very	  hypointense	  
H, hours; d, days;  
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6.2 Mode of delivery and cranial bleeding in newborns with haemophilia: a 
systematic review and meta-analysis  
 
6.2.1 Aim 
 
The purpose of this systematic review was to compare overall incidence of both ICH 
and ECH in newborns with haemophilia and in the general population. A meta-
analysis was performed to assess the impact of MOD on the incidence of ICH. The 
long-term outcome following ICH in both populations was reviewed. 
 
6.2.2 Method 
 
Methodology for this systematic review and meta-analysis were developed according 
to recommendations from Preferred Reporting Items for Systematic Reviews and 
Meta Analysis of Observational Studies in Epidemiology [312] statements.  
 
Studies were included in the systematic review if they assessed incidence of cranial 
bleeding at birth, within a defined newborn period, and a denominator ‘at risk’ 
population (i.e. the total number of babies born with haemophilia in the referral region 
or centre or the total newborns delivered within a maternity unit, during a determined 
period of time). The incidence of ICH and ECH at birth was determined from 
retrospective review of hospital discharge notes (ICD-9 coding), parental interview or 
questionnaires completed by haemophilia treatment centres. Cases were excluded 
when cranial bleeding was iatrogenic, not related to the birth process, or the result of 
extreme prematurity (< 28 weeks gestation).  
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The studies included in the meta-analysis report MOD for each participant. Studies 
that reported the incidence of cranial bleeding, without sufficient information about 
MOD of newborns with ICH or the denominator population were excluded. In order 
to make comparison between MOD in babies with haemophilia, the delivery mode 
was recorded as either assisted vaginal delivery (AVD), which included both forceps 
and vacuum assisted deliveries, and caesarean section (CS), which included both 
emergency and elective CS. The MOD requires this grouping because not all studies 
define the type of instrumentation used (forceps or vacuum). In addition the studies 
report only ‘caesarean delivery’ without distinguishing between CS performed during 
labour or ELCS. The effect measure used for the meta-analysis was odds ratio (OR) 
of experiencing ICH. The odds of experiencing ICH at birth were evaluated in 
participants born by AVD and CS, compared to those born by SVD. The 
heterogenicity across studies was assessed using Cochrane's Q test and I2 statistic and 
studies were assigned appropriate weight based on a fixed-effect model. A rare-events 
model utilising the Peto method was necessary to compare OR in babies born by CS 
compared to SVD [313].  
 
All studies were observational cohort studies or prospective imaging studies. There 
were no randomised trials reporting the incidence of cranial bleeding in newborns 
either in the general population or in newborns with haemophilia. 
 
Search strategy 
A review of EMBASE (1980- October 2014) and MEDLINE (1950- October 2014) 
using the key search terms ‘cranial bleeding’, ‘head bleeding’, intracranial, 
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extracranial, intracerebral, ‘subgaleal hematoma’ OR cephalohematoma, 
cephalohaematoma, AND haemorrhag*, hemorrhag*, bleeding, AND newborn, 
neonat*, ‘at birth’, AND haemophilia, haemophilia, ‘bleeding disorder’ OR 
‘coagulation disorder’ revealed the relevant studies. In addition to searching 
electronic databases the reference lists of review articles were scanned for relevant 
studies. Two investigators independently assessed titles and abstracts to identify 
studies that fitted the inclusion criteria. 
 
6.2.3 Results 
 
Figure 6.4 shows the flow chart for identifying eligible studies for the systematic 
review and meta-analysis. Seventeen studies report the incidence of cranial bleeding 
at birth in both newborns with haemophilia and in the general population. The 
characteristics of the 13 retrospective studies that assess incidence of ‘symptomatic’ 
cranial bleeding at birth are given in Table 6.2. The four prospective studies that 
report ‘asymptomatic’ cranial bleeding are outlined in Table 6.3. An overall incidence 
was calculated for ICH and ECH in both populations.  
 
Only four studies were eligible to evaluate the extent of which MOD impacts on 
incidence of ICH. One study was available in the general population, which gave 
sufficient information regarding the MOD in each participant [251]. Three studies 
assessed the incidence of ICH by MOD in newborns with haemophilia [313-315] 
(Table 6.4). 
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Figure 6.4 Flowchart for identifying eligible articles in newborns in the general 
population (A) and newborns with haemophilia (B) 
 
  EMBASE/MEDLINE 
74 Articles 
(citations retrieved from database) 
46 Articles 
8 used in systematic review 
28 Excluded 
(duplicates) 
38 Excluded 
(did not reach search 
criteria) 
EMBASE/MEDLINE 
29 Articles 
(citations retrieved from database) 
18 Articles 
11 Excluded 
(duplicates) 
9 Excluded 
(did not reach search 
criteria) 
9 used in systematic review 
A 
B 
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Table 6.2 Retrospective studies reporting incidence of symptomatic cranial bleeding 
Author	   Year	   Type	  of	  study	  
Definition	  of	  
neonatal	  
period	  
No	  of	  ICH	   No	  of	  ECH	   Cohort	  
	  
Incidence	  (%)	  
	  
(A)	  In	  the	  general	  population	  
	  
Sachs	  	  
et	  al	  [316]	  
	  
1987	  	  
	  
Descriptive	  
	  
1-­‐11	  days	  
	  
12	  
	  
NS	  
	  
23141	  
	  
0.052	  
	   	   	   	   	   	   	  
Hanigan	  	  
et	  al	  [317]	  	  
1994	   Retrospective	  
cohort	  
0-­‐9	  days	   28	   NS	   81000	   0.035	  
	   	   	   	   	   	   	  
Towner	  	  
et	  al	  [251]	  
1999	   Retrospective	  
cohort	  
‘All	  neonates’	   361	   NS	   583340	   0.062	  
	   	   	   	   	   	   	  
Mosavat	  	  
et	  al	  [318]	  
2008	   Cross-­‐sectional	   ‘All	  neonates’	   Nil	   10	   3340	   0.299	  
	   	   	   	   	   	   	  
Hughes	  
	  et	  al	  [319]	  
1999	   Case-­‐control	  	   ‘All	  neonates’	   Nil	   99	   19901	   0.497	  
	   	   	   	   	   	   	  
Overall	  
incidence	  	  
	   	   401	   	  
109	  
687481	  
23241	  
0.058	  (ICH)	  
0.469	  (ECH)	  
	   	  
(B)	  In	  newborns	  with	  haemophilia	  
	   	   	   	   	   	   	  
Yoffe	  &	  
Buchanan	  
[320]	  
	  
1998	   Retrospective	  
cohort	  
0	  –	  5	  days	   5	   NS	   150	   3.4	  (ICH)	  
Ljung	  	  
et	  al	  [321]	  
1990	  	   Retrospective	  
cohort	  
‘neonatal’	   5	   7	   140	   3.6	  (ICH)	  
5.0	  (ECH)	  
	   	   	   	   	   	   	  
Klinge	  	  
et	  al	  [286]	  
1999	  	   Retrospective	  
cohort	  
0	  –	  1	  week	   11	  
	  
NS	   742	  
	  
1.5	  (ICH)	  
	  
	   	   	   	   	   	   	  
Revel-­‐Vilk	  
et	  al	  [322]	  
2004	   Case-­‐control	   0	  -­‐	  1	  week	   11	   NS	   172	   6.4	  (ICH)	  
	   	   	   	   	   	   	  
MacLean	  
et	  al	  [323]	  
2004	   Retrospective	  
cohort	  
‘neonatal’	   1	   6	   73	   1.4	  (ICH)	  
8.2	  (ECH)	  
	   	   	   	   	   	   	  
Tarantino	  
et	  al	  [292]	  
2007	   Retrospective	  
cohort	  
‘neonatal’	   17	   NS	   580	   2.9	  (ICH)	  
	   	   	   	   	   	   	  
Kenet	  	  
et	  al	  [315]	  
	  
2010	  	   Retrospective	  
cohort	  
0-­‐1	  month	   22	   NS	   633	   3.5	  (ICH)	  
Richards	  	  
et	  al	  [313]	  
2011	   Retrospective	  
cohort	  
	  
‘neonatal’	  
	  
4	  
	  
	  
14	  
	  
508	  
	  
0.8	  (ICH)	  
2.8	  (ECH)	  
Overall	  	  
incidence	  
	   	   76	   	  
27	  
2998	  
721	  
2.5	  (ICH)	  
3.7	  (ECH)	  
	  
ICH; intracranial haemorrhage, ECH; extracranial haemorrhage, NS; not-specified  
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Table 6.3 Prospective studies reporting incidence of asymptomatic cranial bleeding 
Author	   Year	   Imaging	  modality	  
	  
Time	  interval	  
from	  delivery	  
scan	  performed	  	  
	  	  
No	  of	  ICH	   No	  of	  ECH	   Cohort	  
	  
Incidence	  (%)	  
	  
(A)	  In	  the	  general	  population	  
	   	   	   	   	   	   	  
Rooks	  	  
et	  al	  
[324]	  
2008	   MRI	  and	  US	   72	  hours	   46	  (all	  SDH)	   22	   101	   45.5	  (ICH)	  
21.7	  (ECH)	  
	   	   	   	   	   	   	  
Whitby	  
et	  al	  
[325]	  
2004	   MRI	   48	  hours	   9	  (all	  SDH)	   NS	   111	   8.1	  (ICH)	  
	   	   	   	   	   	   	  
Looney	  
et	  al	  
[326]	  
2007	   MRI	   Up	  to	  5	  weeks	   17	   NS	   88	   19.3	  (ICH)	  
	   	   	   	   	   	   	  
Overall	  
incidence	  	  
	   	   72	   	  
22	  
300	  
101	  
24	  (ICH)	  
21.7	  (ECH)	  
	  
(B)	  In	  newborns	  with	  haemophilia	  
	   	   	   	   	   	   	  
Smith	  et	  
al	  [327]	  
2007	   US	  and/or	  
CT	  
7	  days	   3	   6	   20	   15	  (ICH)	  
30	  (ECH)	  
	   	   	   	   	   	   	  
ICH; intracranial haemorrhage, ECH; extracranial haemorrhage, NS; not-specified 
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Systematic review of published literature reporting cranial bleeding in newborns 
with haemophilia and general population 
  
Overall incidence of cranial bleeding in newborns in the general population 
The five [251, 316-319] studies that reported symptomatic cranial bleeding are 
described in Table 6.2. Three retrospective studies reported 401 episodes of ICH in a 
total of 687,481 term newborns, giving an overall incidence of 5.8 per 10,000 
deliveries. Sachs et al measured the incidence of ICH in a population of term 
newborns with birth weight over 2500g and found 12 cases of symptomatic ICH in 
23,000 deliveries giving a similar overall incidence of 5.9 per 10,000 [316]. Hanigan 
et al performed a retrospective review of the cases of ICH in term newborns 
(gestational age >37 weeks and birth weight > 2500g) at a regional neonatal intensive 
care unit over a seven-year period. They found 28 cases of symptomatic ICH in an 
estimated population of 81,000 live births within the referral region [317]. Similarly, 
Towner et al calculated an incidence of symptomatic ICH of 7.3 per 10,000 births in 
live singletons born to nulliparous women with birth weight between 2500 – 4000g. 
This data was collected retrospectively from hospital discharge records over two years 
and included a total of 583,340 deliveries [251].  
 
Two single-centred retrospective studies reported 109 cases of cephalohaematoma in 
23,241 newborns giving an overall incidence of ECH of 47 cases per 10,000 [318, 
319]. A single-centre, retrospective chart review of 3,340 live term neonates assessed 
the incidence of birth injuries and reported 10 cases of cephalohaematoma related to 
delivery, giving an incidence of 0.3%. Overall birth trauma (including clavicular 
fractures, brachial plexus injury and massive haematomas) occurred in 1.3% of 
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vaginal deliveries and 0.5% of caesarean deliveries (p = 0.0001). In this cohort there 
were no SGH reported and no episodes of ICH, although no radiological screening 
was performed [318]. Another retrospective study that assessed incidence of birth-
associated head and neck trauma found 99 cases of cephalohaematoma in a cohort of 
19,901 newborns during a 6 year period, giving an incidence of 0.5%. ICH was not 
reported in this cohort [319]. 
 
Three prospective imaging studies [324-326] reported the incidence of asymptomatic 
cranial bleeding in term newborns in the general population using various imaging 
modalities (Table 6.3). Only one study reported the incidence of ECH in addition to 
ICH with a high incidence 22/101 (22%) experiencing cephalohaematoma [324]. 
Rooks et al performed serial MRI and cranial US in 101 term asymptomatic neonates 
and found 46 neonates (46%) had supratentorial SDH on MRI performed within 72 
hours of birth [324]. Twenty-two neonates had cephalohaematoma noted on initial 
MRI screening, 18 of which occurred in conjunction with SDH. Cranial US were 
performed after the initial screening MRI to monitor the natural evolution of bleeding. 
Only 11/17 (65%) of the posterior fossa SDH that were diagnosed on MRI were 
detected on cranial US. 
 
A case-control study evaluated the prevalence of asymptomatic ICH and its 
relationship to obstetric and neonatal risk factors. Cranial MRI was performed 
prospectively on 88 neonates (>35 weeks) in the first few weeks of life. All newborns 
were categorised into two groups. The first group (n=19) were considered to be at risk 
for psychiatric or neurodevelopmental disorders which included 12 neonates with 
prenatal mild ventriculomegaly, and seven offspring born to mothers with 
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schizophrenia. The remaining controls (n=69) were considered to be without risk for 
psychiatric or neurodevelopmental disorders [326]. Both groups were included in the 
analysis as there is no evidence that prenatal mild ventriculomegaly, or being born to 
a mother with schizophrenia confers an increased risk of ICH. Seventeen (19%) out of 
88 neonates had clinically silent ICH on MRI (15 control neonates, one neonate with 
mild ventriculomegaly, and one offspring of a mother with schizophrenia). The site of 
ICH included 16 posterior fossa SDH, one isolated case of IVH, five with co-existing 
parenchymal haemorrhages and two with SAH. All 17 cases of ICH occurred in 
newborns delivered vaginally which gave an overall prevalence of 26% of vaginal 
births. 
 
Whitby et al found the incidence of clinically silent ICH in term newborns to be 8%. 
Nine babies out of 111 had SDH diagnosed on cranial MRI within 48 hours of 
delivery [325]. All cases were asymptomatic, did not require any specific intervention 
and resolved on MRI by four weeks of age. The overall incidence of clinically silent 
ICH in 300 healthy term newborns imaged prospectively was 24% (range 8-47%). 
 
Overall incidence of cranial bleeding in newborns with haemophilia 
Nine studies [286, 292, 313-315, 320, 322, 323, 327] were available that reported the 
incidence of cranial bleeding in newborns with haemophilia. In eight retrospective 
studies there were 76 cases of symptomatic ICH reported in 2,998 newborns with 
haemophilia giving an overall incidence of 2.5% [286, 292, 313-315, 320, 322, 323]. 
In three retrospective studies there were 27 episodes of ECH reported in 721 
newborns with haemophilia giving an overall incidence of 3.7% (Table 6.2) [313, 
321, 323]. 
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Yoffe and Buchanan were the first authors to report on incidence of cranial bleeding 
in newborns with haemophilia in 1988. They reported five cases of ICH presenting 
within the first five days of life in a population of 150 boys with haemophilia [320]. 
All patients were delivered in different obstetric units in widely disparate 
geographical location over a 20-year time interval. 
 
Two studies reported in the Swedish population collected retrospective data on 
incidence of symptomatic ICH in haemophilia neonates based on a national registry. 
Ljung et al reported 13 cases of head bleeding (five cases of symptomatic ICH) in 140 
newborns over a 27-year period (1960-1987) [321] and at a later date, 16 cases of 
head bleeding (four of which were ICH) in 117 newborns over 20 years (1970-1990) 
[314]. The two studies have derived data from the same national registry and 
therefore the same cohort of patients. The larger cohort was included in this 
systematic review to assess cumulative incidence. The latter study, which reports rates 
of cranial bleeding in relation to MOD, was used in the meta-analysis.  
 
A large cohort study was conducted using surveys sent to 17 HTC across Germany 
and Austria where a total of 742 newborns were included [286]. In this cohort, 11 
cases of ICH occurred within the first week of life. Maclean et al explored the impact 
of unaware carriership on the clinical presentation of haemophilia by collecting data 
from medical records and parent interviews over two years (2002-2004). One episode 
of ICH and six episodes of ECH occurred in 73 deliveries [323]. A retrospective 
cohort study including 580 newborns with IBD recorded on the Nationwide Inpatient 
Sample was reported in the United States [292]. 17 cases of symptomatic ICH were 
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recorded in haemophilia newborns. However, in 11 out of 17 cases there were 
associated co-morbidities that increased the risk of ICH, such as prematurity, 
respiratory distress syndrome and sepsis. 
 
In the United States, haemophilia patients are automatically enrolled in the Universal 
Data Collection (UDC) surveillance project that commenced in 2003, for the Centers 
for Disease Control and Prevention. In 2009, Kulkarni et al [49] and then 
subsequently in 2010, Kenet et al [315] published the results from this project, giving 
data on the frequency of ICH at birth in newborns with haemophilia. From the most 
recent report, a total of 633 patients were diagnosed with haemophilia within one 
month of age, and ICH associated with delivery occurred in 22 babies. 
 
A recent European study evaluating the incidence of major bleeding in the neonatal 
period, reported 18 cases of head bleeding occurring within the first 28 days of life, 
four of which were ICH, and 14 were ECH, in a cohort of 508 newborns with 
haemophilia [313]. 
 
Only one prospective study assessed the incidence of asymptomatic cranial bleeding 
in newborns with haemophilia [327]. The sample size was limited to 20 newborns that 
underwent radiological screening within the first seven days of life. Of these 20 
patients, 13 were diagnosed with haemophilia using cord blood testing or venepunture 
within 24 hours of delivery. The remaining seven cases were diagnosed following 
bleeding symptoms (circumcision, heel prick, ECH). Fifteen per cent (3/20) had SDH 
on cranial CT and 30% (6/10) had ECH; four with cephalohaematomas and two with 
SGH [327]. All three babies that had ICH were born to mothers with unknown carrier 
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status by vacuum extraction and diagnosed with haemophilia due to ECH and 
prolonged bleeding following circumcision. They were asymptomatic for ICH and 
radiological screening was performed within 24 hours of the diagnosis. One baby with 
moderate haemophilia A was diagnosed with ICH on CT following a normal cranial 
US scan.  
 
The odds of experiencing symptomatic ICH at birth in newborns with haemophilia 
compared to the general population are 44 (95% CI 34.7-57.1) (p < 0.01). The odds of 
ECH in newborns with haemophilia compared to the general population are 8.2 (95% 
CI 5.38-12.6) (p  < 0.01). 
 
Meta-analysis to assess impact of mode of delivery on rates of cranial bleeding  
 
Towner et al assessed the risk of ICH in term newborns according to MOD. ICH 
occurred in 1 per 1,990 infants delivered spontaneously, 1 per 860 infants born by 
ventouse delivery, 1 per 664 delivered by forceps, 1 per 907 delivered by CS during 
labour and 1 per 2750 delivered by ELCS [251]. Table 6.4 shows the studies that 
included data on MOD in both the general population and newborns with 
haemophilia. The relative risk (RR) of ICH by MOD comparing both cohorts is 
presented in the column on the right. Newborns with haemophilia delivered by AVD 
have a roughly 60 times increased risk (RR 61; 95%CI, 26-146) of ICH compared to 
the general population. Newborns with haemophilia born by SVD have a roughly 50 
times increased risk (RR 51; 95%CI, 33-79) compared to the general population, and 
newborns with haemophilia born by CS have a 7 times increased relative risk (95% 
CI, 1.8-29.3) of ICH compared to the general population. 
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Figure 6.5 shows OR for ICH comparing all MOD to SVD. ELCS had reduced odds 
of ICH in the general population, although this did not reach statistical significance 
(OR 0.69; 95%CI, 0.39-1.24). All other MOD had an increased OR of ICH, with 
sequential instrumentation increasing the odds of ICH by more than seven fold (OR 
7.45; 95%CI, 4.06-13.68).  
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Table 6.4 Intracranial haemorrhage by mode of delivery in newborns with 
haemophilia and in the general population 
MOD	  
	  
In	  the	  general	  
population	  
	  
In	  newborns	  with	  haemophilia	   	  
	   Towner	  et	  al	  [251]	  
Ljung	  	  
et	  al	  [314]	  
Kenet	  
et	  al	  [315]	  
Richards	  et	  
al	  [313]	   Total	  
	  
RR	  
	  
AVD	   93/	  75299	  
	  
1/17	  
	  
2/15	   2/34	   5/66	   61.3	  	  	  (25.8	  to	  145.9)	  
	  
SVD	  
	  
	  
204/	  
387799	  
	  
	  
2/87	  
	  
	  
18/375	  
	  
	  
2/354	  
	  
	  
22/816	  
	  
51.2	  	  
(33.2	  to	  79.1)	  
	  
CS	   114/	  117425	   1/13
†	   1/182	   0/89	   1/283	  
7.28	  
(1.81	  to	  29.3)	  
	  
 
Numbers in parentheses are 95% confidence intervals. MOD; mode of delivery, 
AVD; assisted vaginal delivery, SVD; spontaneous vaginal delivery, CS; caesarean 
section, RR; relative risk  
† Delivered at 27 weeks gestation – case excluded from meta-analysis due to 
prematurity 
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The risk of symptomatic ICH differs significantly by MOD in newborns with 
haemophilia [313-315]. The odds of experiencing ICH are significantly higher in 
newborns born by AVD compared to SVD (OR 4.39; 95%CI, 1.46-13.7, p = 0.008) 
(Fig 6.6). The odds of experiencing ICH following CS are significantly reduced 
compared to SVD (OR 0.34; 95%CI, 0.14-0.83, p = 0.018) (Fig 6.7). 
 
Neurological outcome in the general population 
Data on the long-term neurological outcome following ICH in newborns in the 
general population was reported in two studies (Table 6.5 [A]). The developmental 
outcome at a median age of 3.4 years (range 1 to 6.5 years) was described in 33 term 
neonates with symptomatic ICH [317]. Five cases were excluded, as ICH was 
iatrogenic. In the remaining 28 cases of spontaneous ICH at birth, one infant died, 
giving a mortality rate of 3.6%. In the remaining survivors 14/27 (52%) experienced 
severe developmental delay, and in one case there was mild developmental delay. 
 
Conversely, in the prospective imaging studies that assessed asymptomatic ICH in 
term newborns the long-term neurological outlook was excellent. In the screening 
MRI study performed by Looney et al, all 46 cases with ICH were clinically 
asymptomatic with normal neurological examination, repeat imaging showed 
spontaneous resolution and clinical follow up at 24-months showed no gross motor 
developmental delay [326]. 
 
Neurological outcome in newborns with haemophilia 
Data on the long-term neurological outcome following ICH in newborns with 
haemophilia was reported in eight studies (Table 6.5 [B]). Two fatalities were 
reported in the eight studies, one as a direct result of intracerebral bleeding, and 
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another as a result of pneumococcal meningitis at the age of 4. Overall neurological 
morbidity was variable ranging from 9-100%. The trend was for the older studies to 
report a higher frequency of neurological morbidity in survivors of ICH. The 
neurological outcome reported included seizures, focal neurological deficit, global 
developmental delay and psychomotor retardation.  
 
In a Canadian case-control study comparing the health, physical function and quality 
of life in boys with and without a history of ICH, 4 cases of symptomatic ICH were 
diagnosed during the first week of life, in a cohort of 172 boys with haemophilia. The 
controls were matched to their cases by age, type and severity of haemophilia. 
Neurological examination, physical function and quality of life were measured using 
standardised quantitative assessments, which demonstrated that boys with 
haemophilia and ICH had a worse clinical outcome. Neurological examination was 
abnormal in 44% of boys with ICH versus 28% of boys without ICH. The mean 
physical function was lower (82% ± 25% vs 93.5% ± 12%, p=0.045) and quality of 
life scores were significantly reduced (6.8 ± 3.2 vs 8.5 ± 1.4, p=0.02) in boys with 
ICH compared to controls [322].  
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Table 6.5 Neurological outcomes following intracranial haemorrhage  
 
PMR; psychomotor retardation, SMR; statomotor retardation 
† Data on morbidity for ICH occurring in all boys aged 0-18 years 
‡ Data on morbidity for all cases of ICH in paediatric patients up to 3 years of age 
 
 
 
  
	   Mortality	  
(%)	  
Morbidity	  
(%)	  
Seizure	  
disorder	  	  
Focal	  
Neurological	  
deficit	  	  
Developmental	  
delay	  	  
Unspecified	  	  
(A)	  In	  the	  general	  population	  
Sachs	  
et	  al	  [316]	  
	  
8.3	   ?	   -­‐	   -­‐	   -­‐	   -­‐	  
Hanigan	  
	  et	  al	  
[317]	  
	  
7.1	   50	   	   1/28	   14/28	   	  
(B)	  In	  newborns	  with	  haemophilia	  
Richards	  
et	  al	  [313]	  
	  
	   11	   -­‐	   -­‐	   -­‐	   2/18	  
Kenet	  
et	  al	  [315]	  
	  
	   9	   2/11	   2/11	   -­‐	   -­‐	  
Smith	  	  
et	  al	  [327]	  
	  
	   66	   1/3	   -­‐	   1/3	   -­‐	  
Revel-­‐Vilk	  	  
et	  al	  [322]	  
†	  
	  
	   44	   -­‐	   7/16	   -­‐	   -­‐	  
Klinge	  	  
et	  al	  [286]	  
‡	  
	  
3.4	   100	   -­‐	   13/29	  (cerebral	  
palsy)	  
-­‐	   17/29	  PMR	  
15/29	  SMR	  
Yoffe	  &	  
Buchanan	  
[320]	  
12.5	   63	   5/8	   -­‐	   -­‐	   5/8	  PMR	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The long-term outcome in boys with haemophilia, who had an ICH before three years 
of age, was assessed in a case-control study [328]. This group found lower intellectual 
functioning, reduced visual-spatial and fine motor skills in the group with ICH 
compared to their aged-matched controls. In addition the boys in the ICH group had 
reduced language and mathematical skills. 
 
6.2.4 Discussion 
 
This systematic review of the literature shows the risk of ICH and ECH at birth in 
newborns with haemophilia is 44 and 8 times higher than in newborns in the general 
population, respectively. A meta-analysis is performed to determine the odds of 
experiencing ICH by MOD in newborns with haemophilia, comparing AVD and CS 
delivery to SVD. The current literature is limited to only three retrospective studies 
that report MOD and outcomes in this population. In the general population only one 
large cohort study was available for comparison. In this study the lowest risk of ICH 
at delivery was in ELCS and the highest risk was in sequential instrumental delivery. 
 
In newborns with haemophilia the odds of experiencing ICH at birth following AVD 
were over four fold increased compared to SVD (OR 4.39; 95%CI, 1.46-13.7). The 
odds of experienced ICH following CS are reduced compared to SVD (OR 0.34; 
95%CI, 0.14-0.83). This combines both elective and emergency (following labour) 
CS. The studies included in this analysis did not distinguish between elective and 
emergency CS. The latter was associated with a greater risk of ICH compared to SVD 
in the general population [251].  
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Relying on retrospective case review to determine the incidence of cranial bleeding 
has limitations. This method relies on historic records, where the accuracy of 
recording clinical diagnoses and the sensitivities of available investigations at the time 
could be unreliable. ICH diagnosed through the onset of neurological symptoms often 
indicates extensive bleeding. Smaller episode of intracranial bleeding may go 
undetected but result in adverse neurological outcome later in life [329]. Fatal cases 
may not have been included in the retrospective data collection, unless reported from 
post-mortem examination. In addition, around 50% of newborns with haemophilia 
have no positive family history and around 30% of cases are ‘sporadic’ due to de novo 
mutation in asymptomatic female carriers [314]. Thus, it is not always feasible to 
safeguard these babies from bleeding complications at the time of delivery. Indeed, 
mothers that are unaware of their carrier status are more likely to undergo an 
instrumental delivery, which is associated with a higher risk of cranial bleeding [323]. 
 
The high incidence of subclinical bleeding detected in the prospective imaging studies 
performed on healthy term newborns in the general population is concerning. It is not 
known how frequently this occurs in newborns with haemophilia due to a lack of data 
in this cohort. For early diagnosis the optimum imaging modality and timing is 
unknown, and no current consensus exists with regard to mode of screening in 
patients with IBDs. Whilst cranial US is inexpensive and readily available, it lacks 
sensitivity to detect bleeding in the posterior fossa. In the three prospective imaging 
studies in the general population [324-326], cranial CT and MRI were more sensitive 
than US at detecting posterior fossa bleeds. CT exposes the neonatal brain to ionising 
radiation making it an unsuitable imaging modality for screening purposes. As 
mentioned previously, neonatal MRI has superior diagnostic potential and considered 
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to be the safest imaging modality available, making it the optimum choice for 
screening for ICH in newborns with IBDs [309].  
 
The risk of cranial bleeding with AVD is well known and guidelines recommend 
against instrumental delivery for potentially affected fetuses [151]. The risk reduction 
in ICH of up to two-thirds with caesarean delivery has not been fully appreciated. 
ELCS is recommended in other obstetric situations where the risk of ICH is increased. 
The National Institute for Health and Clinical Excellence (NICE) recommends that a 
ELCS is offered to women with fetuses in a breech presentation [330]. The reported 
risk of ICH in breech vaginal deliveries is 0.2%, and the relative risk of serious birth 
injury is 3.17 (95%CI, 1.77-5.73) compared to CS delivery [331].  
 
The UKHCDO guideline on O&G management of women with IBDs state that 
spontaneous labour should be allowed where possible, but recommends against 
induction of labour, which is associated with a higher incidence of prolonged labour 
and instrumental delivery [250]. Likewise, the Canadian Haemophilia Society 
guidelines state that an IBD is not an indication per se for CS; a decision to proceed 
with CS should be based on obstetric indications [332]. The American Medical and 
Scientific Advisory Council (MASAC) of the National Hemophilia Foundation state 
that the outcome of labour cannot be predicted, and spontaneous (non-operative) 
vaginal delivery cannot be guaranteed therefore all women with an affected, or 
potentially affected fetus should be given the option of ELCS [333]. All guidelines 
advise against fetal scalp sampling for blood gases and fetal scalp electrodes and 
vacuum extraction and forceps deliveries are to be avoided. The problem with this 
recommendation is that as the fetus descends into the maternal pelvis during labour, 
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there is a ‘point of no return’, beyond which CS is more difficult [334]. The course of 
labour is unpredictable and 20% of women who commence labour spontaneously 
without any risk factors have prolonged labour or fetal distress that require an assisted 
delivery during the second stage [335].  
 
Until further prospective data is available to assess the risk of cranial bleeding and 
MOD the findings of this review should be considered when counselling expectant 
mothers. Carriers of haemophilia with a potentially affected fetus, especially if severe 
haemophilia is expected, should be offered ELCS. On the other hand, it has been 
argued that CS is associated with adverse maternal morbidity, especially where 
multiple repeat CS are expected. The risk of severe PPH with an ELCS has been 
shown to be lower in nulliparous women and women with previous CS compared to 
intended vaginal delivery [336, 337]. A frank discussion should take place in the 
multidisciplinary clinic in advance of the expected delivery date to help the mother 
make an informed decision. This practice has been adopted by some centres and has 
led to an increased CS delivery rate in carriers of haemophilia [1]. However this has 
not correlated with an increase in blood loss at delivery or rates of PPH, especially 
when a multidisciplinary approach is adopted [1]. On the contrary, the carriers who 
delivered at the Royal Free over the past 10 years had a reduced incidence of PPH 
(1.7%) compared to the general population (see Chapter 5.4). 
 
This study has limitations. The available published data on MOD and cranial bleeding 
in newborns with haemophilia is small and of limited quality, from retrospective 
cohort studies only, and therefore subject to bias and inaccuracy. Another important 
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limitation of retrospective data is the inability to control for other factors such as 
knowledge of carrier status and severity of haemophilia.  
 
6.2.5 Conclusion 
 
Cranial bleeding can result in a devastating outcome that further adds to the 
challenges faced by families with haemophilia. Although often cited as being a rare 
event, the risk of symptomatic ICH and ECH is 2.5% and 3.7%, respectively. This is 
44 and 8 times higher than the risk in the general population. CS is the safest MOD 
that is associated with a reduced risk of ICH compared to SVD with an OR of 0.34 
(95%CI, 0.14-0.83) in newborns with haemophilia. The highest risk is with AVD, 
which increases the odds of ICH by over four fold (OR 4.39; 95%CI, 1.46-13.7) and 
this MOD should be avoided in the potentially affected fetus. 
 
The information should be discussed with expectant mothers and appropriate MOD 
should be assessed individually in each case by a multidisciplinary team including the 
mother, the haemophilia team and the obstetrician. An ELCS should be offered to 
mothers expecting a baby with potentially moderate/severe IBD. 
 
 
 
 
 
 
 
 
  
198 
 
6.3 Prospective cranial magnetic resonance imaging screening at birth in 
newborns at risk of inherited bleeding disorders 
 
6.3.1 Introduction 
 
The systematic review of the literature presented in Chapter 6.2 highlighted the lack 
of studies assessing asymptomatic ICH in newborns with IBDs. Prospective screening 
studies in newborns in the general population have demonstrated a high rate of 
clinically insignificant ICH (8-46%) [324-326]. There is very little data on the actual 
incidence of asymptomatic ICH in neonates with IBDs, in whom the consequences 
could be devastating. Only one prospective study assessed the incidence of 
asymptomatic cranial bleeding in newborns with haemophilia. ICH was diagnosed in 
3 out of the twenty newborns who underwent radiological screening within the first 
week of life [327]. There are numerous case reports of ICH in neonates with rare 
IBDs (Table 6.6), however there are no prospective screening studies that assess the 
incidence in these patients.   
 
Cranial MRI is a non-invasive, safe method of screening for ICH in neonates with a 
higher sensitivity than other imaging modalities. Recent advances in MRI technology 
have led to better image quality and faster exam times. The potential for acquiring 
adequate images of the newborn brain, to exclude an acute haemorrhage, is therefore 
more feasible [338].  
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6.3.2 Aim 
 
The aims of this study was to:  
1) Determine the feasibility of undergoing MRI imaging within 72 hours of birth, 
to rule out asymptomatic ICH in newborns at risk of moderate/severe IBD  
2) Assess prevalence of asymptomatic cranial bleeding in neonates with 
moderate/severe IBD at birth 
3) To assess affect of MOD on rate of asymptomatic cranial bleeding 
 
6.3.3 Methods 
 
Participants  
Cranial MRI was undertaken within 72 hours of birth in term newborns with 
confirmed IBDs from July 2013 until May 2016. All pregnant women carrying a fetus 
with a potentially moderate or severe IBD were invited to participate. These included 
moderate and severe haemophilia, severe VWD, and heterozygotes with rare IBD. A 
member of the multidisciplinary team including an obstetrician, haematologist, 
paediatrician and a specialist haemophilia nurse provided both verbal information and 
a written information sheet about the study and the women and her partner were given 
time to consider participation. They were approached again in the second trimester 
and written consent was obtained prior to delivery.  
 
The diagnosis was confirmed either by chorionic villus sampling in early pregnancy, 
or at delivery by cord blood sample. Newborn participants underwent cranial MRI if 
they had a confirmed diagnosis of a moderate/severe IBD. Any uncertainty regarding 
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the diagnosis in relation to the cord blood sample (i.e. mild haemophilia B) was 
resolved when the infant was investigated, usually by peripheral blood sample within 
2 weeks of age. The newborn underwent cranial MRI, but details of their case were 
excluded from the final analysis if the newborn was found to be unaffected. All 
parents were informed of the scan result immediately after. The paediatric 
haemophilia team were informed directly if any acute haemorrhage was detected. 
 
Data collection 
Birth data obtained included onset of labour, use of oxytocin augmentation, duration 
of each stage of labour, MOD, gestational age at delivery and Apgar scores. 
Following delivery, a paediatrician examined for any signs or symptoms of ICH or 
bleeding. The outcome of the MRI was recorded. Details of any necessary treatments 
including factor replacement therapy were recorded. In addition, the paediatric 
follow-up outcome at 12 months of age, including any neurological impairment, 
further bleeds and inhibitor development was recorded. 
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Table 6.6 Case reports of intracranial haemorrhage occurring in term newborns with 
VWD and rare bleeding disorders 
 
 
 
  
Inherited	  bleeding	  
disorder	  
Case	  reports	   Number	  of	  reported	  cases	  
VWD	   Wetzstein	  et	  al.	  2006	  [339]	  
Mullaart	  et	  al.	  1997[340]	  
1	  (severe	  type	  3)	  
	  
1	  (type	  2A)	  diagnosed	  in	  
antenatal	  period	  	  
Fibrinogen	  deficiency	  or	  
abnormality	  
Vorstman	  et	  al.	  2003	  [341]	  
Ataoglu	  et	  al.	  2010	  [295]	  
Tavil	  et	  al.	  2016	  [342]	  
Hariharan	  et	  al.	  2010	  [343]	  
	  
1	  (afibrinogenaemia)	  
1	  (afibrinogenaemia)	  
1	  (afibrinogenaemia)	  
1	  (afibrinogenaemia,	  
diagnosed	  antenatally)	  
	  
FII	  deficiency	   Pasmant	  et	  al.	  2011	  [344]	   1	  (severe)	  
FV	  deficiency	   Salooja	  et	  al.	  2000	  [293]	  	  
Totan	  et	  al.	  1999	  [345]	  
Ellestad	  et	  al.	  2007	  [28]	  
1	  (severe)	  
1	  (severe)	  
1	  (diagnosed	  antenatally)	  	  
	  
FV	  and	  FVIII	  deficiency	   No	  reported	  cases	   	  
FVII	  deficiency	   Wong	  et	  al.	  2000	  [346]	   1	  (severe)	  
FX	  deficiency	   Ermis	  et	  al.	  2004	  [347]	  	  
De	  Sousa	  et	  al.	  1988	  [348]	  
Sumer	  et	  al	  1986	  [349]	  
2	  (siblings,	  both	  severe)	  
1	  (severe)	  
1	  (severe)	  diagnosed	  
antenatally)	  	  
	  
1	  (severe)	  
FXI	  deficiency	   No	  reported	  cases	   	  
FXIII	  deficiency	   Abbondanzo	  et	  al.	  1988	  [350]	   1	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Procedures 
The newborns underwent cranial MRI scan without sedation within 72 hours of 
delivery. A locally agreed scanning protocol was formulated by the radiology and 
research team, and followed for each participant. The newborns were transported to 
the radiology department with their parents in a mobile cot. Imaging was timed to 
occur following a morning feed. Once sleeping the newborn was swaddled and gently 
transferred to the MRI table, under an 8-channel head coil. The head was secured with 
foam sponges to minimise motion. Ear protectors were placed to minimise noise 
distraction. 
 
MRI was carried out with a high-field (1.5 Telsa) Philips Achiever (Philips 
Healthcare, Guildford, UK) using the following sequences: 1) axial, sagittal, and 
coronal T1-weighted spin echo 2) axial T2-weighted turbo spin echo, fast field echo 
and diffusion weight imaging. Slices were 5 mm thick with a 2.5 mm gap. All MR 
images were independently reviewed on a PACS (Centricity; GW Healthcare) by a 
board-certified neuroradiologist. Any abnormalities reported on MR imaging were 
discussed immediately with the haemophilia team and consultant paediatrician. If the 
initial MRI image was normal no further cranial imaging was arranged and the 
neonate underwent routine clinical follow up. In the event of an abnormality the 
follow up scan was arranged as determined by the paediatrician. 
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6.3.3 Results 
 
Table 6.7 shows the characteristics of the initial eight participants, and Table 6.8 
provides the details of labour and delivery. MRI screening did not demonstrated 
asymptomatic ICH in any newborn with IBDs in this cohort.  
 
The majority of women (6/8) made an informed decision to have ELCS following 
counselling regarding MOD at the Joint clinic. The mothers opted for ELCS to avoid 
the risk of ICH; of these six women, one went into spontaneous labour five days prior 
to her scheduled ELCS date, and two women had pre-labour rupture of membranes, 
and underwent EMCS the same day.  
 
The woman who went into spontaneous labour prior to her scheduled CS date was a 
parous woman; her firstborn was affected with severe haemophilia (Case No.3). 
Although she had opted for ELCS to avoid the risk of ICH, she attended the labour 
ward contracting strongly and her cervix was five centimetres dilated. In addition, 
there was a pathological pattern on the fetal cardiotocograph indicating fetal distress. 
Although the progress of labour was not prolonged, the emergency CS was carried 
out for presumed fetal compromise. The neonate was found to have 
cephalohaematoma at birth. 
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Table 6.7 Characteristics of newborns that underwent MRI screening at birth 
 
	  
Case	  
	  
Disorder	  
	  
Mutation*	  
Maternal	  
ethnicity	  
	  
Cord	  factor	  
level	  
(%)	  
Gestational	  
age	  
(weeks)	  
Birth	  
Weight	  
(grams)	  
1	   Severe	  HA	   Intron	  22	  
inversion	  	  
White	  
Caucasian	  
<	  1	   38	   3444	  
2	   Severe	  HA	   Intron	  22	  
inversion	  
Mixed	  –Afro-­‐	  
Caribbean	  
<	  1	   38	   2930	  
3	   Severe	  HA	   Intron	  22	  
inversion	  
Black	  African	   <	  1	   38	   3110	  
	  
4	   Moderate	  HB	  
Leyden	  
c.-­‐35G>A	  
promoter	  
	  
Black	  African	   2	  
(6	  months)	  
39	   3222	  
5	   Severe	  HB	   g.300117T>A	  
(p.Cys222Ser)	  
Asian	   <	  1	   38	   3500	  
	  
6	   Severe	  HA	   Intron	  22	  
inversion	  
White	  
Caucasian	  
<	  1	   39	   3100	  
7	   Severe	  HB	   	   Mixed	  –	  Asian	   <	  1	   39	   3020	  
	  
8	   Severe	  HA	   Intron	  22	  
inversion	  
White	  
Caucasian	  
<	  1	   36	   2500	  
 
* Mutations determined through carrier testing. Mutation nomenclature is based on 
the guidelines of the Human Genome Variation Society [351].  
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Table 6.8 Labour details of neonates born with inherited bleeding disorder 
 
ELCS, elective caesarean section; EMCS emergency caesarean section; MOD, mode 
of delivery; SVD, spontaneous vaginal delivery; EBL, estimated blood loss 
 
 
Table 6.9 shows the follow up outcomes for each participant. The newborn with 
cephalohaematoma diagnosed at birth had severe haemophilia A with inversion 22 
mutation and cord blood FVIII activity level < 1% (Case 3). Cephalohaematoma was 
diagnosed clinically and on cranial CT undertaken immediately to rule out ICH. There 
was no evidence of ICH on both CT and MRI performed on day 0 and 3, respectively. 
The infant was administered recombinant FVIII at a dose of 50 IU kg-1for the first two 
weeks of life. He continued with on demand treatment, where he was administered 
factor concentrate (Advate®) to provide cover for medical interventions (i.e. 
circumcision and insertion of a portacath®), or for treatment of bleeding episodes. He 
had a spontaneous SDH at four months of age, which has resulted in a poor 
	  
Case	  
	  	  
	  
Parity	  	  
	  
Onset	  of	  labour	  
Duration	  
of	  1st	  
stage	  
Duration	  
of	  2nd	  
stage	  
Final	  	  
Cervical	  
dilatation	  
	  
MOD	  
EBL	  at	  
delivery	  
1	   0	   No	  labour	   -­‐	   -­‐	   0	  cm	   ELCS	   500	  
	  
2	   0	   No	  labour	   -­‐	   -­‐	   1	  cm	   EMCS	   300	  
	  
3	   3	   Spontaneous	   90	  mins	   -­‐	   5	  cm	   EMCS	   600	  
	  
4	   2	   Spontaneous	   27	  mins	   5	  mins	   10	  cm	   SVD	   300	  
	  
5	   2	   No	  labour	   -­‐	   -­‐	   0	  cm	   ELCS	   700	  
	  
6	   0	   No	  labour	   -­‐	   -­‐	   0	  cm	   ELCS	   500	  
	  
7	   0	   No	  labour	   -­‐	   -­‐	   0	  cm	   ELCS	   500	  
	  
8	   0	   No	  labour	   -­‐	   -­‐	   1	  cm	   EMCS	   500	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neurological outcome and his treatment was compromised by the development of a 
high titre inhibitor.  
 
Another infant in our cohort (Case 6) experienced a spontaneous SDH at 5 months of 
age. Again, this boy was affected with severe haemophilia A from an inversion 22 
mutation. He presented with high-pitched, irritable crying and his mother, who was 
the daughter of a severe haemophilic, was aware to monitor for signs and symptoms 
of ICH, and promptly sought medical attention. The infant was receiving ‘on demand’ 
treatment but has now converted to regular prophylaxis since the diagnosis of first 
bleeding episode. He had normal neurological development at his last assessment.  
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Table 6.9 Outcome at one year of age 
	  
Case	  
	  
Bleeding	  
episodes	  
	  
Events	  requiring	  
Prophylaxis	  
	  
Current	  
Treatment	  
	  
Inhibitor	  
development	  	  
	  
Neurological	  
outcome	  
1	   Joint	  and	  
muscle	  bleeds	  
at	  10	  month	  
Circumcision	  
Portacath® 
insertion	  
Regular	  
prophylaxis	  
rFVIIa	  (Nova7)	  
Low	  titre	  at	  6	  
months	  
Normal	  
2	   Nil	   Portacath®	  
insertion	  
On	  demand	  
FVIII	  (Advate®)	  
Transient	  at	  9	  
months	  
Normal	  
3	   Spontaneous	  
SDH	  at	  4	  
months	  
Evacuation	  of	  ICH	  
Portacath®	  
insertion	  
Regular	  
prophylaxis	  
FVIII	  (Advate®)	  
High	  titre	   Global	  
developmental	  
delay,	  speech	  and	  
language	  delay	  
4	   Superficial	  
bruising	  lower	  
limbs	  
Circumcision	  
Portacath® 
insertion	  
On	  demand	  
FIX	  
Nil	   Normal	  
5	   Umbilical	  stump	  
bleed	  on	  day	  10	  
Circumcision	  and	  
hernia	  repair	  
On	  demand	  
FIX	  
Nil	   Normal	  
6	   Spontaneous	  
SDH	  at	  5	  month	  
ICH	  and	  Portacath® 
insertion	  
Regular	  
prophylaxis	  	  
FVIII	  (Advate®)	  
Nil	   Normal	  
7	   Superficial	  
bruising	  only	  
Nil	   Received	  TXA	  
only	  
Nil	   Normal	  
8	   Nil*	  	   Nil	   Nil	   Nil	   Normal	  
	   	   	   	   	   	  
ICH; intracranial haemorrhage, SDH; subdural haematoma, FIX; factor IX, FVIII, 
factor VIII, TXA; tranexamic acid, rFVIIa, activated recombinant FVII 
* Assessed at 2 months of age  
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6.3.4 Discussion 
 
This is a pilot study to assess the feasibility of performing cranial MRI to rule out 
ICH on asymptomatic newborns with severe IBD. All participants were successfully 
imaged within 72 hours of age, allowing diagnostic discrimination for acute 
intracerebral haemorrhage at birth. One infant out of 8 (12.5%) experienced an ECH 
that was apparent clinically and treated promptly. No episodes of asymptomatic ICH 
were detected. 
  
One infant (Case 3) experienced cephalohaematoma following EMCS. The 
cephalohaematoma likely occurred when pressure from uterine contractions forced 
the fetal head into the maternal pelvis, resulting in rupture of blood vessels in the 
periosteum. Cranial bleeding may have occurred as a result of the labour process. This 
case supports the argument for ELCS (without labour) in fetuses at risk of severe 
IBDs. The two babies who developed ICH at 4-5 months of age provide a strong 
argument for repeat MRI screening in the first few months of life. The bleeds may 
have occurred at the time of delivery and were too small to be detected on cranial 
MRI carried out within 72 hours of delivery. Serial MRI screening at weekly intervals 
for the first few months may be indicated, especially where the delivery has been 
traumatic, as in case No. 3. This would ensure earlier detection and treatment of ICH 
with improved neurological outcome. The optimum timing for screening for 
asymptomatic ICH in newborns with severe/moderate IBDs is still not known, but 
clearly further research would be valuable. 
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EMCS performed at full cervical dilatation for obstructed labour is a risk factor for 
skull fracture and ECH/ICH, thought to occur when the fetal head is disimpacted from 
the maternal pelvis [325] [352]. Although the evidence for reduced neonatal 
morbidity and mortality is limited to one, non-randomised clinical trial, recently 
NICE have endorsed the use of a balloon devise “fetal pillow”, to elevate the fetal 
head and reduce trauma [353]. Five per cent of the 117 newborns experienced ECH in 
the later study reported by Ljung. There were 12 cases of subgaleal or cephalic 
haematoma, all with severe haemophilia; 10 were delivered by ventouse, 1 by SVD, 
and 1 by CS [314]. In the European cohort study there were 14 cases of 
cephalhaemoatoma in 508 neonates with haemophilia.  Five out of 34 (15%) occurred 
following AVD, 2 out of 53 (4%) occurred following CS, and two occurred out of 316 
(2%) following SVD. In both studies there were cases of prematurity (<36 weeks 
gestation) and the breakdown of ECH by MOD and gestational age were not specified 
[313]. In addition there was no distinction between elective and emergency CS. 
 
All newborns in our cohort were born to mothers who were known carriers, in a 
maternity unit affiliated with a haemophilia centre. Expectant mothers booked at the 
Royal Free Hospital received multidisciplinary care with an individualised plan 
However in both studies the labour details are not provided (emergency or elective 
CS, prolonged labour) and there is no data on the gestational ages of these 
cases.drawn up in advance of labour. All mothers expecting a newborn potentially at 
risk of moderate or severe IBD were offered ELCS. If the mother was keen for 
vaginal delivery this was documented in the plan with recommendations such as 
avoiding fetal blood sampling, scalp electrode, ventouse delivery and difficult (mid-
cavity) forceps with early recourse to EMCS, if any signs of obstructed labour. 
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Adopting this approach resulted in no ICH diagnosed at birth. However, due to the 
limited number of cases in this series it is not possible to comment on the frequency 
of asymptomatic ICH in newborns with IBD. This case series does highlight the high 
incidence of cranial bleeding seen in infants with severe haemophilia (one episode of 
ECH, and two episodes of ICH among 8 children within the first 6 months of age). 
 
Unpublished data on all deliveries of newborns with haemophilia were recorded at 
another UK haemophilia centre (Alder Hay Children’s Hospital, NHS Foundation 
Trust, Liverpool). The carriers delivered at their local hospital and the infants were 
brought to the centre for an MRI scan within the first week of life. Two out of six 
infants (33%) imaged had asymptomatic ICH diagnosed on cranial MRI. One infant 
was delivered by SVD following a prolonged second stage (3 hours and 55 minutes) 
at 39 weeks gestation, weighing 3000 grams to a mother that was a known carrier of 
severe haemophilia A. Neonatal MRI demonstrated bilateral SDH in the posterior 
fossa. Another neonate delivered by SVD prematurely at 36 weeks weighing 2500 
grams to a mother with an unknown carrier status. Investigations for a bleeding 
disorder were carried out following prolonged bleeding from the heal prick 
examination and neonatal jaundice. This demonstrated a prolonged APTT and FVIII 
level < 1%. Although asymptomatic for ICH, the neonate had an anterior IVH on 
MRI scan. Both infants received factor concentrate treatment followed by prophylaxis 
from birth, had repeat MRI scans at six months of age that showed complete 
resolution of the haemorrhages, and subsequently normal neurological outcome.  
 
These cases highlight the benefit of early screening for ICH in asymptomatic 
newborns diagnosed with moderate/severe IBD. The birth process results in 
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mechanical forces that are likened to a traumatic head injury, which would ordinarily 
necessitate urgent radiological imaging in a child with moderate/severe IBD. In 
addition, the clinical signs and symptoms of ICH in a neonate are vague and a failure 
to diagnose ICH and administer factor replacement therapy early in neonates with 
moderate/severe IBD is associated with a poorer neurological outcome [289, 320, 
354]. 
 
One potential side effect of routine MRI screening for ICH in asymptomatic neonates 
with moderate/severe IBDs is the risk of early exposure to factor concentrate 
administration and potential for inhibitor development. Roughly 25% of children with 
severe haemophilia A develop inhibitory antibodies to infused FVIII resulting in 
significant challenges with treatment later in life [355]. Patients with high-titre 
inhibitors have increased risk of potentially life-threatening bleeds and treatment of 
these patients is more complex and costly [356]. In the study by Richards et al 
inhibitor development occurred in 5 patients with neonatal bleeding complications 
[313]. The relative risk (RR) of inhibitor development was 1.9 (95% CI 0.9-4.5) in 
children with neonatal bleeding, although the authors stated that this figure should be 
interpreted with caution because the risk did not adjust for other cofounders. 
Chalmers et al reported on FVIII exposure and subsequent inhibitor development and 
found no significant difference in children treated at different time points during the 
first year of life [357]. The results of the multicentre Concerted Action on 
Neutralising Antibodies (CANAL) study also support these findings; the incidence of 
inhibitors appeared to be associated with age of first treatment, however, after 
adjustment for treatment intensity this association largely disappears. Regular 
prophylaxis was associated with a 60% lower risk of inhibitor development than on 
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demand treatment (RR 0.4; 95%CI, 0.2-0.8) [358]. The risk of developing inhibitors 
was 2.8 (95%CI, 1.5-5.0) times higher in high-risk compared to low-risk mutations. 
The risk of developing inhibitors was 3-fold higher in patients with a positive family 
history of inhibitors. In the recently reported Survey of Inhibitors in Plasma-Product 
Exposed Toddlers (SIPPET) study, male patients (< 6 years of age) with severe 
haemophilia A treated with plasma-derived FVIII containing von Willebrand factor 
had a lower incidence of inhibitors than those treated with recombinant FVIII (hazard 
ratio, 1.87; 95%CI 1.17-2.96) [359].   
 
The UKHCDO recommend primary prophylaxis to be initiated from the time of first 
joint bleed as standard of care in infants with severe haemophilia A. The Research of 
Determinants of INhibitor Development (RODIN) group reported that a second-
generation recombinant FVIII (rFVIII) was associated with a higher incidence of 
inhibitor development [360]. High-dose intensive FVIII treatment was associated with 
increased inhibitor risk (adjusted hazard ratio [aHR] 2.00; 95%CI, 1.3-3.0), whilst 
regular prophylaxis, especially in patients with low-risk f8 mutations, had a reduced 
risk of inhibitor development (aHR 0.61; 95%CI, 0.19-2.0 and aHR 0.5; 95%CI, 1-
1.4, respectively) [360]. Some clinicians advocate prophylaxis from birth, a concept 
that has been gaining popularity among paediatric haemophilia treatment providers 
for many years [361]. The notion of preventing haemorrhages rather than treating 
them once they occur was first recommended in 1994 as optimal management by the 
MASAC of the National Hemophilia Foundation [362]. Whether routine MRI 
screening for intracerebral bleeding at birth would lead to increased factor exposure 
and subsequent inhibitor development requires consideration. However, these studies 
suggest that the risk of inhibitor development is more associated with genetic factors, 
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family history, and treatment intensity, than age of first exposure. Further research 
and careful interpretation of the data is required prior to making recommendations for 
appropriate treatment decisions [363]. 
 
6.3.5 Conclusion 
 
This prospective pilot study provided evidence to support the feasibility of MRI 
imaging within 72 hours of delivery. Imaging was possible in eight cases, to exclude 
acute asymptomatic ICH. All neonates underwent cranial MRI scan without sedation 
and no adverse effects according to the protocol. 
 
Cranial MRI carried out within 72 hours of birth did not detect any asymptomatic 
ICH in this case series of eight newborns with haemophilia. The majority of infants (6 
out of 8) were delivered by ELCS, or semi-elective CS without labour. A high 
frequency of cranial bleeding within 6 month of age was reported; one infant 
experienced cephalohaematoma following an EMCS, and later suffered a spontaneous 
ICH, another infant experienced a spontaneous SDH at 5 months of age. Whether 
these bleeds were truly spontaneous, or delayed onset secondary to the birth process is 
not known. 
 
Recruitment for this study is ongoing. Currently there is insufficient data to allow for 
any meaningful interpretation as to the benefit of MRI screening of asymptomatic 
neonates with IBD. Detection and prompt treatment of any asymptomatic ICH could 
prevent serious long-term neurological sequelae or even death. This would provide a 
strong argument for cranial MRI screening at birth to be standard care in 
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asymptomatic neonates diagnosed with an IBD. Due to the high frequency of delayed 
‘spontaneous’ ICH reported in this cohort, repeat MRI at weekly or monthly intervals 
in the first six months of age would provide additional evidence to guide optimal 
timing of cranial MRI screening.  
 
Only a large multi-centred collaborative study with national, or multi-national 
participant recruitment will provide sufficient evidence to properly assess the effect of 
MOD on rates of cranial bleeding. In addition maternal outcome, such as incidence of 
PPH, or complications from repeat ELCS should be recorded. Long-term neurological 
outcome data and the incidence of inhibitor development in neonates undergoing 
radiological screening should be recorded. Data on asymptomatic cranial bleeding at 
birth and how this evolves in neonates with IBDs is still lacking. An evidence-based 
approach would lead to better outcomes, if serious cranial bleeding can be detected 
and treated at the earliest opportunity.  
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THE CHANGES IN ROTATIONAL THROMBOELASTOMETRY IN 
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7.1 Introduction 
 
Women with FXI deficiency are at an increased risk of bleeding complications at 
delivery. FXI levels are unaffected by pregnancy [157, 158] and the persistence of 
low factor levels in the third trimester is common in women with this condition [49, 
175, 182]. The risks of bleeding do not correlate well with the underlying FXI level 
[364] and relying on this alone may result in inappropriate assessment of the bleeding 
risk. 
 
In normal pregnancy a hypercoagulable state is achieved due to increased levels of 
coagulation factors, and a reduction in anticoagulant free protein S. This is considered 
to be a physiological mechanism that prevents excessive bleeding at parturition. 
Rotational thromboelastometry (ROTEM®) is sensitive to hypercoagulable changes in 
normal pregnancy [365-367] that result in a shortened clotting time (CT) and clot 
formation time (CFT), an increase in the alpha angle and maximum clot firmness 
(MCF) [367, 368].  
 
The aim of this case-control study was to determine whether ROTEM® detects 
hypercoagulable changes in pregnant women with FXI deficiency, by comparing 
parameters with non-parturient controls. In addition, any hypercoagulable changes 
detected in pregnant women with FXI deficiency were compared with healthy 
parturient controls. Bleeding tendency was measured with a bleeding score and FXI 
activity level (FXI:C). Correlation between with ROTEM® parameters, bleeding 
score, and FXI:C was also assessed. 
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7.2 Materials and methods 
 
7.2.1 Study participants 
ROTEM® was performed on 60 women in three distinct groups. The first group 
constituted 27 pregnant women with FXI deficiency in the third trimester of 
pregnancy. Nineteen women had mild FXI deficiency with FXI:C level 20 – 70 IU/dL 
and 8 women had severe FXI deficiency with FXI:C level < 20 IU/dL. The second 
group constitute 20 age-matched parturient control women with uncomplicated 
pregnancies who were in the third trimester of pregnancy. The third group constituted 
14 non-parturient healthy control women. The exclusion criteria was age <18 years or 
> 45 years, weight < 50kg or > 100kg, current use of anticoagulant/antiplatelet 
medication, blood transfusion within the previous 28 days, abnormal full blood count 
and history of smoking or concurrent medical condition (cardiovascular, renal, 
malignancy, or hypertension). Parturient and non-parturient controls had no personal 
or family history of a coagulation disorder.  
 
7.2.2 Blood sampling and laboratory analysis 
Blood samples were obtained following consent during antenatal visits for parturient 
women in the third trimester of pregnancy (28 weeks + 0 days until 42 weeks 
gestation). Blood was obtained from non-parturient control women following consent 
and ensuring there were no exclusion criteria. Following an initial discard, 4.5 mL of 
venous blood was collected from the upper limb without venous occlusion using 
vacutainer tubes containing 0.106 M trisodium citrate (1 part citrate: 9 parts blood, 
Sarstedt, Leicester, UK). Bloods samples were analysed by ROTEM® within 30-120 
minutes of collection. 300µL of citrated whole blood was re-calcified using 20 µL 
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CaCl2 in HEPES buffer pH 7.4 and 0.1% sodium acid (Star-TEM® reagent, 
Pentapharm GmbH, Munich, Germany). The non-activated thrombelastometry test 
(NATEM) was used. Full details of the ROTEM® methodology and analysis are 
provided in Chapter 3.3. FXI:C was measured using a one-stage APTT-based assay as 
described in Chapter 3.1.  
 
7.2.3 Data collection 
The following data were collected from each participant: 1) demographic information 
(age, parity and BMI at booking), 2) baseline and third trimester FXI:C level (cases 
only), 3) ROTEM® parameters, 4) gestational age when ROTEM® was performed 5) 
bleeding score. A qualified haemophilia specialist obtained bleeding scores using the 
condensed MCMDM-1VWD bleeding questionnaire (see Appendix 4) [369, 370].  
 
7.2.4 Statistical analysis 
ROTEM® parameters, FXI:C levels, bleeding scores and demographic data were 
reported as mean and standard deviations (SD) where normally distributed, and 
median and interquartile ranges (IQR) where data was skewed. The differences 
between ROTEM® parameters between groups were compared using student’s 
unpaired t-test for parametric data, and Mann-Whitney U test for non-parametric data. 
A p value of <0.05 was considered statistically significant. Comparison of FXI:C 
levels and bleeding scores with ROTEM® parameters was performed using Pearson’s 
correlation coefficient (r).  
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7.3 Results 
 
Complete ROTEM® and demographic data was available for all 27 case participants. 
One non-parturient participant was excluded due to an error when processing the 
sample. Table 7.1 shows the demographic details of each group.  
 
Table 7.1 Demographic characteristics of the three groups  
 
	  
	  
Non-­‐parturient	  
controls	  	  
(n	  =	  12)	  
	  
Parturient	  controls	  
(n	  =	  20)	  
	  
	  
FXI	  deficiency	  
(n	  =	  27)	  
	  
p	  value	  
	  
	   	   	   	   	  
Age	  at	  delivery	  
(years)	   30	  (4.0)	   31	  (6.0)	   33	  (4.0)	   0.108	  
	   	   	   	   	  
Parity	  at	  delivery	   -­‐	   1.0	  (1.0)	   1.0	  (2.0)	   0.645	  
	   	   	   	   	  
BMI	  at	  booking	  
(kg/m2)	   23	  (3.0)	   23.5	  (3.2)	   23.6	  (4.2)	   0.682	  
	   	   	   	   	  
Gestation	  at	  time	  
of	  ROTEM®	  
(weeks)	  
-­‐	   30	  (8.0)	   31	  (3.0)	   0.592	  
	   	   	   	   	  
 
 
BMI, body mass index; ROTEM®, rotational thromboelastometry; FXI, factor XI 
Numbers presented are means and one standard deviation (BMI, gestation) or median 
and interquartile range (age, parity). P value determined by student’s t-test or Mann-
Whitley U test depending on distribution of data. 
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The median age of parturient women with FXI deficiency was 30 (range 21 to 39 
years). The median age of parturient control women was 31 (range 20 to 38 years) 
and among non-parturient controls was 33 years (range 26 until 39 years). There were 
no significant differences in median age between the groups (p = 0.12). Likewise the 
mean BMI at booking among women with FXI deficiency was 23.6 (range 17.4-35.2 
kg/m2), among parturient controls was 23.5 (range 19.0-28.6 kg/m2), and among non-
parturient controls was 23.0 (22.0-27.0 kg/m2), with no statistical difference seen 
between groups (p = 0.68). ROTEM® was performed between 28 and 37 weeks 
gestation in parturient women with FXI deficiency with a median gestational age of 
30 weeks. In parturient controls ROTEM® was performed between 28 weeks and 38 
weeks gestation with a median gestational age of 31 weeks. There was no statistically 
significant difference detected in the gestational age when ROTEM® was performed 
in the women with FXI deficiency compared to parturient controls (p = 0.59). 
 
7.3.1 Comparison of ROTEM® between groups 
Table 7.2 shows the mean and SD of ROTEM® parameters of women with FXI 
deficiency and both control groups. All parameters (CT, CFT, alpha angle and MCF) 
were statistically different with p < 0.05. Figure 7.1 shows the box and whisker plot 
for the means, SD range and p value to show difference in ROTEM® parameters 
between FXI deficiency patients and the two control groups. Figure 7.2 shows the 
thromboelastogram for the different groups. CT was significantly shorter (p <0.001) 
in both parturient (375 ±SD 55.8 seconds) and non-parturient controls (555 ±SD 85.5 
seconds) compared to patients with FXI deficiency (617 ±SD 194 seconds). CFT was 
significantly shorter (p <0.001) in parturient controls (87 ±SD 23.0 seconds) 
compared to patients with FXI deficiency (136 ±SD 44.8 seconds) and significantly 
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shorter (p <0.001) in patients with FXI deficiency compared to non-parturient 
controls (184 ± 56.3 seconds). Alpha angle was significantly higher (p <0.001) in 
parturient controls (72 ±SD 3.0 degrees) compared to patients with FXI deficiency 
(65 ±SD 6.2 degrees) and significantly higher (p <0.001) in patients with FXI 
deficiency compared to non-parturient controls (57 ± 7.6 degrees). No significant 
difference (p = 0.542) in MCF was seen between parturient controls (64  ± SD 3.7 
mm) and patients with FXI deficiency (63 ±SD 6.5 mm). However MCF was 
significantly higher (p = 0.005) in patients with FXI deficiency compared to non-
parturient controls (60 ±SD 5.0 mm) (Table 7.2). 
 
Table 7.2 Comparison of ROTEM® parameters between groups 
 
 
CT; clotting time, CFT; clot formation time, MCF; maximum clot firmness. Values 
are mean and one standard deviation (SD) or median and interquartile range (IQR). 
Parameters highlighted in grey are statistically different between groups (p < 0.05). 
 
 
 
  
	   Parturient	  
controls	  
(n	  =	  20)	  
	  
p	  value	  
FXI	  deficiency	  
(n	  =	  27)	  
	  
p	  value	  
Non-­‐parturient	  
controls	  
(n	  =	  12)	  
	   	   	   	   	   	  
CT	  (secs)	   375	  ±	  55.8	   <	  0.001	   617	  ±	  194	   <	  0.001	   555	  ±	  85.5	  
	   	   	   	   	   	  
CFT	  (secs)	   87	  ±	  23.0	   <	  0.001	   136	  ±	  44.8	  	   <	  0.001	   184	  ±	  56.3	  
	   	   	   	   	   	  
α	  angle	  (%)	   72	  ±	  3.0	   <	  0.001	   65	  ±	  6.2	  	   	  <	  0.001	   57	  ±	  7.6	  
	   	   	   	   	   	  
MCF	  (mm)	   64	  	  ±	  3.7	   0.542	   63	  ±	  6.5	   0.005	   60	  ±	  5.0	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Figure 7.1 Comparison of ROTEM® between groups  
 
 
 
                p < 0.001   p < 0.001         p < 0.001   p < 0.001 
 
 
           
  
 
 
          
 
        
  
 
 
 
               
    p < 0.001 p < 0.001                                      p = 0.054   p = 0.005     
    
    
     
  
P controls; parturient controls, FXI def; factor XI deficiency, NP controls; non-
parturient controls. Participants divided into three groups for comparison. The data is 
presented in a box-and-whisker plot. The box spans the interquartile range (from the 
25th to the 75th percentiles), and the line within the box denotes the median. The 
whiskers extend from the maximum and minimum 1.5 IQR. 
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Figure 7.2 Thromboelastogram demonstrating mean ROTEM® differences between 
groups 
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  control	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224 
 
7.3.2 Comparison of ROTEM® between parturient and non-parturient controls 
Table 7.3 demonstrates the mean and SD of ROTEM® parameters in both parturient 
and non-parturient controls. All parameters (CT, CFT, alpha angle and MCF) were 
statistically different with p < 0.05. Comparison of ROTEM® parameters between 
both control groups demonstrated that parturient controls had significantly shorter CT 
and CFT (p <0.001) compared to non-parturient controls. The alpha angle (p<0.001) 
and MCF (p = 0.003) were significantly increased in the parturient compared to non-
parturient controls.  
 
7.3.3 Comparison of ROTEM® between mild and severe FXI deficiency patients 
Table 7.4 demonstrates the mean and SD of ROTEM® parameters in both mild and 
severe FXI deficiency. The parameters highlighted in grey (CT, CFT and MCF) were 
statistically significant with a p < 0.05. Figure 7.3 shows the box and whisker plots 
for the mean, standard deviation, range and p values in ROTEM® parameters between 
mild and severe FXI deficiency patients. Figure 7.4 shows the thromboelastogram 
demonstrating the difference between mild and severe FXI deficient patients. CT (531 
±SD 70.3 seconds) and CFT (120 ±SD 19.8 seconds) were significantly shorter (p 
<0.001 and p = 0.002, respectively) in mild compared to severe FXI deficiency 
patients (820 ±SD 245 seconds and 176 ±SD 62.7 seconds, respectively). Alpha angle 
was higher in mild (66.5 ±SD 3.4 degrees) compared to severe FXI deficiency 
patients (61.3 ±SD 9.6 degrees) although this difference was not statistically 
significant (p = 0.15). MCF was significantly lower (p = 0.02) in mild (62.0 ±SD 5 
mm) compared to severe FXI deficiency patients (69.0 ±SD 10 mm). A wider 
variation in MCF was seen in parturient patients with FXI deficiency (49-80 mm) 
compared to parturient (58-72 mm) and non-parturient controls (55-62 mm).  
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Table 7.3 Comparison of ROTEM® parameters between parturient and non-parturient 
controls 
 
 
 
 
 
 
 
 
 
CT; clotting time, CFT; clot formation time, MCF; maximum clot firmness. Values 
are mean and one standard deviation (SD) or median and interquartile range (IQR). 
Parameters highlighted in grey are statistically different between groups (p < 0.05).  
 
 
 
  
	   Parturient	  
controls	  
(n	  =	  20)	  
	  
p	  value	  
Non-­‐parturient	  
controls	  
(n	  =	  12)	  
	   	   	   	  
CT	  (secs)	   375	  ±	  55.8	   <	  0.001	   555	  ±	  85.5	  
	   	   	   	  
CFT	  (secs)	   87	  ±	  23.0	   <	  0.001	   184	  ±	  56.3	  
	   	   	   	  
α	  angle	  (%)	   72	  ±	  3.0	   <	  0.001	   57	  ±	  7.6	  
	   	   	   	  
MCF	  (mm)	   64	  	  ±	  3.7	   0.003	   60	  ±	  5.0	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Table 7.4 ROTEM® analysis between mild and severe FXI deficiency patients 
 
	   Mild	  FXI	  deficiency	  	  
	  (n	  =	  19)	  
	  
p	  value	  
Severe	  FXI	  deficiency	  	  
	  (n	  =	  8)	  
	   	   	   	  
CT	  (secs)	   531	  ±	  70.3	   <	  0.001	   820	  ±	  245	  
	   	   	   	  
CFT	  (secs)	   120	  ±	  19.8	   0.002	   176	  ±	  62.7	  	  
	   	   	   	  
α	  angle	  (%)	   66.5	  ±	  3.4	   0.150	   61.3	  ±	  9.6	  	  
	   	   	   	  
MCF	  (mm)	   62.0	  	  ±	  5	   0.020	   69.0	  ±	  10	  
	   	   	   	  
 
 
CT; clotting time, CFT; clot formation time, MCF; maximum clot firmness. Values 
presented are mean and one standard deviation (SD) or medians and interquartile 
range (IQR). Parameters highlighted in grey are statistically different between groups 
(p < 0.05). 
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Figure 7.3 Comparison of ROTEM® between mild and severe FXI deficiency patients 
 
 
 
 
 
 
 
 
 
     p < 0.001           p = 0.002   
     
 
  
 
          
 
 
 
 
 
 
 
 
 
  p = 0.150            p = 0.020  
        
 
  
 
 
FXI deficiency patients divided into two groups. Those with mild FXI deficiency had 
FXI:C level 20-70 IU/dL, those with severe had FXI:C < 20 IU/dL. The data is 
presented in a box-and-whisker plot. The box spans the interquartile range (from the 
25th to the 75th percentiles), and the line within the box denotes the median. The 
whiskers extend from the maximum and minimum 1.5 IQR. 
 
 
 
 
228 
 
Figure 7.4 Thromboelastogram demonstrating mean ROTEM® differences in mild 
and severe FXI deficient patients 
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7.3.4 Correlation of ROTEM® with FXI:C levels 
 
Figure 7.5 demonstrates the change in FXI levels in 46 pregnancies where the 
baseline and third trimester FXI:C level were recorded. There was no significant 
difference (p = 0.152) between baseline FXI:C level (median 47 IU/dL) and third 
trimester FXI:C level (median 46 IU/dL). Table 7.5 demonstrates the correlation 
coefficients between ROTEM® parameters and FXI:C level. When comparing 
ROTEM® parameters with FXI:C levels, a significant negative correlation was 
detected between CT (r= -0.65, p<0.001) and CFT (r = -0.59, p = 0.002). No 
significant correlation was detected between FXI:C levels and alpha angle ( r = 0.37, 
p = 0.06) and MCF (r= -0.23, p=0.24). 
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Figure 7.5 Changes in factor XI level during pregnancy (n = 46) 
 
 
 
 
 
 
 
 
 
 
 
FXI:C; factor XI activity level. The data is presented in a box-and-whisker plot. The 
box spans the interquartile range (from the 25th to the 75th percentiles), and the line 
within the box denotes the median. The whiskers extend from the maximum and 
minimum 1.5 IQR. 
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Table 7.5 Correlation between ROTEM® parameter and FXI level 
 
	   r	   r2	   p	  value	  
CT	  (secs)	   -­‐0.65	   0.42	   <	  0.001	  
CFT	  (secs)	   -­‐0.59	   0.35	   0.002	  
α	  angle	  (¢)	   0.37	   0.14	   0.057	  
MCF	  (mm)	   -­‐0.23	   0.05	   0.241	  
 
Values are Pearson’s correlation coefficient (r) and r2 
 
 
Table 7.6 Correlation between ROTEM® parameters and bleeding score 
 
	   r	   r2	   p	  value	  
CT	  (secs)	   0.58	   0.34	   <	  0.001	  
CFT	  (secs)	   0.42	   0.18	   0.003	  
α	  angle	  (¢)	   -­‐0.45	   0.21	   0.001	  
MCF	  (mm)	   0.03	   0.00	   0.831	  
 
 
Values are Pearson’s correlation coefficient (r) and r2 
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7.3.5 Correlation of ROTEM® with bleeding score 
 
The bleeding score ranged from -2 to 7 (median 3) in women with FXI deficiency, 
and from -1 to 3 in controls (median 0). Table 7.6 demonstrates the correlation 
coefficients between ROTEM® parameters and the bleeding score. CT had a 
significant positive correlation (r = 0.58, p<0.001) with bleeding score. A positive 
correlation was detected between CFT and bleeding score (r = 0.42, p = 0.003) and a 
negative correlation was detected between alpha angle and bleeding score (r = -0.45, 
p = 0.001). There was no significant correlation between MCF and bleeding score. 
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7.4 Discussion 
 
This is the first study to report ROTEM® changes in parturient women with FXI 
deficiency compared to parturient and non-parturient controls. On average, parturient 
women with FXI deficiency took longer to clot (prolonged CT) compared to both 
parturient and non-parturient controls. This was more pronounced in patients with 
severe FXI deficiency. The role of FXI in clot initiation is still not fully understood. 
FXI activation occurs initially via the extrinsic pathway, with the resultant activated 
FIX contributing to sustained thrombin generation through a feedback loop [45]. In 
the consolidation phase of coagulation, a small amount of thrombin generated in the 
initiation phase is sufficient to activate FXI, which then activates FIX to augment the 
thrombin burst [48]. Clot consolidation and clot strength was increased in parturient 
patients with FXI deficiency compared to non-parturient controls. On average, the 
increase in clot consolidation was not as pronounced as in parturient controls. An 
explanation for the increase in clot consolidation and clot strength seen in FXI 
deficient women could be due to the progressive rise in coagulation factors (F)VII, 
FVIII, FX, FXII, fibrinogen and VWF [155-157] (Chapter 2.3.2). The rise in 
coagulation factors, especially FVIII and VWF, are most pronounced in the third 
trimester. The change in coagulation factor levels is accompanied by a reduction in 
physiological anticoagulants, most significantly a reduction in protein S activity levels 
and an acquired protein C resistance [160]. These changes could account for the 
increase in clot consolidation and clot strength in pregnant women with FXI 
deficiency compared to non-parturient controls.  
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In non-parturient patients with FXI deficiency those with reduced clot stability and a 
reduction in fibrin network density have an increased bleeding tendency [242]. There 
was a strong correlation between CT and CFT with bleeding score but no correlation 
with MCF. In addition, the range of MCF differed greatly in parturient patients with 
FXI deficiency compared to control participants, reflecting the unpredictability of 
changes in clot strength. Pregnancy induced haemostatic changes; mainly the 
significant rise in fibrinogen may have led to improved or corrected overall clot 
strength in some women with FXI deficiency. These findings are important and 
should be considered when assessing the bleeding risk in parturient women with FXI 
deficiency. Women with prolonged CT and CFT in the third trimester of pregnancy 
may be at increased risk. ROTEM® analysis should be incorporated into the clinical 
assessment during the third trimester of pregnancy. The following chapter in this 
thesis aims to assess the role of ROTEM® in assessment of bleeding risk in pregnant 
women with FXI deficiency.  
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7.5 Conclusion 
 
Measurement of whole blood viscoelasticity with ROTEM® provides a global 
assessment of haemostasis during pregnancy in women with FXI deficiency. 
Pregnancy causes an increase in clot consolidation and clot strength in women with 
FXI deficiency compared to non-parturient controls. Women with FXI deficiency had 
shorter CFT, (p<0.001), increased alpha angle (p<0.001) and increased MCF (p = 
0.005). However, they had significantly prolonged CT (p<0.001) compared to non-
parturient controls. 
 
Overall, pregnancy induced hypercoagulation in women with FXI deficiency, 
although these changes were not as pronounced as in the normal parturient 
population. Women with FXI deficiency had prolonged CT and CFT (p <0.001), and 
reduced alpha angle (p <0.001), compared to parturient controls. No difference was 
detected in clot strength (MCF p=0.054). Prolonged CT and CFT were associated 
with higher bleeding scores in women with FXI deficiency, and these women could 
have an increased risk of bleeding at delivery.  
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CHAPTER 8 
THE ROLE OF ROTATIONAL THROMBOELASTOMETRY IN 
ASSESSMENT OF HAEMOSTASIS AND RISK OF BLEEDING AT 
DELIVERY IN WOMEN WITH FXI DEFICIENCY  
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8.1 Introduction 
 
Pregnancy and delivery in women with FXI deficiency pose a particular challenge for 
the obstetrician. The incidence of both primary and secondary postpartum 
haemorrhage (PPH) is increased in women with FXI deficiency, as demonstrated in 
numerous studies [49, 175, 182, 211]. The bleeding phenotype is highly variable and 
does not correlate well with the underlying FXI activity (FXI:C) level. Relying on 
FXI:C levels alone may result in inappropriate assessment of the bleeding risk and 
overuse of FXI concentrates, which are associated with a risk of thromboembolic 
complications, and the potential for viral transmission. In addition, regional 
anaesthesia may be withheld in a woman with FXI deficiency due to concerns over 
bleeding complications resulting in spinal injury. 
 
In the previous chapter of this thesis, ROTEM® parameters during pregnancy in 
women with FXI deficiency were compared to non-parturient and parturient controls. 
Women with prolonged CT, and CFT had significantly higher bleeding scores, and 
were considered to be at increased risk of bleeding. The ability of ROTEM® to assess 
bleeding tendency in FXI deficiency has been controversial. In a recent study a 
significantly prolonged CT was the only parameter to differentiate between bleeders 
and non-bleeders in patients with severe FXI deficiency [241].  
 
The main objective of this prospective cohort study was to evaluate the use of 
ROTEM® in assessment of bleeding risk and provision of haemostatic cover during 
delivery in women with FXI deficiency. 
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8.2 Materials and Methods 
 
8.2.1 Study participants  
The cohort constituted pregnant women with FXI deficiency who attended the 
multidisciplinary joint obstetric haemophilia clinic at the Royal Free Hospital from 
October 2004 until October 2014. A management plan was made in the third trimester 
for labour and delivery to determine the haemostatic prophylaxis required to provide 
safe regional anaesthesia and to reduce the risk of PPH. A haemophilia specialist 
obtained bleeding scores using the condensed MCMDM-1VWD bleeding 
questionnaire [369]. A score of ≥3 was indicative of increased risk of bleeding [371].  
 
ROTEM® analysis during the third trimester of pregnancy was introduced as part of 
the bleeding risk assessment in women with FXI deficiency attending the clinic from 
2009. Subsequently, all deliveries were managed using this additional investigation. 
The decision was individualised for each patient and took into account her previous 
bleeding history and FXI level. In addition, obstetric factors such as provision of 
regional anaesthesia and mode of delivery (MOD) were important considerations for 
type of treatment. 
 
In order to assess the impact of ROTEM® analysis on clinical management, women 
with FXI deficiency were divided into two groups for comparison: i) women who 
delivered pre-2009 (without ROTEM® analysis) and, ii) women who delivered post-
2009 (with ROTEM® analysis). The latter group were further subdivided according to 
the ROTEM® findings.  
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8.2.2 Data collection 
The following clinical data were collected: 1) demographic information (age, parity 
and BMI at delivery), 2) bleeding score; 3) baseline and third trimester FXI activity 
level; 4) ROTEM® parameters in the third trimester; 5) haemostatic cover for labour 
and delivery; 6) mode of delivery; 7) estimated blood loss (EBL); 8) haemorrhagic 
complications at delivery; 9) obstetric risk factors for PPH; 10) use of regional 
anaesthesia with any documented complications. 
 
Primary PPH was defined as an estimated blood loss ≥500 mL within 24 hours 
following vaginal delivery and ≥1000 mL following caesarean delivery. Secondary 
PPH was defined as heavy or excessive lochia occurring after 24 hours to six weeks 
following delivery. The bleeding score was obtained using the condensed MCMDM-
1VWD bleeding questionnaire [369, 370].  
 
8.2.3 Statistical analysis 
Chi-squared or Fisher’s exact test was used to test statistically significance of 
proportional data. A p value of <0.05 was considered statistically significant. 
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8.3 Results 
 
8.3.1  Pregnancy outcomes 
From 2004 until 2014 a total of 57 deliveries occurred in 37 women with FXI 
deficiency. The median gestation at delivery was 40 weeks (range 35-42 weeks). The 
MOD was 31/57 (54%) vaginal deliveries, 11/57 (19%) emergency caesarean, 9/57 
(16%) elective caesarean and 6/57 (11%) instrumental deliveries (all forceps). 
 
The diagnosis of mild FXI deficiency was unknown at the time of delivery in 8 cases. 
Twenty-two deliveries were managed prior to 2009, before the introduction of 
ROTEM®. Of these, 18 deliveries were in women with mild FXI deficiency and the 
remaining 4 were in women with severe FXI deficiency. Twenty-seven deliveries 
were managed following the introduction of ROTEM®. Of these, 19 were in women 
with mild and 8 were in women with severe FXI deficiency. The women were placed 
into three categories depending on how many ROTEM® parameters were within the 
range of parturient controls (Table 8.1). Category 1 comprised of 10 women (5 mild, 
5 severe) who had 1 or no parameters in keeping with normal pregnancy. Category 2 
comprised of 13 women (10 mild, 3 severe) who had 2 or 3 parameters in keeping 
with normal pregnancy. Category 3 comprised 4 women with mild FXI deficiency 
who had four ROTEM® parameters in keeping with normal pregnancy. 
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Table 8.1 Normal pregnancy ROTEM® parameters  
 
ROTEM®  
parameters 
 
Range of parameters in normal 
pregnancy 
 
 
CT (secs) 
 
312 - 498  
 
CFT (secs) 
 
74 - 135 
 
Alpha angle (degrees) 
 
69 - 76 
 
MCF (mm) 
 
 
60 - 72 
 
CT; clotting time, CFT; clot formation time, MCF; maximum clot firmness. 
This table demonstrates the reference range for ‘normal’ parturient NATEM 
ROTEM® parameters. The figures are determined by the 95% reference limits (two 
standard deviations from the mean), from control parturients in the third trimester of 
pregnancy, reported in Chapter 7. 
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8.3.2 Haemorrhagic complications 
Three primary PPH and one secondary PPH occurred in eight deliveries where the 
diagnosis of FXI deficiency was unknown, leading to investigations that revealed an 
underlying bleeding disorder (cases 1-4, Table 8.2). In pregnancies with known FXI 
deficiency, the overall incidence of primary PPH was 12% (6/49) and secondary PPH 
2% (1/49) (cases 5-11, Table 8.2). No significant correlation was demonstrated 
between ROTEM® parameters and the EBL at delivery among women with FXI 
deficiency. In addition, there was no significant difference in the mean and standard 
deviation of ROTEM® parameters in women who experienced PPH (n = 6) and those 
who did not (n = 21). 
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Table 8.2 Cases of postpartum haemorrhage in women with FXI deficiency 
 
Case 
No 
 
FXI 
level ROTEM  
Mode of 
delivery 
Haemostatic 
cover 
Primary or 
secondary 
EBL 
(mL) Obstetric factors 
Diagnosis of FXI deficiency not known at delivery 
        
1 46 - ELCS None Secondary 2400 ELCS for multiple 
pregnancy 
 
2 42 - SVD None Primary 1000 Nil 
 
3 55 - Forceps None Primary 900 Retained placenta 
 
4 29 - EMCS None Primary 2000 Uterine atony requiring B-
lynch suture 
 
Diagnosis of FXI deficiency known at delivery 
        
5 36 Pre- 2009 SVD  FXI and TXA Primary 1000 Episiotomy and bilateral 
vaginal lacerations 
 
6 45 Pre- 2009 EMCS TXA Primary 1400 Uterine atony 
 
        
7 2 Category 1 SVD rFVIIa and TXA Secondary - Represented to A&E with 
heavy lochia 
  
8 2 Category 1 ELCS FXI and TXA Primary 3000 Grade IV placenta praevia 
        
9 50 Category 2 EMCS TXA Primary 1300 Delivered at 35 weeks for 
severe IUGR 
 
10 52 Category 2 Forceps TXA Primary 1000 Episiotomy 
11 36 Category 3 EMCS TXA Primary 2000 Uterine atony and lateral 
extension of uterine 
excision 
FXI; factor XI, ROTEM®; rotational thromboelastometry, EBL; estimated blood loss, 
EMCS; emergency caesarean, ELCS; elective caesarean, SVD; spontaneaous vaginal 
delivery, TXA; tranexamic acid 
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A primary PPH occurred in two out of 22 (9%) deliveries in women with mild FXI 
deficiency managed pre-2009, prior to the introduction of ROTEM®. Both cases were 
considered to be secondary to obstetric causes (cases 5 and 6). Four primary PPH 
(14.8%) and one secondary PPH (4%) occurred in two women with mild and three 
with severe FXI deficiency among 27 deliveries managed post-2009 following the 
introduction of ROTEM® (Cases 7-11, Table 8.2). All cases of primary PPH had 
coexisting obstetric risk factors including placenta praevia, uterine atony, and trauma. 
One secondary PPH occurred in a woman with severe FXI deficiency who presented 
with excessive lochia two weeks following an uncomplicated vaginal delivery. This is 
the only case that may have occurred solely due to FXI deficiency. There was no 
significant difference in the rate of PPH between both groups (0% pre-2009 vs 4% 
post-2009, p = 1.0). 
 
Figure 8.1 shows the treatment and pregnancy outcomes according to third trimester 
ROTEM® parameters in women with FXI deficiency. FXI concentrate was 
administered to cover labour and delivery (4 severe and 3 mild FXI deficiency) in 
seven out of 22 (32%) deliveries managed pre-2009 prior to the introduction of 
ROTEM®. FXI concentrate was administered on the basis of FXI level and previous 
bleeding history. Among 27 deliveries managed post-2009 following the introduction 
of ROTEM®, haemostatic cover with rFVIIa or FXI concentrate was provided in six 
(22%) cases. Thus, the introduction of ROTEM® reduced the overall use of blood 
product administered, although this finding was not statistically significant (32% pre-
2009 vs 22% post-2009, p = 0.45). Two women with severe FXI deficiency were 
treated with tranexamic acid only. 
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Regional anaesthesia was administered in 29 deliveries (21 with mild, 8 with severe 
FXI deficiency) without bleeding complications. The diagnosis of mild FXI 
deficiency was not known at the time of delivery in four cases where regional 
anaesthesia was sited. In the cases managed pre-2009 without ROTEM® analysis, 
regional block was sited in eight out of 22 (36%) deliveries (5 with mild, 3 with 
severe FXI deficiency). Seven women received FXI concentrate and one woman 
received tranexamic acid prior to siting regional anaesthesia.  
 
In the group managed post-2009 with ROTEM® analysis, regional anaesthesia was 
sited in 17 out of 27 (63%) deliveries (12 with mild, 5 with severe FXI deficiency). 
Four women with severe FXI deficiency had rFVIIa and one had FXI concentrate to 
cover regional anaesthesia. Twelve patients with mild FXI deficiency were 
administered tranexamic acid to cover regional anaesthesia. Thus overall there was 
significantly reduced blood product usage for regional anaesthesia in the patients 
managed post-2009 with ROTEM® analysis (88% pre-2009 vs 29% post-2009, p = 
0.01).  
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Figure 8.1 Treatment and pregnancy outcomes according to third trimester ROTEM® 
parameters in women with FXI deficiency 
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8.4 Discussion 
 
Assessment of coagulation with ROTEM® in women with FXI deficiency has been 
carried out as part of routine care at the Royal Free Hospital since 2009. Prior to this, 
assessment of bleeding risk and the considered administration of rFVIIa/FXI 
concentrates was primarily based on a woman’s bleeding history and FXI:C level 
[49]. One study published in Israel evaluated 164 deliveries in 62 women with severe 
FXI deficiency (FXI:C < 17u/dL). They concluded that as bleeding did not occur in 
43 out of 62 women, plasma replacement therapy was not always necessary [211]. 
However, the rate of primary PPH (22% of all deliveries) in this population was still 
considerably higher than in the general population. Hence the need for an additional 
mechanism to assess bleeding risk in FXI deficient patients. 
 
A lower proportion of patients received FXI concentrate or rFVIIa in the group 
managed with ROTEM® analysis. In addition, the use of ROTEM® enabled treatment 
decisions for providing haemostatic cover for regional anaesthesia. The findings of 
the ROTEM® analysis provided confidence to avoid the use of blood product that 
would otherwise have been administered [250]. After performing ROTEM® two cases 
of severe FXI deficiency were managed successfully with tranexamic acid. Thus these 
patients were able to avoid unnecessary exposure to blood product and the associated 
risk of thrombotic complications. 
 
The lack of any correlation between ROTEM® parameters and EBL, and no 
discernible differences in the ROTEM® parameters of women who had a PPH, more 
likely reflects the practice of providing haemostatic cover to women with abnormal 
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ROTEM® parameters. From this data it was not possible to predict likelihood of PPH 
in women with FXI deficiency based on ROTEM® analysis solely. It is also not 
possible to determine whether using ROTEM® analysis to guide therapy has any 
effect on the overall rate of PPH. An interventional study with prospective 
randomisation would be more appropriate to properly evaluate this.  
 
The cases with abnormal ROTEM® parameters in the third trimester were corrected 
with either rFVIIa/FXI administration or tranexamic acid. Four women out of 23 still 
experienced a PPH (Cases 7 - 10, Table 8.2). Whilst three of the four cases were due 
to obstetric causes, one secondary PPH occurred after the completion of a postnatal 
course of tranexamic acid. This highlights the increased risk of bleeding during times 
of high fibrinolytic activity that occurs in patients with FXI deficiency. An extended 
course of antifibrinolytic treatment may be necessary in such cases. Further research 
is required to assess serial FXI:C levels, or global haemostatic changes measured 
through thromboelastometry, in FXI deficient women during the postnatal period. 
This will help to determine how quickly they normalise, and therefore the duration of 
therapy that is required to prevent secondary PPH. 
 
There was one case of pulmonary embolus in a woman with mild FXI deficiency who 
had significant VTE risk factors including prolonged labour, emergency caesarean 
and severe PPH. This woman had ROTEM® parameters in keeping with normal 
pregnancy and no significant bleeding history. Tranexamic acid was administered to 
provide cover for regional anaesthesia. It could be argued that as her ROTEM® 
parameters were in keeping with normal pregnancy this intervention was not 
necessary, and increased her risk for developing VTE. In addition, 
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thromboprophylaxis was withheld for 24 hours due to potential bleeding risk because 
of FXI deficiency. Although FXI deficiency may be protective against venous 
thromboembolism [372], it is important that risk factors are assessed and 
thromboprophylaxis is given appropriately. 
 
8.5 Conclusion 
 
Women with FXI deficiency have an unpredictable bleeding risk at delivery that is 
challenging to predict and manage. They require an individualised risk assessment 
incorporating the bleeding history or score, FXI level, and ROTEM® analysis to help 
determine bleeding risk and enable treatment decisions regarding use of haemostatic 
cover. The use of ROTEM® results in less overall blood product usage to cover 
delivery and for regional anaesthesia. Further research is required to evaluate the role 
of ROTEM® in this setting.  
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EVALUATING THE EFFECT OF PROTHROMBOTIC MARKERS ON 
BLEEDING PHENOTYPE IN WOMEN WITH INHERITED BLEEDING 
DISORDERS 
 
 
9.1 Introduction 
9.2 Methods 
 9.2.1 Study participants 
 9.2.2 Laboratory methods 
 9.2.3 Statistical analysis 
9.3 Results 
9.3.1 Correlation of bleeding score with haemostatic variables 
9.3.2 Effect of thombotic variables on bleeding score 
9.4 Discussion 
9.5 Conclusion 
 
 
  
251 
 
9.1 Introduction 
 
Bleeding tendency in women with IBDs is highly variable and in clinical practice is 
often challenging to predict. Consideration of the bleeding risk prior to any 
haemostatic challenge such as the onset of menses, childbirth or anticipated surgery is 
an important management aspect. A better appreciation of the overall bleeding risk is 
important when considering the need for haemostatic prophylaxis.  
 
The aim of this study was:  
1) To quantify bleeding tendency (phenotype) in women with IBDs using the 
condensed MCMDM-1VWD bleeding questionnaire (Appendix 4) [369]. 
 
2) To assess the correlation between the phenotype and haemostatic variables  
 
3) To assess if underlying prothrombotic variables, or the presence of thrombotic 
genotype modified the overall bleeding phenotype. 
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9.2 Method 
 
9.2.1 Study participants 
This was a collaborative study with women recruited from the Royal Free Hospital in 
North London, and the Haemophilia Treatment Centre (HTC) in Duisburg, Germany. 
A total of 68 women were recruited from the UK centre and 35 women were recruited 
from the HTC in Germany. Women with a confirmed diagnosis of von Willebrand 
disease (VWD) or carriers of haemophilia A or B who attended the joint 
multidisciplinary gynaecology haemophilia clinic were invited to participate. Data 
collected on each participant included age, diagnosis, baseline factor level.  
 
The bleeding phenotype was described using the modified, condensed MCMDM-1 
bleeding questionnaire developed by Tosetto et al (Appendix 4). This has been 
validated in the clinical setting to discriminate severity of bleeding symptoms [373]. It 
has reasonable inter-observer reliability, where 24 subjects (of a total 259) were 
administered the questionnaire by two different observers three months apart (inter-
observers Spearman’s Rho 0.72 and inter-class correlation of 0.8) [370].  
 
9.2.2 Laboratory methods 
50 mL of venous blood was collected from each participant using a 19-gauge butterfly 
with minimal occlusion of the antecubital fossa vein into blood collection tubes 
containing 106 mol/L sodium citrate [Sarstedt monovettes, Sarstedt, Leicester, 
UK].  After centrifugation for 10 minutes at 2000g, plasma and white blood cells 
were separated. High molecular weight DNA was isolated from the white blood cell 
fraction by standard methods. The presence of mutations in the factor V gene (1691, 
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G>A) and the prothrombin gene (20210, G>A) were determined as previously 
described [374, 375]. Protein C and protein S activities were measured on ACL TOP 
coagulometer [Instrumentation Laboratory] using the PROCHROM assay 
[Instrumentation Laboratory], and the protein S free latex assay [Instrumentation 
Laboratory] respectively. Antithrombin III (ATIII) was measured on an ACL 300R as 
previously described [376]. The laboratory methods used to measure coagulation 
factors (VWF:Ag, VWF:RCo, VWF:CB, FVIII:C and FIX:C) are described in 
Chapter 3.1. 
 
9.2.3 Statistical analysis 
Pearson’s correlation coefficient was used to analyse the association between 
bleeding scores and haemostatic variables (VWF:Ag, VWF:RCo, FVIII:C, FXI:C). 
As multiple variables were recorded for each patient, multilinear regression analysis 
was used to determine if any thrombotic variable, or the presence of a thrombotic 
gene mutation, altered the bleeding score.  
 
Correlation of bleeding score with VWF:Ag, VWF:RCo and VWF:CB was for 
patients with VWD only. The results from the carriers of haemophilia were separated 
from this part of the analysis. Correlation of bleeding scores with FVIII and FXI 
levels included both VWD patients and women who were carriers of haemophilia A 
and B. 
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9.3 Results 
 
A total of 103 women with IBDs were recruited for this study; 91 women had VWD, 
12 were carriers of haemophilia. Only carriers of haemophilia with FVIII/FIX level < 
70 IU/dL were included. Of the 91 women with VWD, 75 women had type 1 VWD, 
11 women had type 2 VWD, and 5 women had type 3 VWD. The median age of all 
participants was 35 (range 18-59). The median bleeding score was 5 (range -1 to 25). 
Age was an independent variable that affected the bleeding score with a significantly 
increased score seen in older women (r = -0.44, r2 = 0.19; p < 0.001), [Fig 9.1]).  
 
Seventeen women out of 103 (17%) tested positive for a thrombotic marker, which 
was a deficiency in anticoagulant activity level in eleven women, or prothombotic 
gene mutation in five women (Table 9.1). Three women tested positive for 
heterozygous factor V (FV) Leiden gene mutation, one woman for heterozygous 
prothrombin 20210 gene mutation, and one for lupus anticoagulant. The mean protein 
C activity level (protein C:Ac) was 107 IU/dL (standard deviation [SD]±21) with a 
range of 10-150 IU/dL. The mean protein S activity level (protein S:Ac) was 86 
(SD±19) with a range of 32-145 IU/dL. The mean antithrombin III activity level 
(ATIII:Ac) was 100 (SD±11) with a range of 55-130 IU/dL. There was no significant 
correlation between anticoagulant activity levels and bleeding score.  
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Figure 9.1 Correlation of bleeding score with age 
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Table 9.1 Anticoagulant deficiency or presence of prothrombotic marker in women 
with inherited bleeding disorder 
	  
Thrombotic	  marker	  	  
	  
Normal	  lab	  
reference	  range	  
	  
No	  of	  women	  
(n)	  
	  
Activity	  level	  
(IU/dL)	  
	  
	   	   	   	  
Protein	  C	  deficiency	   70-­‐140	  IU/dL	   1	   10	  
	   	   	   	  
Protein	  S	  deficiency	  	   71-­‐130	  IU/dL	   10	   32,	  45,	  52,	  53,	  59,	  
61,	  61,	  62,	  64	  
	   	   	   	  
Antithrombin	  III	  deficiency	   86-­‐114	  IU/dL	   2	   72,	  55	  
	   	   	   	  
FV	  Leiden	  gene	  mutation	   Heterozygote	  	   3	   	  
	   	   	   	  
Prothrombin	  20210	  gene	  
mutation	  
	  
Heterozygote	   1	   	  
Lupus	  anticoagulant	  
	  
	   1	   	  
 
 
9.3.1 Correlation of bleeding score with haemostatic variables 
VWF:Ag, VWF:RCo and FVIII:C had a statistically negative correlation with 
bleeding score. Table 9.1 shows the mean and standard deviation and correlation 
coefficient with bleeding score for each variable. FVIII:C had the strongest negative 
correlation with bleeding score (r = -0.43, r2 0.19; p < 0.001 [Fig 9.2]). VWF:Ag and 
VWF:RCo also had negative correlation with bleeding score (r = -0.23, r2 = 0.06; p = 
0.023 [Fig 9.3] and (r = -0.21, r2 =  0.051; p = 0.042 [Fig 9.4], respectively). There 
was no correlation demonstrated with bleeding score and VWF:CB and FIX:C (Fig 
9.5 and 9.6). 
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Figure 9.2 Correlation of bleeding score with FVIII activity level 
 
FVIII:C, factor VIII activity level 
r = -0.43, r2 0.19; p < 0.001 
 
 
  
258 
 
Figure 9.3 Correlation of bleeding score with VWF:Ag level 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VWF:Ag; von Willebrand factor antigen 
r = -0.23, r2 = 0.06; p = 0.023  
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Figure 9.4 Correlation of bleeding score with VWF:RCo level 
 
VWF:RCo; von Willebrand factor ristocetin cofactor  
r = -0.21, r2 =  0.051; p = 0.042   
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Figure 9.5 Correlation of bleeding score with VWF:CB activity level 
 
VWF:CB, von willebrand factor collagen binding assay 
r = -0.32, r2 = 0.1, p = 0.06 
  
261 
 
Figure 9.6 Correlation of bleeding score with FXI activity level 
FXI:C, factor XI activity level 
r = -0.12, r2 = 0.01, p = 0.46 
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Table 9.2 Correlation of bleeding score and haemostatic variables 
 
 
  
Mean ± 
Standard 
deviation 
 
Correlation 
coefficient 
(r) 
 
r2 
 
 
p value 
     
VWF:Ag 51.7 (±22.8) - 0.234 0.055 0.023 
     
VWF:RCo 43.0 (±22.8) - 0.226 0.051 0.034 
     
VWF:CB 44.5 (±30) - 0.315 0.099 0.07 
     
FVIII:C 72.3 (±29) - 0.431 0.186 < 0.001 
     
FIX:C 
 
100.4 (±19) - 0.121 0.015 0.464 
 
VWF:Ag, von Willebrand factor antigen; VWF:RCo, von Willebrand factor ristocetin 
activity level; VWF:CB, von Willebrand factor collagen binding activity level; 
FVIII:C, factor VIII activity level; FIX:C, factor IX activity level. Areas highlighted 
in grey are statistically significant (p < 0.05). 
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9.3.2 Effect of thombotic variables on bleeding score 
 
No significant correlation was detected between anticoagulant variables (protein C, 
protein S and ATIII activity levels) and bleeding score. Table 8.3 shows the mean and 
standard deviation and correlation coefficient with bleeding score for all variables. 
 
Table 9.3 Correlation of bleeding score and thrombotic variables 
 
Mean ± 
Standard 
deviation 
Correlation 
coefficient 
(r) 
 
 
r2 
 
p value 
     
Protein C:Ac 107.6 (21) -0.064 0.004 0.526 
     
Protein S:Ac 85.6 (18.9) 0.168 0.028 0.093 
     
ATIII:Ac 100.4 (11.0) 0.172 0.030 0.086 
     
 
Protein C:Ac, Protein C activity level; Protein S:Ac, Protein S activity level; 
ATIII:Ac, antithrombin III activity level 
 
 
In the multiple regression analysis the presence of a thrombotic marker (either 
prothrombotic gene mutation or deficiency in protein C:Ac, protein S:Ac or 
ATIII:Ac) altered the correlation between VWF:RCo and bleeding score (p = 0.015) 
(Fig 9.5). The presence of a thrombotic marker caused a shift to the left in bleeding 
score. No other relationship between haemostatic variable and bleeding score was 
affected by the presence of a thrombotic marker. 
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Figure 9.7 Presence of a thrombotic marker alters relationship between VWF:RCo 
and bleeding score 
 
 
 
 
VWF:RCo, von Willebrand factor ristocetin cofactor activity level 
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9.4 Discussion 
 
Patients with severe haemophilia can have a milder bleeding tendency than expected 
[377]. Severe f8/f9 gene mutations, referred to as null mutations, are usually 
associated with virtually undetectable factor activity. The non-null mutations are 
usually associated with a variable factor level. However, different clinical phenotypes 
have been reported in patients with the same mutation [31, 32]. The basis for this 
heterogeneity in clinical expression of severe haemophilia is poorly understood.  
 
Inherited thrombophilia, notably FV Leiden have been postulated to alter the bleeding 
tendency in patients with severe haemophilia. FV Leiden occurs with a relatively high 
frequency (3-7%) in the general population [378]. The mechanism by which FV 
Leiden affects the clinical phenotype of haemophilia involves increased thrombin 
generation by reducing thrombin downregulation through the activated protein C 
pathway [379]. A systematic review reported that co-inheritance of other 
thrombophilia, such as protein C and protein S deficiency, and prothrombin gene 
mutation, may affect the clinical phenotype and even result in thromboembolic 
disease in patients with severe haemophilia [380].  
 
The clinical expression of VWD is very heterogeneous with a large variability in 
bleeding frequency and severity seen between patients. The bleeding phenotype is 
strongly associated with type of VWD, and the VWF:Ag. VWF:RCo and FVIII:C 
levels [381]. Tosetto et al developed and validated a bleeding score for patients with 
type 1 VWD, to quantify the number and severity of bleeding symptoms [369]. 
Bowman et al developed a condensed version of this bleeding score and applied it to 
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42 patients in whom VWD was previously diagnosed, including all types of VWD, 
and found a significant difference in bleeding score (with type 3 >> type 2 >> type 1, 
ANOVA p = 0.001) [370]. The effect of co-inheritance of thrombophilia on clinical 
expression of VWD patients has not been previously evaluated. 
 
The findings of this study demonstrate that FVIII:C level is the strongest predictor of 
bleeding risk in women with VWD and haemophilia A carriers (Fig 9.2) as this 
variable had the strongest correlation with bleeding score. In haemophilia, this finding 
is expected as bleeding severity consistently correlates well with factor levels [34, 37, 
382], however, in VWD the relationship is less clear. The fact that higher FVIII levels 
in women with VWD may be protective against bleeding requires further 
consideration and may have important implications in its clinical management. 
 
Poor correlation was seen between bleeding score and VWF:CB assay (Fig 9.5). This 
is likely due to fact that the majority of women recruited to this study had type 1 
VWD, without a functional impairment. Due to the limited sample size, all 
participants with VWD were analysed together. Poor correlation was also seen 
between bleeding score and FIX levels (Fig 9.6). The majority of patients included in 
this analysis had VWD, which does not affect FIX levels. Only a very small number 
(n = 2) of participants were haemophilia B carriers and therefore it was not possible to 
interrogate the correlation between bleeding tendency and factor level in these 
patients. Future studies that explore bleeding tendency in women IBDs would be 
more informative if the different types, and subtypes of VWD and haemophilia are 
analysed separately.  
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The presence of a co-inherited thrombophilia appears to influence the bleeding 
phenotype that is milder than expected in women with IBDs. The presence of a 
thrombotic marker alters the relationship between VWF:RCo level, with a lower than 
expected bleeding score seen in these patients (Fig 9.7, p = 0.015). This is an 
important finding, which may help to explain the variability in bleeding phenotype 
seen in women with IBDs. 
 
A better understanding of bleeding phenotype is important when anticipating the 
bleeding risk and the requirement for prophylactic cover prior to a haemostatic 
challenge (the onset of menses in adolescence, in pregnancy and at delivery, or prior 
to undergoing any surgical procedure). 
 
Women with VWD or haemophilia who have a lower than expected bleeding score 
should undergo thrombophilia screening as this may be of clinical significance. Not 
only is this important to gain a better appreciation of bleeding risk, but also could 
identify women who may be at increased risk for thromboembolic disease later in life. 
Patient with type 1 VWD experience age-related increase in VWF:Ag and VWF:RCo, 
which can result in normalisation of VWF levels over time [383]. It is also likely that 
carriers of haemophilia experience an age-dependent increase in FVIII:C level, which 
has been confirmed in patients with mild haemophilia [384]. A prothrombotic marker 
detected in these patients should result in consideration of thrombotic risk, depending 
on other factors. The use of the oral combined contraceptive pill or hormone 
replacement therapy (HRT), which is associated with increased thrombotic risk in the 
general population, may be contraindicated in these women. In addition, this has 
important implications in the management of women with coinheritance of IBDs and 
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thrombophilia during pregnancy. Thrombotic risk should be considered due to the 
pro-thrombotic state of pregnancy. Thromboprophylaxis should be administered 
especially if additional venous thromboembolism risk factors arise at delivery (i.e. 
operative delivery, postpartum haemorrhage, infection, immobility).  
 
In this study, age resulted in higher bleeding scores. This finding is expected as 
patients are exposed to more haemostatic challenges (pregnancy, surgery) throughout 
their lifetime. In addition, women who are approaching menopause may experience 
heavy menstrual bleeding (HMB) related to gynaecological causes (endometrial 
pathology, fibroids). Further research should be untaken to assess bleeding phenotype, 
including thrombin generation studies, in women with co-inherited bleeding disorders 
and thrombophilia. International collaboration may be required to recruit sufficient 
number of women with rare IBDs. Prospective measurement of factor levels, bleeding 
score and frequency of thromboembolic complications with increasing age should be 
assessed in women with IBDs. 
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9.5 Conclusion 
 
The presence of a thrombotic marker causes the bleeding score to be lower than 
expected for a given VWF:RCo level. This indicates that the co-inheritance of 
thrombophilias may be protective (lowers the bleeding tendency) in patients with low 
VWF:RCo levels. In addition, these patients may also be at increased risk of 
thromboembolism, especially as FVIII:C and VWF normalises with age, or during 
pregnancy, or with oral contraceptive medication. Thrombophilia testing should be 
considered in cases were there is as a discrepancy in phenotype and VWF:RCo level, 
to gain a better appreciation of bleeding and thrombotic risk in these patients.  
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CHAPTER 10 
CONCLUSION AND FUTURE STUDIES 
 
10.1   Overall conclusion 
10.2   Suggestions for future research 
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10.1   Overall conclusion 
 
Women with IBDs have increased obstetric and gynaecological morbidity due to 
increased risk of bleeding. Endometriosis is associated with a higher frequency of 
platelet aggregation defects to one agonist (p = 0.005), multiple agonists (p < 0.05) 
and epinephrine (p = 0.02). Women with severe (stage IV) endometriosis have 
reduced VWF activity levels. These findings could be explained by increased 
retrograde menstruation resulting in higher rate of ‘seeding’ within the pelvic cavity. 
Impaired local haemostasis within endometriotic implants result in recurrent cyclical 
internal bleeding, exacerbating the spread of the condition throughout the pelvic 
cavity. This could have important implications in the management of endometriosis. 
Targeted screening for platelet aggregation defects in women with a positive bleeding 
history could reduce the risk of perioperative bleeding. Women found to have 
endometriosis and a PFD should be advised to avoid anti-platelet analgesics. 
 
The rate of uptake for invasive prenatal diagnosis and termination of affected 
pregnancies is decreasing among carriers of haemophilia. Severity of haemophilia and 
family history of haemophilia-related complications affect the uptake for invasive 
testing. Women are choosing to have non-invasive methods such as ffDNA to 
determine fetal gender, which is more acceptable and associated with less 
psychological stress. Invasive testing may be carried out in order to make a plan for 
delivery, and in cases where the fetus is unaffected the woman may be referred back 
to her local maternity unit. A non-invasive method using ffDNA in maternal plasma 
to rule out haemophilia in the fetus is highly welcomed by carriers of haemophilia and 
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the uptake is likely to be high. It will provide women with more birth options, and has 
the potential to reduce the caesarean section rate among carriers of haemophilia.  
 
Systematic review of the current literature demonstrates that newborns with 
haemophilia have 44 fold-increased risk of symptomatic ICH at birth (OR 44; 95% CI 
34.7-57.1, p < 0.01) compared to the general population. The odds of ECH in 
newborns with haemophilia compared to the general population are 8 (95% CI 5.38-
12.6) (p  < 0.01). In the meta-analysis the odds of experiencing ICH at birth following 
an AVD are over four fold increased compared to SVD (OR 4.39; 95%CI, 1.46-13.7) 
in newborns with haemophilia. The odds of experienced ICH following CS are 
reduced compared to SVD (OR 0.34; 95%CI, 0.14-0.83).  
 
The incidence of asymptomatic ICH in the general population is around 24%. The 
incidence of asymptomatic ICH in newborns with IBDs and how this evolves is not 
known. The current literature is limited to a small number of retrospective case 
review studies that report incidence of symptomatic ICH and extracranial 
haemorrhage only. There is only one published study that assesses incidence of 
asymptomatic ICH through radiological screening in neonates with haemophilia 
[327]. All women who are pregnant with a potentially affected fetus should have a 
frank discussion within a multidisciplinary antenatal setting, where the risks of cranial 
bleeding and risks associated with CS are discussed. Women who are pregnant with a 
fetus potentially affected by a moderate/severe IBD should be offered a ELCS to 
reduce the risk of bleeding complications at delivery. 
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Cranial MRI carried out within 72 hours of birth in eight newborns with 
severe/moderate IBD proved feasible without sedation, to exclude asymptomatic ICH. 
In this small series none of the affected neonates showed evidence of asymptomatic 
ICH occurring at birth on MRI screening. There were three episodes of cranial 
bleeding reported in two infants by 6 months of age. One male infant was born with 
cephalohaematoma following an EMCS. He later suffered a spontaneous ICH with 
high titre inhibitor development by 4 months of age. The detection and treatment of 
any asymptomatic ICH at birth has potential to reduce serious long-term neurological 
sequelae or even death in neonates with IBDs. This would provide a strong argument 
for MRI screening at birth to be standard care. Larger collaborative studies are 
required to properly assess the incidence, outcome and effect of MOD of 
asymptomatic ICH in neonates with IBDs. 
 
Pregnancy induces a hypercoagulable status in the third trimester of pregnancy in 
women with FXI deficiency, due to increase in other coagulation factors. Pregnancy 
causes an increase in clot consolidation (reduced CFT), and an increase in clot 
strength (increased MCF) in pregnant women with FXI deficiency compared to non-
parturient controls. On average, women with FXI deficiency take longer to clot 
(prolonged CT) compared to both parturient and non-parturient controls. This was 
more pronounced in women with severe FXI deficiency. If hypercoagulable changes 
are not achieved by the third trimester of pregnancy (i.e. prolonged CT and CFT, 
reduced alpha angle and MCF), these women should be considered as having an 
increased risk of bleeding. 
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Women with FXI deficiency have an unpredictable bleeding risk at delivery that is 
challenging to predict and manage. They require an individualised risk assessment 
incorporating their bleeding history or score, FXI level and ROTEM® analysis. Using 
ROTEM® analysis in the third trimester evaluation of bleeding risk in pregnant 
women with FXI deficiency enables treatment decisions for providing haemostatic 
cover for labour and delivery, and results in less blood product usage. Woman with 
severe FXI deficiency can be managed safely with tranexamic acid, including 
provision of regional anaesthesia, if ROTEM® parameters indicate hypercoagulable 
status. These patients can avoid the risk of thrombotic complications that are 
associated with blood product usage. Using ROTEM® analysis to guide therapy had 
no discernable effect on the overall rate of PPH, which is still high (12% and 2% for 
primary PPH and secondary PPH, respectively) compared to rates in the general 
obstetric population (3-6% and 1%, respectively). Larger prospective, randomised 
trials may provide more evidence to support the role of ROTEM® on bleeding risk in 
pregnant women with FXI deficiency.  
 
The presence of a thrombotic marker (anticoagulant deficiency or prothrombotic gene 
mutation) alters the bleeding score for a given VWF:RCo level in women with IBDs 
(p = 0.015). This indicates that co-inheritance of thrombophilia may be protective (i.e. 
reduce bleeding phenotype). Bleeding score increases with age with positive 
correlation seen (r = -0.44, r2 = 0.19; p < 0.001). However, factor levels (VWF and 
FVIII) also increase with age, and thus the risk of thromboembolic disease should be 
considered in these patients. 
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10.2   Suggestions for future research 
 
The finding of increased frequency of platelet aggregation defects in women with 
endometriosis, and reduced VWF activity level in women with more severe rASRM 
laparoscopic staging requires further investigation. Platelet testing in a larger cohort 
of women, including control subjects who have no laparoscopic evidence of 
endometriosis, should be undertaken. 
 
The effect of administering haemostatic therapy in addition to hormonal treatments, to 
women with a bleeding disorder and endometriosis should be assessed in a clinical 
trial. Oral tranexamic acid or DDAVP (i.e. intranasal desmopressin) can be 
administered prior to or during menses to assess if this affects endometriosis 
symptoms or rate of endometriosis progression.  
 
Further research is required to develop a non-invasive prenatal diagnostic test using 
ffDNA to detect haemophilia mutations, specifically the intron 22 mutation, which 
causes about half the cases of severe haemophilia A. This will provide a universal test 
that can be used worldwide for a significant number of severe cases that are more 
likely to opt for and benefit from prenatal diagnosis. Future studies should evaluate 
the impact of a non-invasive prenatal diagnostic test. Having a non-invasive test 
available could enable treatment decision in early pregnancy, and has the potential to 
provide more birth options for carriers of haemophilia. Whether the availability of 
such a test impacts on reproductive choices and CS rates in carriers of haemophilia 
should be assessed. A qualitative study should be undertaken to properly assess 
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anxiety levels of women who undergo invasive procedures to ensure that appropriate 
levels of psychological support are available. This would provide a stronger argument 
to make a non-invasive test widely available.  
 
Cranial MRI within 72 hours of birth was proven to be feasible and safe and able to 
exclude asymptomatic ICH in newborns with IBDs. There is now an urgent need to 
encourage other haemophilia centres to adopt this protocol. Only a larger, 
collaborative, multi-centred study will properly assess the incidence of asymptomatic 
ICH in newborns with moderate/severe IBDs. Where possible, screening should be 
carried out at multiple time points during the first few weeks of life to determine the 
optimum timing and highest detection rate for asymptomatic head bleeds. Large 
numbers of participants are required to assess the effect of MOD on cranial bleeding 
and provide better evidence on optimum management. In addition, maternal outcomes 
such as frequency of PPH and complications resulting from multiple CS could be 
evaluated in women with IBDs who opt for ELCS to reduce the risk of neonatal 
bleeding. This will only be achieved through multi-centre and multinational 
collaboration. Long-term developmental studies should be undertaken in neonates 
with moderate/severe IBDs who have undergone MRI screening at birth. In addition, 
treatment regimes, bleeding episodes, and rates of inhibitor development should 
continue to be reviewed in infants with haemophilia.   
 
An interventional study with prospective randomisation will help to evaluate the 
effect of ROTEM® analysis on rates of PPH in women with FXI deficiency. 
Postpartum ROTEM® analysis and measurement of clot lysis using additional 
ROTEM® assays (FIBTEM and EXTEM) should be undertaken in women with FXI 
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deficiency. This would provide useful data to guide the optimum duration of 
postpartum haemostatic therapy, and reduce risk of secondary PPH that may occur 
once other clotting factors return to pre-pregnancy levels. 
 
Bleeding phenotype and correlation with factor levels should be interrogated 
separately in women with different types and subtypes of VWD, and in haemophilia 
carriers. Women found to have a lower bleeding score than expected should be 
assessed for an underlying thrombophilia. Further large collaborative studies should 
assess whether the presence of a thrombotic marker influences the bleeding score in 
women with different types of IBDs, including rare IBDs. Bleeding phenotype should 
be assessed with thrombin generation studies or thromboelastometry in women with 
co-inherited bleeding disorders and thrombophilia to gain a better appreciation of 
bleeding and thrombotic risk. Prospective measurement of factor levels, bleeding 
score and frequency of thromboembolic complications with increasing age should be 
assessed in women with IBDs. 
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APPENDIX 1 
 
Pictorial Blood Assessment Chart 
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APPENDIX 2 
PAIN IMPACT QUESTIONNAIRE (PIQ-6) 
 
If you are not sure about a question, please give the best answer you can. There 
are no right or wrong answers to these questions. Thank you for completing this 
survey! For each of the following questions, please select the response that best 
describes your answer 
 
1. How much bodily pain have you had during the past 4 weeks? 
 
      None           Very mild      Mild     Moderate     Severe  Very severe 
 
 
 
 
2. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)?  
 
      Not at all           A little bit       Moderately     Quite a lot     Extremely 
 
 
 
 
3. In the past 4 weeks, how much of the time did pain interfere with your 
enjoyment of life?  
 
            Never              Rarely              Sometimes        Very often      Always 
   
 
 
 
4. In the past 4 weeks, how often did pain make simple tasks hard to 
complete?  
 
     Never              Rarely              Sometimes        Very often       Always 
   
 
 
 
5. In the past 4 weeks, how often were your leisure activities affected by 
your pain (including exercise and hobbies)? 
 
     Never              Rarely              Sometimes        Very often       Always 
   
 
 
 
6. In the past 4 weeks, how often did pain make you feel fed up and 
frustrated? 
 
     Never              Rarely              Sometimes        Very often       Always 
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APPENDIX 3 
 
Haemophilia	  Carrier	  Questionnaire	  
	  
Part	  1	  –	  General	  Information	  about	  you	  
	  
Name:	  
	  
Date	  of	  Birth:	  
	  
Age:	  
	  
Type	  of	  haemophila	  (A	  or	  B):	  _____	  	  	  	   	  Baseline	  level:	  ________	  
	  
Severity	  of	  haemophilia	  in	  family	  (if	  known)	  	  	  	  	  	  	  	  	  	  
	   	   	   	   	   	   Mild	   	   	   	   □	  
	   	   	   	   	   	   Moderate	  	   	   	   □	  
	   	   	   	   	   	   Severe	  	  	   	   	   □ 
	  
Family	  history	  of	  haemophilia-­‐related	  complications:	  
	   	   	   	   	   	   HIV/Hepatitis	   	   	   □	   	  
	   	   	   	   	   	   Inhibitors	   	   	   □	  
	   	   	   	   	   	   Early	  death	   	   	   □	  
	   Other,	  please	  	   	  
	   specify________________________________________________
	   ______________________________________________________	  
	  
What	  is	  your	  relationship	  to	  the	  affected	  individual	  in	  the	  family?	  
(daughter/mother/sister)	  
	  
	   ______________________________________________________	  
	  
Have	  you	  undergone	  genetic	  testing	  to	  confirm	  your	  carrier	  status?	  
	   	   	   	   	   	   	   Yes	   	   	   □	  
	   	   	   	   	   	   	   No	   	   	   □	  
	   	   	   	   	   	   	   Not	  sure	   	   □	  
	   	   	   	   	  	  
Haven’t	  had	  any	  children?	  	  please	  go	  on	  to	  Part	  3	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Part	  2	  –	  Pregnancy	  related	  information	  
	  
For	  each	  ongoing	  pregnancy	  please	  complete:-­‐	  
	  
Pregnancy	  No.1________________________________________________________	  
	  
Year	  of	  pregnancy:	  
	  
Were	  you	  aware	  of	  your	  carrier	  status	  prior	  to	  or	  during	  this	  pregnancy?	  	   	  
	   	   	   	   	   	   	   	   Yes	  □ No	  □	  
	  
Were	  you	  offered	  prenatal	  diagnosis?	  	   	   	   Yes	  □	  No	  □ 
Did	  you	  opt	  for	  prenatal	  diagnosis?	  	  	  	  	   	   	   Yes	  □ No	  □	  
	  
Type	  of	  prenatal	  diagnosis:	   	  
Was	  this	  invasive	  prenatal	  diagnosis?	  
	   	   	   Chorionic	  Villus	  Sampling	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	   □	  
	    Amniocentesis	  in	  2nd	  Trimester	  (week	  15-­‐28)	   	   □	  
	   	   	   	   	   	   	  
Did	  miscarriage	  occur	  due	  to	  invasive	  test?	  	   	   	   Yes	  □	  No	  □	   	  
	  
If	  unsure,	  please	  
comment_____________________________________________________________
_____________________________________________________________________
_____________________________________________________________________	  
	  
Was	  this	  non-­‐invasive	  prenatal	  diagnosis?	  
Ultrasound	  to	  determine	  gender	  	   	   	   	   	   	   □ 
(please	  state	  gestational	  age	  this	  was	  performed_____________)	  
Free	  fetal	  DNA	  (blood	  test)	  to	  determine	  gender	  	  	  	   	   	   	   □	  
Free	  fetal	  DNA	  (blood	  test)	  to	  determine	  haemophilia	  status	  (currently	  	   □
	   only	  available	  in	  the	  research	  and	  development	  stage)	   	   	  
	   	   	   	   	   	  
Was	  this	  3rd	  Trimester	  Amniocentesis	  (usually	  performed	  after	  weeks	  34	  
gestation)?	   	   	   	   	   	   	   Yes	  □	  No	  □	  
	   	   	   	   	   	   	   	  
Complications:	   	   	   	   	   	   	  
Unsuccessful	   	   	   	   □	  
Required	  more	  than	  one	  attempt	   □	  
Premature	  labour	   	   	   □	  
Premature	  rupture	  of	  membranes	   □	  
Fetal	  or	  maternal	  bleeding	   	   □	  
	  
If	  unsure,	  please	  
comment_____________________________________________________________
_____________________________________________________________________	  
_____________________________________________________________________	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Part	  2	  –	  Pregnancy	  related	  information	  	  
	   	  
Reasons	  for	  opting	  for	  prenatal	  diagnosis	  	  
To	  undergo	  termination	  of	  affected	  foetus	  	   	   	   □	   	  
	   To	  be	  aware	  of	  haemophilia	  status	  so	  that	  a	  	   	   	  
	   management	  plan	  could	  be	  made	  about	  delivery	   	   □	   	  
	   Reasons	  other	  than	  haemophilia	  (please	  state)	   	   □ 
	   	   	  
_____________________________________________________________________
_____________________________________________________________________	  
  	   	  
Reasons	  for	  not	  opting	  for	  prenatal	  diagnosis	  
	   Fear	  of	  fetal	  loss	  from	  prenatal	  diagnosis	   	   	   	   □	  
	   Fear	  of	  procedure	  and	  potential	  adverse	  effects	   	   	   □	  
	   Did	  not	  think	  haemophilia	  was	  severe	  enough	  to	  warrant	  	  	   	   □	  
	   prenatal	  diagnosis	   	   	   	   	   	   	   	   	  
	   Weren’t	  aware	  or	  given	  options	  for	  prenatal	  diagnosis	   	   □	  
	   Accepting	  of	  possibility	  of	  having	  a	  child	  with	  haemophilia	   	   □	  
	   Being	  opposed	  to	  having	  a	  termination	   	   	   	   □	  
	   Other	  (please	  state)	   	   	   	   	   	   	   □	  
_____________________________________________________________________
_____________________________________________________________________
	   	   	   	   	  
	   	  
Outcome	  of	  prenatal	  diagnosis	  
	   Fetus	  male	   	   	   Yes	  □	  No	  □	  
	   Fetus	  affected	  	   	   Yes	  □	  No	  □	  
	   	  
Opted	  for	  termination	  during	  this	  pregnancy?	   	   Yes	  □	  No	  □	  
	  
What	  was	  the	  mode	  of	  delivery?	  
	   	   	   Normal	  vaginal	  delivery	   	   	   	   □	  
	   	   	   Ventouse	  delivery	   	   	   	   	   □	  
	   	   	   Forceps	  delivery	   	   	   	   	   □	   	  
	   	   	   Emergency	  casearean	  section	   	   	   □	  
	   	   	   Elective	  caesarean	  section	   	   	   	   □	   	  
	  
If	  you	  (and	  the	  doctors)	  were	  unsure	  of	  the	  haemophilia	  status	  of	  the	  fetus	  were	  you	  
offered	  caesarean	  section	  as	  mode	  of	  delivery?	  
	   	   	   	   	   	   	   	   	   Yes	  □	  No	  □	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Part	  2	  –	  Pregnancy	  related	  information	  
	  
For	  each	  ongoing	  pregnancy	  please	  complete:-­‐	  
	  
Pregnancy	  No.2________________________________________________________	  
	  
Year	  of	  pregnancy:	  
	  
Were	  you	  aware	  of	  your	  carrier	  status	  prior	  to	  or	  during	  this	  pregnancy?	  	   	  
	   	   	   	   	   	   	   	   Yes	  □ No	  □	  
	  
Were	  you	  offered	  prenatal	  diagnosis?	  	   	   	   Yes	  □	  No	  □ 
Did	  you	  opt	  for	  prenatal	  diagnosis?	  	  	  	  	   	   	   Yes	  □ No	  □	  
	  
Type	  of	  prenatal	  diagnosis:	   	  
Was	  this	  invasive	  prenatal	  diagnosis?	  
	   	   	   Chorionic	  Villus	  Sampling	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	   □	  
	    Amniocentesis	  in	  2nd	  Trimester	  (week	  15-­‐28)	   	   □	  
	   	   	   	   	   	   	  
Did	  miscarriage	  occur	  due	  to	  invasive	  test?	  	   	   	   Yes	  □	  No	  □	   	  
	  
If	  unsure,	  please	  
comment_____________________________________________________________
_____________________________________________________________________
_____________________________________________________________________	  
	  
Was	  this	  non-­‐invasive	  prenatal	  diagnosis?	  
Ultrasound	  to	  determine	  gender	  	   	   	   	   	   	   □ 
(please	  state	  gestational	  age	  this	  was	  performed_____________)	  
Free	  fetal	  DNA	  (blood	  test)	  to	  determine	  gender	  	  	  	   	   	   	   □	  
Free	  fetal	  DNA	  (blood	  test)	  to	  determine	  haemophilia	  status	  (currently	  	   □
	   only	  available	  in	  the	  research	  and	  development	  stage)	   	   	  
	   	   	   	   	   	  
Was	  this	  3rd	  Trimester	  Amniocentesis	  (usually	  performed	  after	  weeks	  34	  
gestation)?	   	   	   	   	   	   	   Yes	  □	  No	  □	  
	   	   	   	   	   	   	   	  
Complications:	   	   	   	   	   	   	  
Unsuccessful	   	   	   	   □	  
Required	  more	  than	  one	  attempt	   □	  
Premature	  labour	   	   	   □	  
Premature	  rupture	  of	  membranes	   □	  
Fetal	  or	  maternal	  bleeding	   	   □	  
	  
If	  unsure,	  please	  
comment_____________________________________________________________
_____________________________________________________________________	  
_____________________________________________________________________	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Part	  2	  –	  Pregnancy	  related	  information	  	  
	   	  
Reasons	  for	  opting	  for	  prenatal	  diagnosis	  	  
To	  undergo	  termination	  of	  affected	  foetus	  	   	   	   □	   	  
	   To	  be	  aware	  of	  haemophilia	  status	  so	  that	  a	  	   	   	  
	   management	  plan	  could	  be	  made	  about	  delivery	   	   □	   	  
	   Reasons	  other	  than	  haemophilia	  (please	  state)	   	   □ 
	   	   	  
_____________________________________________________________________
_____________________________________________________________________	  
  	   	  
Reasons	  for	  not	  opting	  for	  prenatal	  diagnosis	  
	   Fear	  of	  fetal	  loss	  from	  prenatal	  diagnosis	   	   	   	   □	  
	   Fear	  of	  procedure	  and	  potential	  adverse	  effects	   	   	   □	  
	   Did	  not	  think	  haemophilia	  was	  severe	  enough	  to	  warrant	  	  	   	   □	  
	   prenatal	  diagnosis	   	   	   	   	   	   	   	   	  
	   Weren’t	  aware	  or	  given	  options	  for	  prenatal	  diagnosis	   	   □	  
	   Accepting	  of	  possibility	  of	  having	  a	  child	  with	  haemophilia	   	   □	  
	   Being	  opposed	  to	  having	  a	  termination	   	   	   	   □	  
	   Other	  (please	  state)	   	   	   	   	   	   	   □	  
_____________________________________________________________________
_____________________________________________________________________
	   	   	   	   	  
	   	  
Outcome	  of	  prenatal	  diagnosis	  
	   Fetus	  male	   	   	   Yes	  □	  No	  □	  
	   Fetus	  affected	  	   	   Yes	  □	  No	  □	  
	   	  
Opted	  for	  termination	  during	  this	  pregnancy?	   	   Yes	  □	  No	  □	  
	  
What	  was	  the	  mode	  of	  delivery?	  
	   	   	   Normal	  vaginal	  delivery	   	   	   	   □	  
	   	   	   Ventouse	  delivery	   	   	   	   	   □	  
	   	   	   Forceps	  delivery	   	   	   	   	   □	   	  
	   	   	   Emergency	  casearean	  section	   	   	   □	  
	   	   	   Elective	  caesarean	  section	   	   	   	   □	   	  
	  
If	  you	  (and	  the	  doctors)	  were	  unsure	  of	  the	  haemophilia	  status	  of	  the	  fetus	  were	  you	  
offered	  caesarean	  section	  as	  mode	  of	  delivery?	  
	   	   	   	   	   	   	   	   	   Yes	  □	  No	  □	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Part	  2	  –	  Pregnancy	  related	  information	  	  
	  
For	  each	  ongoing	  pregnancy	  please	  complete:-­‐	  
	  
Pregnancy	  No.3________________________________________________________	  
	  
Year	  of	  pregnancy:	  
	  
Were	  you	  aware	  of	  your	  carrier	  status	  prior	  to	  or	  during	  this	  pregnancy?	  	   	  
	   	   	   	   	   	   	   	   Yes	  □ No	  □	  
	  
Were	  you	  offered	  prenatal	  diagnosis?	  	   	   	   Yes	  □	  No	  □ 
Did	  you	  opt	  for	  prenatal	  diagnosis?	  	  	  	  	   	   	   Yes	  □ No	  □	  
	  
Type	  of	  prenatal	  diagnosis:	   	  
Was	  this	  invasive	  prenatal	  diagnosis?	  
	   	   	   Chorionic	  Villus	  Sampling	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	   □	  
	    Amniocentesis	  in	  2nd	  Trimester	  (week	  15-­‐28)	   	   □	  
	   	   	   	   	   	   	  
Did	  miscarriage	  occur	  due	  to	  invasive	  test?	  	   	   	   Yes	  □	  No	  □	   	  
	  
If	  unsure,	  please	  
comment_____________________________________________________________
_____________________________________________________________________
_____________________________________________________________________	  
	  
Was	  this	  non-­‐invasive	  prenatal	  diagnosis?	  
Ultrasound	  to	  determine	  gender	  	   	   	   	   	   	   □ 
(please	  state	  gestational	  age	  this	  was	  performed_____________)	  
Free	  fetal	  DNA	  (blood	  test)	  to	  determine	  gender	  	  	  	   	   	   	   □	  
Free	  fetal	  DNA	  (blood	  test)	  to	  determine	  haemophilia	  status	  (currently	  	   □
	   only	  available	  in	  the	  research	  and	  development	  stage)	   	   	  
	   	   	   	   	   	  
Was	  this	  3rd	  Trimester	  Amniocentesis	  (usually	  performed	  after	  weeks	  34	  
gestation)?	   	   	   	   	   	   	   Yes	  □	  No	  □	  
	   	   	   	   	   	   	   	  
Complications:	   	   	   	   	   	   	  
Unsuccessful	   	   	   	   □	  
Required	  more	  than	  one	  attempt	   □	  
Premature	  labour	   	   	   □	  
Premature	  rupture	  of	  membranes	   □	  
Fetal	  or	  maternal	  bleeding	   	   □	  
	  
If	  unsure,	  please	  
comment_____________________________________________________________
_____________________________________________________________________	  
_____________________________________________________________________	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Part	  2	  –	  Pregnancy	  related	  information	  	  
	   	  
Reasons	  for	  opting	  for	  prenatal	  diagnosis	  	  
To	  undergo	  termination	  of	  affected	  foetus	  	   	   	   □	   	  
	   To	  be	  aware	  of	  haemophilia	  status	  so	  that	  a	  	   	   	  
	   management	  plan	  could	  be	  made	  about	  delivery	   	   □	   	  
	   Reasons	  other	  than	  haemophilia	  (please	  state)	   	   □ 
	   	   	  
_____________________________________________________________________
_____________________________________________________________________	  
  	   	  
Reasons	  for	  not	  opting	  for	  prenatal	  diagnosis	  
	   Fear	  of	  fetal	  loss	  from	  prenatal	  diagnosis	   	   	   	   □	  
	   Fear	  of	  procedure	  and	  potential	  adverse	  effects	   	   	   □	  
	   Did	  not	  think	  haemophilia	  was	  severe	  enough	  to	  warrant	  	  	   	   □	  
	   prenatal	  diagnosis	   	   	   	   	   	   	   	   	  
	   Weren’t	  aware	  or	  given	  options	  for	  prenatal	  diagnosis	   	   □	  
	   Accepting	  of	  possibility	  of	  having	  a	  child	  with	  haemophilia	   	   □	  
	   Being	  opposed	  to	  having	  a	  termination	   	   	   	   □	  
	   Other	  (please	  state)	   	   	   	   	   	   	   □	  
_____________________________________________________________________
_____________________________________________________________________
	   	   	   	   	  
	   	  
Outcome	  of	  prenatal	  diagnosis	  
	   Fetus	  male	   	   	   Yes	  □	  No	  □	  
	   Fetus	  affected	  	   	   Yes	  □	  No	  □	  
	   	  
Opted	  for	  termination	  during	  this	  pregnancy?	   	   Yes	  □	  No	  □	  
	  
What	  was	  the	  mode	  of	  delivery?	  
	   	   	   Normal	  vaginal	  delivery	   	   	   	   □	  
	   	   	   Ventouse	  delivery	   	   	   	   	   □	  
	   	   	   Forceps	  delivery	   	   	   	   	   □	   	  
	   	   	   Emergency	  casearean	  section	   	   	   □	  
	   	   	   Elective	  caesarean	  section	   	   	   	   □	   	  
	  
If	  you	  (and	  the	  doctors)	  were	  unsure	  of	  the	  haemophilia	  status	  of	  the	  fetus	  were	  you	  
offered	  caesarean	  section	  as	  mode	  of	  delivery?	  
	   	   	   	   	   	   	   	   	   Yes	  □	  No	  □	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Part	  3	  –	  Future	  developments	  in	  prenatal	  diagnosis	  and	  haemophilia	  care	  
	  
	  
Did	  you	  ever	  made	  a	  conscious	  decision	  not	  to	  have	  children,	  or	  not	  	  
to	  have	  any	  more	  children?	  	   	   	   	   	   Yes	  □	  No	  □	  
	  
If	  so,	  could	  you	  please	  state	  reasons,	  or	  factors	  influencing	  your	  decision?	  
	  
	   Fear	  of	  passing	  haemophilia	  on	  to	  your	  child	  	   	   	   □	  
	   Previous	  experience	  of	  haemophilia	   	   	   	   	   □	  
	   The	  stress	  of	  going	  through	  prenatal	  tests	   	   	   	   □	  
	  
Other,	  please	  state	   	   	   	   	    
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________	  
	  
If	  you	  currently	  fell	  pregnant,	  would	  you	  opt	  for	  3rd	  trimester	  amniocentesis	  to	  
diagnosis	  the	  haemophilia	  status	  of	  your	  child,	  considering	  there	  is	  a	  1%	  risk	  of	  
preterm	  labour?	   	   	   	   	   	   	  
	   	   	   	   	   	   	   	   Yes	  □	  No	  □ Unsure	  □ 
 
If	  available,	  would	  you	  opt	  for	  a	  non-­‐invasive	  blood	  test	  to	  diagnosis	  the	  haemophilia	  
status	  of	  your	  child,	  considering	  there	  is	  no	  risk	  to	  you	  or	  the	  pregnancy?	   	  
	   	   	   	   	  
	   	   	   	   	   	   	   	   Yes	  □	  No	  □ Unsure	  □	  
	  
Would	  having	  the	  option	  of	  diagnosing	  haemophilia	  safely,	  effectively	  and	  early	  on	  in	  
pregnancy	  influence	  your	  decision	  to	  have	  children?	  	   	  
	   	   	   	   	   	   	   	   Yes	  □	  No	  □ Unsure	  □	  
	   	   	   	   	   	   	   	   	  
	  
Further	  comments	  if	  you	  wish:	  
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________	  
	  
	   	   	   	   	   	   	   	   	   	  
	  
What	  is	  your	  estimation	  as	  to	  the	  risk	  of	  intracranial	  haemorrhage	  (bleeding	  in	  the	  
brain)	  occuring	  during	  delivery	  of	  a	  male	  baby	  with	  haemophilia?	  
	  
1/1000	  	  □  1%	  	  □  5%	  	  □  10%	  □	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Which	  of	  these	  figures	  would	  you	  consider	  to	  be	  a	  signifcant	  risk?	  
	  
1/1000	  	  □  1%	  	  □  5%	  	  □  10%	  □ 
 
At	  what	  level	  of	  risk	  would	  you	  opt	  for	  caesarean	  section?	  
	  
1/1000	  	  □  1%	  	  □  5%	  	  □  10%	  □ 
	  
Further	  comments	  if	  you	  wish:	  
_____________________________________________________________________
_____________________________________________________________________	  
_____________________________________________________________________	  
_____________________________________________________________________	  
	  
	  
If	  you	  are	  happy	  to	  be	  contacted	  by	  the	  Clinical	  Research	  Doctor,	  please	  could	  you	  
provide	  us	  with	  your	  contact	  telephone	  number	  below?	  This	  would	  very	  useful	  if	  we	  
need	  to	  clarify	  any	  information	  you	  have	  provided.	  
	  
	  
Telephone	  number:	  
	  
	  
	  
MANY	  THANKS	  FOR	  GIVING	  UP	  YOUR	  TIME	  TO	  COMLETE	  THIS	  QUESTIONNAIRE.	  
YOUR	  FEEDBACK	  IS	  APPRECIATED.	  
	  
Please	  return	  this	  questionnaire	  in	  the	  pre-­‐paid	  envelope	  provided	  to:	  
	  
Miss	  Rezan	  Kadir,	  
The	  Haemophilia	  Centre,	  
The	  Royal	  Free	  Hospital,	  
Pond	  Street,	  	  
Hampstead,	  
London,	  NW32QG	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APPENDIX 4 Condensed MCMDM-1 Bleeding questionnaire 
Scoring Key  
 
 Score      
Symptom -1 0 1 2 3 4 
Epistaxis -- No or trivial 
(less than 
5) 
> 5 or more 
than 10’ 
Consultation 
only 
Packing or 
cauterization 
or 
antifibrinolytic 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Cutaneous -- No or trivial 
(< 1cm) 
> 1 cm and no 
trauma 
Consultation 
only 
-- -- 
Bleeding from  
minor wounds 
-- No or trivial 
(less than 
5) 
> 5 or more 
than 5’ 
Consultation 
only 
Surgical 
hemostasis 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Oral cavity -- No Referred at 
least one 
Consultation 
only 
Surgical 
hemostasis or 
antifibrinolytic 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Gastrointestinal 
bleeding 
-- No Associated 
with ulcer, 
portal 
hypertension, 
hemorrhoids, 
angiodysplasia 
Spontaneous Surgical 
hemostasis, 
blood 
transfusion, 
replacement 
therapy, 
desmopressin, 
antifibrinolytic 
-- 
Tooth 
extraction 
No 
bleeding in 
at least 2 
extractions 
None done 
or no 
bleeding in 
1 extraction 
Reported, no 
consultation 
Consultation 
only 
Resuturing or 
packing 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Surgery No 
bleeding in 
at least 2 
surgeries 
None done 
or no 
bleeding in 
1 surgery 
Reported, no 
consultation 
Consultation 
only 
Surgical 
hemostasis or 
antifibrinolytic 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Menorrhagia -- No Consultation 
only 
Antifibrinolytics, 
pill use 
Dilation & 
curettage, iron 
therapy, 
ablation 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
or 
hysterectomy 
Postpartum 
hemorrhage 
No 
bleeding in 
at least 2 
deliveries 
None done 
or no 
bleeding in 
1 surgery 
Consultation 
only 
Dilation & 
curettage, iron 
therapy, 
antifibrinolytics 
Blood 
transfusion or 
replacement 
therapy or 
desmopressin 
Hysterectomy 
Muscle 
hematomas 
-- Never Post trauma, 
no therapy 
Spontaneous, 
no therapy 
Spontaneous 
or traumatic, 
requiring 
desmopressin 
or 
replacement 
therapy 
Spontaneous 
or traumatic, 
requiring 
surgical 
intervention 
or blood 
transfusion 
Hemarthrosis -- Never Post trauma, 
no therapy 
Spontaneous, 
no therapy 
Spontaneous 
or traumatic, 
requiring 
desmopressin 
or 
replacement 
therapy 
Spontaneous 
or traumatic, 
requiring 
surgical 
intervention 
or blood 
transfusion 
Central 
nervous 
system 
bleeding 
-- Never -- -- Subdural, any 
intervention 
Intracerebral, 
any 
intervention 
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